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ABSTRACT 
In prostate cancer (PCa) the laminin binding integrin (LBI) 61 is involved in the 
extra capsular and muscle invasion of cohesive tumor clusters in part through 
dissemination via peripheral nerves expressing laminin. This invasion results in 
part due to the posttranslational modification (PTM) of the 61 integrin (6) by 
the serine protease urokinase plasminogen activator (uPA, PLAU) and its cognate 
receptor (uPAR, PLAUR). The cleavage results in a tumor specific variant form of 
the 6 integrin called 6p1 (6p). This leads to altered biophysical adhesive 
properties of the cohesive cancer clusters. This PTM occurs early in progression 
from indolent and confined tumors to aggressive and invasive phenotypes. Current 
strategies have the capability to detect aggressive cancers that have invaded, but 
are unreliable for identification of tumors that have an early signature of 
invasiveness. Therefore, an identification of a reliable diagnostic method that 
stratifies confined and indolent (low risk) tumors that lack migratory capability from 
one that will progress to early invasive phenotypes will aid informed and objective 
decisions for specific treatment strategies. 
Utilizing an emerging technique of multiplex immunohistochemistry (IHC) detection 
of primary antibodies specific for protein biomarkers within a single formalin fixed 
paraffin embedded (FFPE), LBI protein interactions and associations were 
detected within prostate tissue samples. The interaction of LBI biomarkers with 
uPAR, the essential cell-cell adhesion protein E-cadherin were detected. In 
addition, associations with the pathway regulating tumor suppressor protein PTEN 
in concert with the transcription factor ERG in human prostate tissue samples were 
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also detected. These interactions were detected in tissues exhibiting various 
stages of PCa disease progression. These protein interactions and associations 
were also the basis for generating image analysis algorithms to quantify protein 
expression. Using brightfield multiplex and standard DAB IHC image analysis, two 
separate quantitation algorithms were created and tested utilizing multiplex 
chromogen and IHC DAB detections. One quantitative algorithm allowed 
differentiation of individual chromogenic stain intensities and co-incidence of LBIs 
and E-cadherin biomarkers within focal regions of interest in PCa tissues. The 
results also displayed increased ratio of 6 integrin and E-cadherin cell-cell co-
distribution in early pre-malignant events compared to aggressive tumors. The 
other algorithm designed identified specific localization patterns of 6 integrin in 
association of PTEN and ERG status. This indicated that localization of 6β1 
integrin correlating to PTEN and ERG status could be used as an indicator of PCa 
aggressiveness.   
In this study, the role of the 6β1 integrin cleavage plays in cohesive tumor 
invasion through muscle was characterized.  A CRISPR Cas9 mouse model 
muscle invasion assay with DU145 prostate tumor cells injected with a transfected 
uncleavable 6 mutant (6AA) exhibited significantly reduced tumor onset and 
extravasation (6 weeks) while mice injected with cells with a transient knockout of 
31 integrin (3) increased tumor burden and invasion sites in xenograft tissues. 
Analysis of xenograft sample tissue confirmed a significant decrease in tumor 
burden and reduced muscle invasion. Overall, these results suggest a loss of 3 
integrin plays a role in aggressive tumor burden and muscle invasion in PCa via 
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the cleavage of 6β1 integrin. Also, the results indicate a blockage of the 6β1 
integrin cleavage demonstrate a promising mechanism to inhibit the progression 
of aggressive disease.  
 
I. Main introduction 
PROSTATE CANCER 
Prostate cancer (PCa) is the most common type of cancer in males and second 
leading cause of cancer deaths (after lung and bronchus) in males (Harryman et 
al., 2019; Chapter 10; Siegel et al., 2019). It has been estimated that 174,650 new 
cases of prostate cancer (20% of all cancer cases) will be diagnosed in 2019 
(Siegel et al, 2019). Of these cases 31,620 (10% of all cases) will result in death. 
It is a unique type of cancer that presents with two phenotypes, an indolent 
confined form and aggressive an invasive form. Cancer that is localized (confined 
to the gland) is considered curable with a 5-year survival rate of almost 100% 
(Kascinta et al., 2014; Harryman et al., 2016). This 5-year survival rate dramatically 
decreases to less than 30% with extracapsular tumor escape (Kasinta et al., 2014; 
Harryman et al., 2019, Chapter 10).  
Treatment for prostate cancer is dependent upon the early detection of aggressive 
disease. Although the diagnostic capabilities have improved over the past 
decades, the ability to identify invasive potential remains difficult. Most low-risk 
stage one confined prostate disease will involve watchful waiting and active 
surveillance. High-risk PCa is treated by radical prostatectomy, external beam 
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radiation or implanted radioactive seeds. Advanced stage and metastatic PCa is 
usually treated with prostatectomy, androgen deprivation therapy (ADT) and/or 
radiation therapy (RT). Although a study showing the combination of prostatectomy 
and ADT improved overall survival by about 40% (Rusthoven et al., 2016), the 
cancers will become unresponsive and lead to the highly aggressive castration 
resistant form in under 3 years and regression of cancer within 12-18 months 
(Marques et al., 2010; Karatanos et al., 2016). Currently, the inability to stratify low-
risk disease from high-risk metastatic PCa leads to overtreatment or misdiagnosis. 
Therefore, the need for more specific detection methods to identify the cancers 
with metastatic potential is critical for patient treatment decisions.  
Prostate tumor progression is complex process occurring in steps with transition 
from normal glands (Figure 1.1, A), to metastatic tumors. It begins with transition 
of normal secretory glands to early premalignant lesions called prostatic 
intraepithelial neoplasia (PIN) lesions (Figure 1.1, B). The process begins with the 
attenuation of basal cell layer and loss of critical laminin components in the 
extracellular matrix displaying gaps. Following this event, clusters of tumor cells 
escape through the gaps into the surrounding stroma and then to the laminin rich 
peripheral nerves for extracapsular escape in a process known as perineural 
invasion (PNI) (Figure 1.1, C). PNI is defined as the invasion of tumor clusters in 
and around the nerve and is identified as a known pathological feature of 
aggressive disease. After extracapsular escape via peripheral nerves, the primary 
metastatic site for prostate tumors is the bone, although ~20% of the time the brain, 
liver and lung are also common sites for metastatic prostate disease.  
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The expression of LBIs and other surface proteins play a significant role in invasive 
tumor migratory capacity through dynamic matrix and cell-cell adhesion 
modulations. The mechanotransduction of signal cues via interactions with the 
matrix environment regulate adhesion responses driving migration and directional 
polarization. Our group and others have previously demonstrated the blocking of 
integrin function mitigates PCa metastasis (Ports et al., 2009; Degrosellier and 
Cheresh., 2010; Landowski et al., 2014). Therefore, specific targeting of these 
functions in conjunction with compensatory signaling molecules may mitigate 
metastatic colonization. 
 
Figure 1.1. Hematoxylin and Eosin (H*&E) stained prostate tissue slides. Images representative of stages 
in prostate cancer progression. (A) Image of normal gland. (B) Image of early prostatic intraepithelial neoplasia 
(PIN) lesion. (C) Perineural invasion (PNI) with cancer cells (Ca) invading around peripheral nerves (N).   
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LAMININ BINDING INTEGRINS (LBIs): 6β4, 3β1, 6β1: Laminin binding 
integrins are cellular signaling and adhesion molecules that play a critical role in 
normal human developmental processes such as embryonic development, cellular 
migration, wound healing and repair, cellular signaling and also a substantial role 
in cancer progression. Laminin binding integrins are transmembrane cell-surface 
glycoprotein receptors comprised of non-covalently associated  and β subunits. 
There are 18  and 8 β subunits that combine to form at least 24 known integrin 
heterodimer combinations that demonstrate a ligand binding specificity to 
substrates in the ECM (Van de Flier et al., 2001; Ports et al., 2009; Barcyzk et al., 
2010) (Figure 1.2). The  and  integrin extracellular domains function as a 
receptor for components of the ECM and is required for binding to proteins such 
as fibronectin, fibrinogen, vitronectin, laminin, and collagen. The cytoplasmic tails 
connect to proteins of the cytosol (Delwel et al., 1995). They also have the 
capability to bind vascular and coagulator proteins such as thrombospondin, von 
Willebrand’s factor, factor X and other cellular adhesion molecules (CAMs) 
(Makrilia et al., 2009). Integrins are involved in bidirectional signal transduction 
when activated by intracellular and/or extracellular signals. Intracellular signals 
induce conformational alterations in the ligand binding properties and is known as 
inside-out signaling, whereas ligation with extracellular proteins constitute outside-
in signaling for activation of cellular processes. These integrin-protein associations 
are essential for integrin regulation of normal functions such as gene expression, 
cell polarity, cell survival and proliferation, cell cycle progression, cellular adhesion, 
development, stem cell homing, morphogenesis and wound healing (Makrilia et 
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al., 2009). Integrins are also key mediators of epithelial cell migration and 
metastasis (Landowski et al., 2014).  
 
Figure 1.2. Integrin receptor superfamily and associated extracellular ligands. The 18  and 8  integrin 
subunits and associated extracellular ligand or Ig-super family counter receptor specificities for the 24 
different heterodimer conformations. (Modified from Hynes, 2002). 
The 6 integrin subunit primarily forms a heterodimer with the 4 or 1 subunit 
respectively to form the laminin binding integrin conformations. The 6 integrin 
(P23229) is 1073 amino acids in length and contains two polypeptides linked by a 
disulfide bridge between the 110-kDa N-terminal heavy chain and 30-kDa light 
chain (Sonnenberg et al., 1987; Tamura et al., 1990., Hogervorst et al., 1991) 
(Figure 1.3). There are two known splice variants of 6, each containing similar 
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heavy chains and two variable light chains 6A and 6B (Hogervorst et al., 1991). 
The 6A isoform (Alpha6X1) is the most common form (Delwel et al., 1995), is 
found in prostate cancer and the isoform studied here.  The heavy chain has an 
875-amino acid extracellular region and a cytoplasmic domain that contains a 
highly conserved five amino acid residue GFFKR sequence motif that is necessary 
for heterodimerization to  integrin subunits for cell surface expression (De Melker 
and Sonnenberg., 1996; De Melker et al., 1997).   
 
Figure 1.3. Schematic diagram of the full-length α6 integrin and the tumor specific variant 6p. A 
schematic representation of the 6 integrin sequence with amino acid heavy chain region at 24-899 and light 
chain amino acid region at 903-1073 (Modified from Davis et al 2001). 
The LBIs 6β4 (CD104), 6β1 (CD49f) and 3β1 (CD49c) are required for normal 
cellular adhesion to laminin, a major component of the basal lamina (basement 
membrane), as their extracellular ligand. Laminins are members of a family of 800 
kDa heterotrimeric basement membrane glycoproteins that contain three chains; 
one ,  and ɤ subunit that are crosslinked by disulfide bonds that form the shape 
of a cross-like structure with two shorts arms and one long arm (Chang et al., 1995; 
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Durbeej., 2010) (Figure 1.4). The primary laminins recognized by these integrins 
are laminins 111, 332, 551, and 521 (laminins 1, 5, 10 and 11 respectively). The 
6β4 integrin is associated with the nucleation of hemidesmosomes and 
intermediate filaments (Kurpakus et al, 1991., Jones et al., 1991., Cress et al., 
1995). The 6β1 integrin is found to be a constituent of focal adhesions and is 
associated with cytosolic molecule vinculin (Hogervorst et al., 1993., Cress et al., 
1995).  Of the LBIs, a6b1 has the broadest specificity binding to all laminin isoforms 
with preference for laminin 111, laminin 332 and laminin 511 (Nishiuchi et al., 
2006) and can support the undifferentiated growth of human stem cells (Miyazaki 
et al., 2008). In normal tissue, the primary laminin for 6β4 is laminin 332 (LMN 5) 
which is expressed in basal lamina of normal prostate glands. In normal tissue the 
primary laminin ligand for 6β1 is laminin 551 (LMN 10), which is a key constituent 
of the normal basal lamina of the prostate gland and the muscle stroma. However, 
of all the LBIs, the a6b1 integrin has the ability to bind all laminin isoforms it may 
encounter, with laminin 511 as the most preferred ligand (Nishiuchi et al., 2006). 
These are crucial factors involved in aggressive tumor dissemination into 
surrounding tissues for successful metastasis through laminin lined 
microenvironments.  
Early PCa progression from normal glandular epithelium is considered by many to 
be initiated by early pre-malignant prostatic intraepithelial neoplasia (PIN) 
precursor lesions. This involves the attenuation of basal cells, the intermittent 
preservation of ECM laminin-5 expression in which remaining basal cells are 
bound, the loss of hemidesmosomes which coincide with the downregulation of 
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the 6β4 and 3β1. This has been suggested to potentially be of high predictive 
value for adenocarcinoma (Wang et al., 1999; Soares et al., 2002). Laminin-10 
expressed within the stroma becomes available for tumor cell interaction due to 
the intermittent expression of the laminin-5.    The gaps of laminin 5, provide access 
to laminin-10 ligation of 6β1. This event is then exploited by proliferating invasive 
tumor cells. Our understanding of these associations may ultimately lead to 
defining a signature for first step invasiveness and with that foundation, the ability 
to target and inhibit the invasion. 
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Figure 1.4. Structure of laminin.  Schematic representation of laminin-1. The heterotrimeric laminin structure 
with , β and γ-chains comprising of globular domains. The laminin structure encompasses the long α-chain 
contain three globular domains in the top region that associate with components of the ECM and a lower 
region containing 5 globular regions, three for integrin binding and two for dystroglycan binding. The -chain 
is associated by the β and γ-chains both with two globular domains coiled in a helical formation. Note: The 5 
and the 3 chains for laminin 10 and laminin 5 are different from the illustration depicted here. (Image courtesy 
of MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany. Sitterley, George. BioFiles 
2008, 3.8, 11). 
 
6 INTEGRIN AND UPA/UPAR IN PROSTATE CANCER 
Although 64 (β4) and 31 integrins play an integral role in progression from 
non-neoplastic to neoplastic lesions in PCa, events leading to progression of 
cancer is due to the absence of protein epitope expression. The 6β1 integrin role 
in tumor invasiveness is critical specifically due to the posttranslational 
modification event. Previous work by our group has demonstrated that an invasive 
PCa specific variant form of 6β1 integrin called 6p1 (6p) is mediated by the 
protease uPA when it is associated with its receptor called uPAR. This modification 
precedes the progression of indolent or confined tumors to a more cohesive 
aggressive phenotype with the propensity of capsular penetration and muscle 
invasiveness into surrounding tissues. 
6 Integrin. Along with 3β1 integrin, the 6β1 integrin is the common laminin 
binding integrin heterodimer receptor pair that remains expressed in prostate 
cancer (Cress et al., 1995., Nagle et al., 1995., Ports et al., 2009). In invasive 
prostate carcinomas, most of the integrin heterodimers are downregulated and not 
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expressed on the cellular surface (Cress et al., 1995). However, between 10% and 
69% of those invasive cancers express 3β1 and 6β1, respectively (Demetriou 
and Cress., 2004). A previous study by our lab incorporating 135 prostate cancer 
biopsies from 61 patients observed that approximately 80% of those cases 
expressed either 3 or 6 integrin (Schmelz et al., 2002; Demetriou and Cress., 
2004). Various other studies have implicated these integrins in other aggressive 
cancers such bladder cancers, colorectal cancers, glioblastoma and pancreatic 
adenocarcinomas (Weinel et al., 1995; Rabinovitz and Mecurio., 1996).  
The increased cell surface expression of 6β1 integrin is linked with progressive 
downregulation of β4 integrin in the natural history of prostate cancer involving 
prostatic intraepithelial neoplasia (PIN), carcinoma in situ, and adenocarcinoma 
invasion of adjacent structures and lymphoid involvement and metastasis to bone 
(Cress et al., 1995). The decreased expression of β4 integrin subunit coincides 
with the decreased expression of the associative laminin-5. There remains laminin-
10 in which the 6β1 has a preferred specificity (Nishiuchi et al., 2006). Although 
the 3 integrin subunit has been demonstrated to be functional receptor for 
laminin-10 in vivo, other studies have shown that laminin-5 was the preferred 
ligand (Kikkawa et al., 2000). The increased exposure of laminin-10 and the 
preference for laminin-5 binding is accompanied by downregulation of 3 subunit.  
Thus, an increased qualitative association of the 6 with the β1 and corresponding 
increased surface expression of 6β1 which activates downstream signaling 
pathways (Fornaro et al., 2001; Goel et al., 2008).  
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The increased surface expression of 6β1 (here by referred to as 6 integrin), 
results in integrin clustering. The pathways activated are involved in cancer cell 
survival, proliferation, adhesion, cytoskeletal reorganization and regulation of 
cancer cell motility such as the focal adhesion kinase (FAK) which is a non-
receptor tyrosine kinase (Ilic et al., 1995; Goel et al., 2009). Once phosphorylated, 
FAK interacts with various other signaling factors that are found altered in PCa 
such as Cas, Src kinases, paxillin and phosphatidylinositide 3-kinase (PI3K) that 
has been shown to promote prostate cancer cell invasion (Goel et al., 2009). 
uPA/uPAR. The serine protease uPA and its glycosylphosphatidylinositol (GPI) -
anchored receptor uPAR are key molecules in several normal developmental, 
wound healing and maintenance functions. These molecules also been discovered 
to have pleiotropic functions in pathogenesis of inflammation, fibrinolysis, innate 
and adaptive immunity and pathology (Modino and Blasi., 2004). They also 
function as key facilitators of ECM degradation and remodeling, intracellular 
signaling, migration, tumor invasion, and are attributed to the production of 6p1 
variant in prostate adenocarcinoma. The inactive precursor form of uPA (pro-uPA), 
secreted by cells, remains in an inactive soluble form until activation. The anchored 
uPAR is composed of three domains (D1, D2 and D3) that together have a high 
affinity for pro-uPA (zymogen), uPA and ECM protein vitronectin (Mondino and 
Blasi., 2004). The activation of uPA occurs once bound to the GPI anchored uPAR, 
which not only localizes uPA but regulates signaling activity and cellular 
differentiation and migration through the ECM (Busso et al.,1994; Shariat et al., 
2007). The activated uPA catalyzes the conversion of the inactive zymogen 
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plasminogen to the active plasmin form. The active plasmin form activates matrix 
metalloproteases (MMPs) that actively cleave protein components of the ECM to 
allow dissolution of the membrane (LeBeau et al., 2015). In turn, this process 
releases various growth factors, cytokines and other molecules from within the 
matrix.  The activated plasmin also feeds into the proteolytic positive feedback loop 
by the cleavage and activation of the pro-uPA resulting in increased expression of 
the uPA/uPAR complex. This is a key event during tumor growth, invasion and 
metastasis (Mahmood et al., 2018).  
Once the uPA is bound to the uPAR, this stimulates membrane receptor clustering, 
potentially within detergent-resistant cholesterol rich regions known as lipid rafts 
(Cunningham et al., 2003; Smith and Marshall., 2010). This clustering enhances 
vitronectin binding resulting in increased associations with integrins, particularly 
with 6β1 integrin. The uPA/uPAR complex can also activate downstream 
signaling pathways involved in proliferation, migration and invasion such as Ras-
mitogen-activated protein kinase (MAPK), Signal transducer and activator of 
transcription (STAT), FAK, Janus  kinase (JAK) and phosphatidylinositide 3-kinase 
(PI3K)-Akt (Ma et al., 2001; Li and Cozzi., 2007, Smith and Marshall., 2010). 
However, the signaling through the uPA/uPAR complex is independent of the uPA 
proteolytic activity but dependent upon transmembrane co-receptors such as 
integrins (Nusrat et al., 1991; Smith and Marshall., 2010).  
The proteolytic activity of uPA is regulated by members of the serine protease 
inhibitor (serpine) superfamily, plasminogen activator inhibitors type I and 2 (PAI1 
and PAI2) and by uPAR (Li and Cozzi., 2007). In return, uPA has the ability to 
25 
 
cleave the uPAR in the linker between the D1 and D2 domain regions resulting in 
soluble D1 fragment and leaving a membrane bound D2-D3 fragment (Smith and 
Marshall., 2010). This in turn inactivates the proteolytic activity of the complex by 
mitigating the uPA binding to the uPAR. The proteolytic cleavage of the GPI linker 
could also result in soluble full length and D2-D3 fragments (Smith and Marshall., 
2010). The activated uPA bound to uPAR is recruited to cells of the leading edge 
of migrating cells bordering the ECM for localized pericellular remodeling of the 
matrix molecules promoting the invasive potential (Friedl., 2004; Friedl et al., 2004; 
Friedl et al., 2009). The presence of the uPA/uPAR complex is highly increased in 
many malignant human cancers and expression is frequently prognostic of poor 
survival, predictive of invasion and metastasis (Smith and Marshall., 2010). The 
expression of uPAR has also been shown in populations of inflammatory cells such 
as tumor associated macrophages (TAMs) and also within stromal cells of 
interstitial tissues of PCa (Li and Cozzi., 2007). This demonstrates an intricate 
process by which normal cellular migration and movement proceeds within the 
complex environment. This exploitation of deregulated processes by invasive 
tumors is a major reason why specific targets indicative of early aggressiveness 
are extremely difficult to elucidate. 
Overall, the involvement of the uPA/uPAR complex as a mediator of tumor 
progression and dissemination through the ECM has been determined to involve 
the association of laminin binding integrins 6β1 and 3β1. It is noted that uPA 
and uPAR as well as 61 expression is increased in aggressive prostate cancer 
(Sroka et al., 2011). However, the specific role of 3β1 in this progression has not 
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been fully discerned. The increased expression of uPA/uPAR has been shown to 
be responsible for the significantly increased pericellular proteolysis in patients 
with advanced PCa (Lippert et al., 2016). Pericellular proteolysis includes the 
production of a tumor-specific receptor that is a laminin binding integrin variant, a 
novel form of the 6 integrin with altered biophysical adhesion properties. Our lab 
has previously characterized the production of the tumor specific variant 6pβ1 
resulting from PTM of the laminin binding domain of 6β1 due to the proteolytic 
activity of the uPA/uPAR complex. It is evident that although the mechanistic 
pathways that initiate this modification has yet to be uncovered, the association of 
these proteins “bear fruit” to phenotypic switches that precedes the metastatic 
potential and thus may be targeted as proteins of interest for early invasiveness.   
COLLECTIVE TUMOR INVASION AND MIGRATION 
Tumor invasion and migration of cohesive tumor cells through muscle to distant 
sites involves the laminin binding integrin association with various critical adhesion 
molecules such as Kindlin-2, Talin and integrin-linked kinase (ILK) and protein 
receptors E-cadherin, beta-catenin. Initial testing using formalin fixed paraffin 
embedded (FFPE) tissues involved developing a diagnostic assay to evaluate the 
uPA and 6β1 (6) association. This initially was to become a dual detection 
immunostain using antibodies against uPAR and 6 integrin. The purpose was to 
profile the potential posttranslational modification of 6 integrin in early invasive 
tumors by utilizing chromogen multiplex detection. However, the antibody utilized 
against the uPAR lost viability and was discontinued by the vendor leaving this 
particular pathway unavailable for further pursuit. Therefore, the integrin 
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association with cell-cell adhesion proteins, such as E-cadherin, became the 
prevailing focus.There are three hallmarks that characterize collective cell 
migration (Friedl et al., 2009). Collective tumor invasion through tissues involves 
cell-cell and cell-matrix proteins that allow physical and functional connectivity of 
the cohesive groups of cancer cells to retain integrity of the adhesive junctions for 
preservation of cellular motility and migration. These proteins transduce signals 
that initiate groups of cells to organize their actin cytoskeleton in a polarized 
fashion to generate traction and protrusion forces for migration. They migrate 
through the extracellular matrix (ECM) as collective sheets, chords or clusters that 
also involves structural tissue remodeling and modification of the ECM that may 
result in basement membrane deposition.  
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DISSERTATION OBJECTIVES 
The discovery and detection of a biomarker signature in prostate cancer tissues 
that is a definitive indication of aggressive disease that will disseminate to distant 
tissue remains and elusive undertaking. When prostate cancer invades, it 
breaches through the smooth muscle walls of the prostatic capsule and migrates 
in a single cell fashion or a cellular cohesive collective. Our initial focus was to 
utilize various antibody detection strategies such as standard 
immunohistochemistry, chromogen multiplexing and proximity assays on human 
prostate tissues to target the distribution of cell surface protein expressions. This 
would allow our lab develop an IHC assay to recognizing an early cohesive 
migratory cancer phenotype. This cohesive group utilizes several substrate and 
cell-cell adhesion proteins to remain pliable and intact during dissemination. The 
secondary objective of this research was to develop a model assay system that 
would interrogate the associations between these proteins and allow detection and 
quantification of protein expression levels to identify an early signature related to 
invasiveness. 
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II. Loss of 6β4 and 3β1 integrins in PCa track with early PCa progression 
ABSTRACT 
This chapter characterizes the roles of 6β1 and 3β1 integrins in early prostate 
cancer progression through IHC detection methods to visualize protein expression 
in human FFPE tissues. Immunohistochemistry assays utilizing antibodies specific 
for these receptors were developed to determine expression patterns associated 
with early PCa progression. The transformation of normal prostate glandular 
epithelium to neoplastic lesions initiates with changes to the microenvironment that 
include altered expression and function of the 6β4 and 3β1 integrin at the 
surface membrane of basal cells for most epithelia. The epithelium of normal 
glands consists of a contiguous layer of stable hemidesmosome structures 
accentuated by the expression of 6β4 (β4 integrin) at the cell-ECM contact and 
3β1 (3 integrin) localized to the cell-ECM focal adhesion sites. In early transition 
of these normal glands an attenuation of the basal cell layer is observed along with 
the loss in polarization of β4 integrin localized surface expression and subsequent 
loss of 3 integrin. These precursory lesions are called prostatic intraepithelial 
neoplasia (PIN) lesions and result in loss of homeostasis and are considered in 
situ carcinoma. In the progression from PIN lesions to high grade PIN (HGPIN) 
then onto aggressive PCa, the increasing loss of the β4 and 3 integrin is 
demonstrated in most PCa tissues. The protocols utilizing IHC with 3, 3’-
diaminobinzidine (DAB) were optimized for in situ detection of protein expression 
of the β4 and 3 integrin epitopes in human prostate cancer tissues. Utilizing these 
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detection strategies, it is evident that the loss of β4 and 3 integrin play a critical 
role leading to progression of invasive prostate cancer and with further 
understanding of mechanisms initiating this event that may lead to defining the 
factor specific for initiating the early transition to the aggressive phenotype. 
INTRODUCTION 
The laminin binding integrins 6β4 and 31 are transmembrane surface proteins 
that are expressed in abundance on epithelial cells to facilitate adherence to the 
basement membrane. The laminin specificity for either of these integrins is laminin-
332 (laminin-5) and laminin 511 (laminin 10) (Nishiuchi et al., 2006). Although they 
display a common functionality as laminin-5 receptors, these integrins are recruited 
to distinctly separate structures for cellular adhesion (DiPersio et al., 1997). The 
β4 integrin functions as a key factor in nucleation of hemidesmosomes to stabilize 
and anchor basal keratinocytes to the basement membrane in normal epithelia 
tissue. The 3 integrin, although is also found within the basement membrane in 
human epithelia in various tissues, is primarily recruited to focal contacts of the 
keratinocytes and other cells and plays a role in facilitation of linking the ECM to 
components of the cytoskeleton (Carter et al., 1990b; DiPersio et al 1995). 
Historically, in the lifetime of the average male, what typically occurs within the 
normal prostate during the 3rd and 4th decade of life is an observed histological 
contextual change to the microenvironment that continues to increase with 
advancing age (A. Sakr et al., 1996; Harryman et al., 2019). The evidence of that 
transformation has begun within these glands is visualized with loss of basal cells 
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lining the glands leading to PIN lesions. PIN lesions are associated with focal loss 
of the normal morphological associations of the epithelium to the environment of 
the stroma (Bonkhoff and Remberger., 1995; Montironi et al., 2002; Nagle and 
Cress., 2011).  PIN lesions demonstrate sporadic basal cell presence and 
disordered layers of luminal cells with incomplete differentiation.  Also, the nuclei 
become enlarged with prominent nucleoli and begin to demonstrate traits of loss 
of homeostasis with visual evidence of heterochromatic appearance and 
pleomorphic attributes (Figure 2.1). The loss of the normal basal cell component 
is a key factor initiating PIN that results in gaps in laminin-5 resulting in cellular 
exposure to a new environment of laminin-10 and growth factor enriched 
surrounding muscle stroma (Rosario and DiSimone., 2010; Harryman et al., 2019). 
There has been a growing evidence that confirm PIN lesions are the pre-malignant 
stage (Bostwick., 1996; Bostwick et al 2004., Wang et al., 2017). The continued 
genomic instability and loss of homeostatic environment of PIN lesions result in 
HGPIN lesions that are indicative of early invasive PCa development.  HGPIN 
lesions are defined by increased loss or attenuation of the basal cell layer and 
ECM (Bostwick et al 2004., Wang et al., 2017).  HGPIN also displays proliferation 
of the glandular epithelial cells with increasing cytological atypia (Zhou., 2018). 
This chapter investigates the ability to detect the loss of surface expression of β4 
integrin and 3 integrin in progression from normal prostate glandular epithelium 
in human prostate tissue that are associated with progression to invasive PCa. 
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Figure 2.1. High-grade intraepithelial neoplasia (HGPIN). Hematoxylin and eosin stained image of HGPIN 
showing large heterochromatic nuclei (black arrow), and prominent nucleoli (white arrow). (Reprinted with 
permission of MedReviews®, LLC. Bostwick DG, et al. High-grade prostatic intraepithelial neoplasia. Rev Urol. 
2004; 6:171–179. All rights reserved).  
6β4 Integrin. Normal human prostate glands exhibit an ordered layer of basal 
cells with continuous surface expression of β4 integrin that is necessary to anchor 
basal cells via laminin-5 present in the ECM to hemidesmosomes to stabilize the 
adhesion (Nagle et al 1995., Wang et al 2017). HGPIN lesions have a 
discontinuous layer of β4 integrin because of the attenuation of basal cell 
attachment to the basal lamina. The discontinuous layer of β4 integrin is also 
indicative of laminin-5 loss of expression. The loss in laminin-5 results in gaps in 
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the defective basal layer which promotes cellular budding and migration of 
dedifferentiated cell clusters. These gaps also give rise to exposure to laminin-10 
expressed in the muscle stroma, contributing to tumor escape and dissemination 
via 6 integrin. These results demonstrate the loss of β4 integrin is involved in the 
initial steps of tumor progression. 
3β1 Integrin. Similar to β4 integrin, 3 integrin also demonstrates an abundant 
cell surface expression on normal cells in the basement membrane of normal 
prostate glandular epithelium. The 3 integrin has also been described as a weak 
receptor for other ECM proteins such as fibronectin, collagen, laminin-1, 
thrombospondin and nodogen (Dipersio et al., 1995, Dipersio et al., 1997). 
Although 3 integrin exhibits overlapping functions with laminin-5 similar to β4 
integrin, 3 integrin is suggested to demonstrate a post-adhesion role in basement 
membrane integrity (DiPersio et al., 1997). It is also suggested that 3 integrin may 
be required to maintain strength and integrity of the basement membrane 
independently of initial assembly of the receptor (DiPersio et al., 1997). This 
strengthens the narrative that 3 integrin can act as a negative regulator of motility, 
which studies utilizing 3 null keratinocytes showed enhanced migration in vitro 
and faster wound healing (Margadant et al., 2009; Stipp ., 2010). 
One particular mechanism in which 3 integrin maintains strength and membrane 
integrity is by transduction of signals through Abl kinase family to restrain Rho 
GTPase activity (Figure 2.2). This restraint supports the activation of the Hippo 
pathway suppressor function of inhibiting proto-oncogenic transcriptional 
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activators YAP/TAZ, in turn restraining a transition to prostate cancers with anchor-
independent growth, migratory and invasive capabilities (Varzavand et al., 2016). 
The Hippo pathway has been shown to regulate extracellular inputs such as 
cellular adhesion, cellular detachment, cell-cell contact and growth factor signaling 
from cell receptor-ECM association (Johnson and Hadler., 2014; Piccolo et al., 
2014; Yu et al., 2015; Varzavand et al., 2016). It is also noted that the Hippo 
pathway is influenced by cell adhesion. In addition, the adherens junction 
homodimer E-cadherin, was identified as one of the few adhesion receptors with 
upstream inputs to influence the pathway. Varzavand et al. 2016 presented 
evidence that 3 integrin can also be included as one of those influential receptors. 
Interestingly, separate studies using HT-29 and CaCo-2 colon adenocarcinoma 
cells showed that 3 integrin adhesion to laminin-5 promoted E-cadherin 
localization to cell-cell adherens junctions (Schreider et al., 2002; Chartier et al., 
2006). This particular function is believed to be the result of collaborative signaling 
of 3 integrin and laminin-5 with E-cadherin to induce stabilized cell-cell adhesion 
complexes. This signaling reduces the downstream activity of Rho-GTPase and 
the induction of effectors such as Rho-associated kinase (ROCK) and Diaphanous 
related formin (mDia). These effectors initiate cellular migration. It should be noted 
that Rho activity is required for cell-cell adhesion but is tightly regulated since 
increased levels of Rho cause a disruption in cell-cell adhesions (Zhong et al., 
1997).  
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Other groups providing evidence that signaling from 3 integrin ligated to laminin-
5 inactivates RhoA. However, they demonstrated that this activity in squamous 
cells promoted migration and invasion through upregulated Cdc42/Pak1 activity 
whereas collagen bound 2β1 integrin strongly activated RhoA enhancing focal 
contact formation and impeding migration (Zhou et al., 2005). These results 
contrasted with the work by Nguyen et al., 2001 that showed 3 integrin ligation to 
laminin-5 would activate RhoA-dependent adhesion of human foreskin 
keratinocytes. These results, compared to results of our studies and various 
others, indicate that there is a clear difference in responses depending on the 
specific cell type utilized in testing models and type of integrin receptor ligation 
elicited.  
 
Figure 2.2. The 3 Integrin cooperative signaling with E-cadherin. The 3 integrin associated 
with tetraspanin CD151 allows collaboration with E-cadherin to inhibit activity of Rho-GTPases that 
may elicit anti-migratory activity counteracting the 3 integrin promigratory function (Adapted from 
Stipp, 2010). 
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RESULTS 
Loss of 6β4 in PCa Progression. A rat anti-human antibody (BD Pharmingen) 
specific for the β4 integrin subunit was initially formulated for immunostaining on 
FFPE human prostate tissue at a 1:100 dilution in several antibody diluents to test 
for specificity and non-specific immunostaining of endogenous proteins and 
structures. An immunostaining protocol was prepared for the Ventana Benchmark 
ULTRA platform (Benchmark ULTRA) utilizing high temperature (72oC) de-
paraffinization (de-waxing) step, a heat induced epitope retrieval (HIER) step at 
95oC and antibody incubation time of 60 minutes at 36oC. The detection kit used 
was a modified Ventana ultraView Universal DAB Detection kit (uV Detection) with 
a substitution of the (mouse) Universal Multimer linker dispenser with a 
DISCOVERY rat anti-human Ultramap HRP multimer. De-identified prostate tissue 
samples were sequentially sectioned and an H&E stained slide prepared from the 
initial sectioning for evaluation by a board-certified pathologist for normal and 
tumor histological content. The execution of the protocol resulted in selection of 
the optimal results in β4 integrin immunostaining with the 1:100 dilution in Tris HCL 
buffer with Brij-35. Membrane localization of the β4 integrin was observed in 
normal prostate basal cells. Furthermore, as expected, positive immunostaining 
was observed in endothelial cells of vessels and on the peripheral nerves (Figure 
2.3, A and D). Also, the loss of a continuous layer of β4 integrin expression in the 
basal lamina is indicative of early transformation to an invasive PCa in human 
prostate tissue. The loss of basal cells was evident in tissues containing pre-
malignant PIN lesions that demonstrated increased proliferation of staggered 
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patterns of luminal cells, enlarged nuclei and nucleoli in clusters of cells budding 
through gaps in the discontinuous layer (Figure 2.3, B and E).  The results also 
demonstrate the loss of β4 integrin in cohesive tumor collectives invading 
perineural spaces (via PNI) surrounding laminin coated myelinated nerves that 
exhibited positive β4 integrin expression (Figure 2.3, C and F). This optimized 
procedure allowed for the demonstration of membrane specific localization of the 
β4 integrin within each tissue sample and for reproducibility across multiple 
sampling sizes.  
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Figure 2.3. β4 Integrin expression is deregulated in human prostate cancer progression.  
Images A-C are 20x magnification. (A) De-identified FFPE prostate tissue resection IHC stained with 
anti-β4 antibody exhibits continuous basal expression in normal gland bordered by cancer (Ca) 
lacking expression. (B) HGPIN lesion depicted demonstrating discontinuous expression of 6β4 
integrin in attenuated basal cell layer (red arrowhead). (C) Lack of anti-β4 intensity in cancer (Ca) 
region of PNI. (D-F) Enlarged views of the indicated fields at 40x. (D) Positive controls Vessels (V) 
and nerves (white N) in normal glands, (E) cellular cluster budding through layer absent of β4 integrin, 
(F) Tumor demonstrates negative immunostaining for anti-β4 surrounding nerve (N) that is positive 
for β4 integrin expression. 
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Loss of 3β1 integrin in PCa progression. To demonstrate the expression of 3 
integrin in human FFPE prostate tissue samples, the rabbit polyclonal antibody 
(clone HPA008572) specific for the transmembrane domain was used. After 
optimizing the antibody formulation similar to β4 integrin testing, a 1:200 dilution of 
the anti-3 integrin antibody utilized in IHC testing on human prostate FFPE. The 
results revealed immunostaining localized to areas similar to β4 integrin in the 
basal cells of normal prostate glands (Figure 2.4, A and D). As expected, the loss 
of 3 integrin expression was evident in pre-malignant PIN lesions in a similar 
fashion to β4 integrin (Figure 2.4, B and E).  Although, previous work distinguished 
three prostate tumor phenotypes based on integrin expression. Type I co-
expressing 6 and 3 integrins, type II expressing only 6 integrin and type III 
expressing 3 integrin only (Schmelz et al., 2002). Since the 3 integrin was not 
observed in the tissue samples containing primary tumors, this may indicate that 
these tumors were of the type II phenotype observed in Schmelz et al., 2002. Also, 
it was noted that the 3 integrin expression was absent in endothelial cells of 
vessels and was not expressed in peripheral nerves or prostate tumor cells 
invading the peripheral nerve space via PNI (Figure 2.4, C and F).   
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Figure 2.4. 3 integrin expression is lost in prostate cancer progression. Images A-C are 20x 
Magnification. (A) De-identified prostate FFPE tissue sample slides immunostained with anti-3 antibody 
demonstrating continuous basal cell expression in normal prostate gland. (B) An observed pre-malignant PIN 
lesion with discontinuous 3 integrin expression (blue arrow). (C) Lack of 3 integrin expression exhibited in 
peripheral nerves of prostate, endothelial cells of vessels and tumor cells within PNI. (D-F). Enlarged views of 
indicated fields are 40x. (D) Normal glands with intact basal cell layer positive for 3 integrin (blue arrowhead). 
(E) Evidence of tumor cluster budding through discontinuous layer of 3 integrin (black arrow). (F) Nerves (N) 
and vessels (V) lack 3 integrin expression. 
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DISCUSSION 
The loss of β4 and 3 integrin expression in the normal cells of the basal cell layer 
in human prostate tissues indicate a clinically relevant event in which loss in 
homeostasis, impaired cell-ECM adhesion and attenuation of critical ECM proteins 
result in destabilization of epithelial morphology. This hallmarks the transition from 
normal to pre-malignant architecture. We investigated the expression patterns of 
these protein biomarkers utilizing antibodies in de-identified patient prostate tissue 
samples to determine if the downregulation of these biomarkers could be detected. 
Our results demonstrate that the specificity and sensitivity of these antibodies for 
in situ detection, in patient samples, could translate into a potent tool necessary 
for accurate diagnostic and predictive indicators of early invasive phenotypes.  
Because our lab (and others) have previously assessed how the loss of each of 
these integrin receptors impact the cellular adhesion to critical ECM components 
in mice (Raymond et al., 2004) and facilitates invasion via cord networks in model 
systems of 3D Matrigel, it was prudent that the expression levels were determined 
in human clinical samples.  
Studies showed that highly invasive subpopulations of PCa were selected by the 
decrease in β4 and 3 integrin expression leading to the propensity of metastatic 
invasion (Dedhar et al., 1993). Although, it has been stated that the relationship of 
3 integrin expression in PCa is complex because heterogeneous nature of the 
tumors result in several phenotypes that display either positive or negative 
expression of 3 integrin (Schemlz et al.,2002). The scientific community often 
42 
 
disagrees on the specific role that 3 integrin expression plays in the progression 
or inhibition of PCa. Some groups have suggested 3 integrin induces migration 
(Nguyen et al., 2001; Stipp., 2010, Zhou et al., 2014). Other groups have 
demonstrated shown that 3 integrin inhibits migration (Kim et al., 1992; 
Varzavand et al., 2013., Varzavand et al., 2016; Ramovs et al., 2019). 
Our lab has was postulated that the loss of 3 integrin would promote a migratory 
phenotype in prostate cancer by increasing 6 integrin internalization. In order to 
test this hypothesis, an in vitro model interrogating gene edited DU145 cell lines in 
SCID xenografts was used as the working model. For the testing, the cells used 
were DU145 WT, DU145 cells transfected with a small interference RNA (siRNA) 
to knockdown (KD) 3 integrin (si3) expression and DU145 cells transfected with 
siRNA to knockdown 6 integrin (si6). This working model showed the loss of 3 
integrin increased 6 integrin internalization rates and accumulation to Rab4 early 
endosome antigen 1 (EEA1) containing vesicles. This ultimately promoted 
recycling the 6 integrin to cell-cell lateral membranes increasing tumor cell 
migration by 1.8-fold (Das et al., 2017 unpublished). The increase in fold migration 
was dependent upon the 6 integrin function and cleavage regulated by uPAR.  
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III. 6 integrin and uPAR co-distribution in early aggressive PCa 
ABSTRACT  
This chapter describes the co-distribution of 6 integrin and uPAR in progression 
from normal prostate cells to invasive and metastatic prostate cancer. Metastatic 
cancer is a progressive cascade in which the invasion beyond primary tumor to 
colonize distant tissue occurs. The progression to metastatic disease is regulated 
by mechanisms that involve the change in the adhesive properties of 6 integrin 
due to modification regulated by uPAR. The co-distribution of these proteins 
initiates a phenotypic switch from non-malignant to aggressive and invasive tumors 
by co-opting a mechanism that is traditionally reserved for events in early 
embryogenesis. These include embryonic tissue and organ development, 
response to foreign agents, and tissue repair. This has been found to be an 
aberrant event that leads to aggressive tumors. An IHC detection assay was 
developed utilizing antibodies targeting the laminin binding N-terminal domain of 
the 6 integrin and the uPAR. The purpose was to characterize the expression of 
each of these target epitopes in human FFPE prostate tissue to further develop a 
chromogen multiplex assay with the potential of identifying a quantifiable signature 
for early invasion. The results indicated that the co-distribution of these two 
biomarkers can be detected and is linked with tumor grade and invasiveness. 
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INTRODUCTION 
Previous studies have demonstrated that during progression from normal prostate 
glands to perineural intraepithelial neoplasia (PIN), an attenuation of basal cells 
combined with the loss of 6β4 occurs along with gaps in LMN 5 deposition leading 
to the exposure of LMN 10 in the muscle stroma (Nagle et al 1995., Davis et al., 
2001., Nagle and Cress., 2011., Wang et al., 2017). This exposure of LMN 10 
(laminin 511) is significant since laminin 511 is the most preferred ligand for laminin 
binding integrins and has the highest affinity, as determined by dissociation 
constants, for 61 integrin (Nishiuchi et al., 2006).  The increased exposure of LMN 
10 enhances the association of 6β1 integrin with both the urokinase plasminogen 
activator (uPA) and its receptor (uPAR, CD87). The attenuation of the basal lamina 
and loss of laminin expression are both hallmarks of progressive prostate disease 
and coincide with the attenuation of 6β4. The 6 and 3 integrins are stated to 
be expressed in 80% of prostate cancers (PCa) with ~26% exhibiting loss of 3 
and increased expression of 6 (Schmelz et al., 2002). Both of these LBIs are 
considered to be crucial factors in cohesive prostate cancer migration and 
invasion. However, due the heterogenous nature of PCa the expression of 6 
and/or 3 is phenotypically dependent. Incidentally, recent studies suggest that 3 
integrin inhibits progression to aggressive PCa via transduced signals to the Abl 
kinase-Hippo tumor suppressor pathway to restrain Rho GTPase activity and 
inhibit activity of YAP/TAZ cell proliferation transcription factors (Varzavand et al., 
2016). The reduction in 3 integrin in promotion of aggressive disease, as also 
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shown by Ramovs et al., 2019 in the Her2 driven breast cancer, shows the 
importance of 3 integrin loss in the initiation and progression of various types of 
aggressive cancers.  
A switch to a more dynamic “quick-release” adhesion event occurs through the 
interaction of the 6 integrin and uPA which generates a tumor specific post 
translational modification (PTM) producing a variant of α6β1 called α6pβ1, lacking 
the laminin binding domain. The variant is produced on the tumor cell surface by 
PTM (cleavage) action of the uPA. The interaction is postulated to be a result of 
redistribution of 6 integrin to uPAR due to the loss of 3 integrin. The uPAR was 
shown to preferentially complex with 3 integrin in previous studies (Wei et al., 
2001). The uPAR was also shown to be increased in aggressive tumors, including 
prostate cancer (Miyake et al., 1999; Usher et al., 2005). Thus, the loss of 3 integrin 
not only increases 6 integrin surface expression (Das et al., 2017) but is postulated 
to result in increased interaction of 6 integrin with uPAR and increased production 
of the tumor variant in aggressive tumors. uPA is initially secreted in zymogen form 
(pro-uPA) that binds to uPAR and is then cleaved by plasminogen to its active 
single chain form. This interaction results in increased production of the 6p 
integrin variant due to uPA cleavage culminating into aggressive prostate cancer 
(Figure 3.1). This mechanism is responsible for the permissive migration within 
the ECM and within and around the laminin rich peripheral nerves. This has also 
been reported in the promotion of HER-2 driven breast cancer in vivo (Ramovs et 
al., 2019). 
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Figure 3.1. uPAR regulates cleavage of 6 integrin to 6p. Schematic representation of posttranslational 
modification of integrin 6 by proteolytic activity of uPA bound to uPAR. 
In addition to association of 6 integrin with uPAR (Wei et al., 2001; Kacsinta et al., 
2014), it has been reported that 6 integrin complexes with E-cadherin in 
metastatic liver disease (Marchio et al., 2012). E-cadherin and integrin crosstalk is 
a crucial factor in invasion and metastasis in various types of cancers (Marchio et 
al., 2012; Canel et al., 2013; Weber et al., 2011; Mui et al., 2016). This cross talk 
between integrins and E-cadherin mediates the dynamic interplay that contributes 
to the plasticity of tumor cells in response to environmental cues and allows 
effective migration (Canel et al., 2013). This plasticity is necessary for intact and 
functional cell-cell adhesion of these tumors to migrate through the muscle. Some 
of the reported modes of tumor migration are single cell, chords, sheets and as a 
cohesive collective. Collective migration of cohesive cells is a mechanism that is 
utilized in developmental events and embryogenesis (Llense and Martin-Blanco., 
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2008; Friedl and Gilmour., 2009).  E-cadherin and 6 are co-distributed 
intermittently within these cohesive tumor collectives. The expression of this 
complex is found on the lateral cell-cell associations within the migrating tumor 
clusters and is believed that integrin signaling may have a significant role in the 
destabilization of E-cadherin-mediated adhesion complexes (Giehl and Menke., 
2008). This loosening of the adhesive cell-cell association is sufficient to permit 
collective migration and invasion (Canel et al., 2013).  In prostate cancer, a major 
sign of disease progression is capsular escape of these groups via PNI or 
Endoneural invasion (ENI) (Figure 3.2). These cohesive groups surround the 
nerve (PNI) or invade into nerves (Harryman et al., 2016). Once these cohesive 
tumors have escaped via the nerves, this is called extracapsular extension (ECE).  
ECE, is associated with an increased risk of biochemical recurrence, distant metastases 
and lower prostate cancer-specific survival (Fleshner et al., 2016; Grignon et al., 2018).  
Since migration, invasion and colonization of distant tissues is likely to depend 
upon integrins as stated by Goel et al., 2008 (reviewed in Fornaro et al., 2001 and 
Felding-Habermann., 2003), mitigating aberrant integrin functionality may be 
critical for inhibiting extracapsular escape. 
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Figure 3.2. Aggressive prostate tumors invade within peripheral nerves. H&E image of FFPE human 
prostate tissue perineural invasion (PNI) of cohesive cancer cell cluster (Ca) invading in and nerves (N, 
annotated dashed lines) and nerve tissue containing vessels (V). [Magnification image 40x] 
RESULTS 
IHC detection of 6 integrin and uPAR in Human PCa tissue. The rabbit polyclonal 
antibody, anti-6 (AA6NT), recognizes the full-length 6 integrin and targets the 
laminin binding extracellular domain. This antibody also recognizes the cleaved N-
terminal fragment of the 6 remaining attached to laminin the ECM. The mouse 
monoclonal antibody (ADG3937) recognizes the receptor for urokinase 
plasminogen activator. The AA6NT was optimized at a 1:800 titration in Tris HCL 
diluent with Brij-35. The protocol for 6 integrin detection was executed with a 64-
minute heat induced epitope retrieval (HIER) at 100oC and antibody incubation 
time of 24-minutes at 36oC. This protocol resulted in the detection of the 6 integrin 
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expression in the membrane of basal cells in glands of normal prostate tissues 
(Figure 3.3, A). In contrast, the uPAR exhibited an apical cytoplasmic expression 
localized in the luminal cells of normal prostate glands (Figure 3.3, B).  The AA6NT 
also displayed membranous basal lateral expression in HGPIN lesions and primary 
tumors and membranous and/or cytoplasmic expression in higher-grade tumors in 
FFPE PCa tissues. 
 
Figure 3.3. 6 integrin and uPAR expression localization in normal prostate glands in FFPE tissue.  (A) 
IHC DAB immunostaining using anti-6 antibody demonstrates the expression of 6 integrin in basal cells of 
normal epithelial glands (black arrowhead). (B) Immunostaining with anti-uPAR antibody demonstrates the 
expression of uPAR in apical regions of luminal cells in normal gland (red arrow). [Magnification images, 40x] 
Dual Chromogen IHC of 6 integrin and uPAR reveal co-distribution: Serial 
sections were prepared from de-identified human prostate tissue samples blocks. 
H&E stained slides were prepared from the first sample slide in the series. A board 
certified pathologist evaluated the H&E stained slides for normal glandular 
structures, tumor composition and specific Gleason grades. Samples selected for 
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testing contained normal prostate glands, Gleason grade 3+3 primary tumor and 
Gleason 4+4 tumor (Figure 3.4, A). We performed a dual chromogen IHC 
immunostaining using the anti-6 and anti-uPAR specific antibodies. The normal 
prostate glands demonstrated polarized 6 integrin expression with chromogen 
detection (teal) in the basal cell layers in comparison to the apical localization of 
uPAR detected chromogen (yellow) in luminal cells, as expected (Figure 3.4, B). 
In the Gleason 3+3 sample, the loss of the basal layer (evident by the loss of 6 
integrin expression) was observed and expression of the 6 integrin associated 
with uPAR exhibited a co-associative chromogen mix (teal + yellow = green). The 
absence of the 6 integrin was observed in the Gleason 4+4 sample suggesting 
the laminin binding domain was not available for antibody detection. However, the 
uPAR expression remained evident. This may suggest the cleavage product (6p) 
could be the prevalent form in aggressive high-grade tumors which may account 
for the invasive potential. 
An image-merge was performed to compare the amount of 6 integrin and uPAR 
co-distribution within the regions of interest (Figure 3.4, C). The merge revealed 
little to no co-distribution of 6 integrin and uPAR in normal glands but an increase 
in co-distribution was demonstrated with the image merge of the Gleason 3+3 
primary tumor region (Figure 3.4, D). This result suggests the initiation of PTM of 
the laminin binding region of the full-length 6 integrin and a phenotypic switch to 
a more mobile tumor. 
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Figure 3.4. Multiplex IHC detection of 6 integrin N-terminal domain and uPAR co-distribution in 
human prostate tissue. Columns (A-B) Depicting architecture of human prostate in FFPE. (A) H&E stained 
slides of prostate tissue stages of Normal, Gleason 3+3 (low-grade tumor) and Gleason 4+4 (high-grade 
tumor). (B) Dual chromogen IHC using anti-6 and anti-uPAR antibodies. Normal demonstrates 6 integrin 
N-terminal polarized localization in basal layer (blue) as expected and uPAR expression in luminal region 
(yellow).  Low-grade tumor   (3+3) displays loss of basal polarity of 6 integrin and intracellular localization 
demonstrating chromogen co-distribution color (green) in with association uPAR. High-grade tumor (4+4) 
exhibits loss of 6 integrin N-terminal domain expression in tumor region and retention of uPAR luminal 
expression with comparative adjacent normal gland retaining 6 integrin expression in basal region. (C) Single 
channel merged images of normal and low-grade tumor image (Panel B) depicting co-distribution of 6 integrin 
N-terminal domain and uPAR. [Scale bars, 25µm] 
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DISCUSSION 
Integrins are considered key uPAR signaling co-receptors that have an intricate 
association that is critical for normal early processes such as tissue remodeling, 
organ development and wound repair (Smith and Marshall., 2010). Integrins 
mediate cell-ECM adhesion and regulate the signaling pathways that control cell 
proliferation, differentiation and ECM remodeling (Smith and Marshall., 2010). The 
uPAR is a key regulator of coordinated ECM proteolysis, cell-ECM interactions and 
cell signaling (Smith and Marshall., 2010). In addition, uPAR regulates the activity 
of the plasminogen activation system and proteolysis of a range of components of 
the ECM (Smith and Marshall., 2010). The uPAR association with uPA activates 
the plasmin proteolytic function of the plasminogen which reciprocally activates the 
uPA-uPAR axis. This activation of plasminogen activity by bound uPA-uPAR 
facilitates pericellular proteolysis directing cellular migration through the ECM 
(Smith and Marshall., 2010). Together, 6 integrin regulation of signaling pathways 
for cell-ECM adhesion and cellular migration and uPAR regulation of ECM 
remodeling are postulated to create the condition for invasive tumor dissemination. 
During the progression from normal prostate to aggressive and invasive prostate 
tumors, the increased surface expression of 6 integrin and uPAR results in 
subsequent co-distribution (as seen in Gleason 3+3 sample in Figure 3.4, B). The 
co-distribution may result in a PTM event that produces a tumor specific variant 
(6p), as detected by loss of the N-terminal epitope of 6 integrin in higher grade 
tumor.  Previous work has shown that loss of the N-terminal epitope is the same 
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as loss of the laminin binding domain of the receptor (Davis et al., 2001; Demetriou 
et al., 2004).  Since the ligand binding domains of both the  and subunits of 
integrins are required for activation (Hynes., 2002), it is expected that the PTM 
would result in aberrant cell signaling that drives progression signifying a specific 
switch from confined primary tumor to aggressive and invasive phenotype. Utilizing 
an antibody specific for 6 integrin detection in human prostate tissues 
demonstrates 6 integrin is expressed in a uniform polarized basolateral 
expression in basal cells in normal prostate epithelia. The immunodetection of 
uPAR using a specific antibody demonstrates an apical expression within luminal 
cells in normal prostate glands.  It remains to be determined if the conversion of 
low grade (indolent) to high grade (aggressive) lesions is accompanied by a 
conversion of 6 integrin (N-terminal domain):uPAR complexes to loss of the N-
terminal 6 integrin membrane signal.  Loss of the N-terminal ligand binding 
domain from the tumor cell surface is expected to mark aggressive disease since 
recent experimental systems using gene editing have shown preventing the PTM 
will prevent aggressive disease (Rubenstein et al., 2019). 
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IV. 6 integrin and E-cadherin co-distribution in early aggressive PCa 
ABSTRACT 
As the focal point of tumor cell dissemination shifts towards cohesive invasion, the 
discussion involving the role of cellular adhesions and crosstalk between integrin 
and cadherin-mediated adhesions has intensified. The current chapter 
characterizes how the co-distribution of 6 integrin and E-cadherin is involved with 
early PCa progression and how their association shows potential for indication of 
tumor stage. Individual IHC DAB assays were developed to investigate protein 
distribution and modulation in prostate progression. In FFPE prostate tissues 
containing various stages of prostate cancers, IHC assay showed localization of 
6 integrin lateral (cell-cell) and intracellular (cytoplasmic) expression within tumor 
regions and demonstrated co-distributive expression with E-cadherin. Deletion of 
3 integrin in aggressive tumor model resulted in downregulation of the E-cadherin 
protein, which correlated with low membrane expression of tumor cells. In addition, 
the deletion of 3 integrin resulted in production of the tumor specific variant 6p, 
as expected, indicating a role of PTM in 6 integrin expression with the loss of 3 
integrin. The inhibition of 6 integrin PTM resulted in a 1.8-fold increase in E-
cadherin protein density in tumor cells, in conjunction with inhibiting production of 
6p.  
These results indicate that coordination between 3 and 6 integrin expression 
exists and that deletion of 3 integrin, in aggressive tumor model, correlates with 
6p production. Reduction in 3 integrin protein expression in a migratory tumor 
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phenotype model also identified a role the reduction of E-cadherin plays in tumor 
progression. A co-distribution of 6 integrin and E-cadherin was also observed in 
aggressive FFPE tumors in tissue with IHC detection. A coordination between 6 
integrin and E-cadherin was demonstrated by upregulation of E-cadherin protein 
during 6 integrin PTM inhibition in an aggressive tumor model. This upregulation 
of E-cadherin increased tumor cell-cell adhesive clustering and may decrease 
migratory potential. A loss in E-cadherin can promote invasive and metastatic 
behavior in epithelial tumors (Birchmeier and Behrens., 1994). These data suggest 
phenotype switch to non-migratory phenotype via E-cadherin positive pathway 
activation.  
  
INTRODUCTION 
Early prostate tumor progression from confined to an invasive tumor phenotype 
employs dynamic cell-cell and cell-ECM interactions for migration through the 
surrounding environment and for dissemination to distant tissue environments. 
This is associated with a coordinated modulation of E-cadherin mediated cell-cell 
adherens junctions and integrin-mediated focal adhesions that are in contact with 
the ECM (Canel et al., 2013). 
E-cadherin is a calcium dependent transmembrane glycoprotein that is a crucial 
component of the adherens junctions, which is a structure that is necessary for the 
adhesive interactions of adjacent cells and the stability of the epithelium (Cousin 
et al., 2017). The extracellular domain of E-cadherin (and all cadherins) is 
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important for cell-cell adhesion due to a conserved tryptophan residue (Trp2) in 
the extracellular domain that forms a side chain that docks to a hydrophobic pocket 
in the extracellular domain of the partner cadherin (Huang et al., 2016). The 
extracellular domain contains five 100 amino acid sequence tandem repeats (E1-
E5) with Ca2+ binding domains between the repeats. The adhesive activity is 
retained in the biggest part of the N-terminal of the repeats (Pecina-Slaus., 2003). 
The extracellular domains form homodimers with parallel domains that interdigitate 
with the dimers of a neighboring cell to form points of adhesion and stabilize the 
cell-cell adherens junction (Pecina-Slaus., 2003). 
E-cadherin is linked to the actin cytoskeleton through a series of cytoplasmic 
adaptor proteins (Itoh et al., 1997., Ghadimi et al., 1999; Turner et al., 2009; Hwang 
et al., 2012). The most notable of these cytosolic adaptor proteins are β-catenin 
and p120-catenin, which link the E-cadherin to the actin cytoskeleton through -
catenin (Canel et al., 2013). It is reported that the β-catenin acts to chauffer a newly 
synthesized E-cadherin to the plasma membrane and remains in complex while 
the p120-catenin stabilizes the complex at the membrane (Chen et al., 1999; Ireton 
et al., 2002; Canel et al., 2013). The E-cadherin cell surface levels are controlled 
by the regulation of cadherin trafficking (Davis et al., 2003; D’Souza-Schorey., 
2005; Canel et al., 2013).  
Several studies have stated that the decrease of E-cadherin cell surface 
expression (or altered localization) in advanced high-grade tumors may be linked 
to higher incidence of metastasis and tumor recurrence (Birchmeier and Berhens., 
1994; Berx and van Roy.,2009; Canel et al., 2013). It is also noted that E-cadherin 
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and β-catenin remain expressed in lower grade PCa adenocarcinomas that result 
in survival advantage of the tumor cells (Nagle and Cress., 2011). But E-cadherin 
may also exhibit suppression of tumor invasion because it may decrease the 
cellular motility rate by polarizing the direction of cell migration (Nagle and Cress., 
2011). Overall, these studies indicate that the most common cause of the reduction 
of E-cadherin surface expression is the transcriptional silencing by the 
hypermethylation of its promotor or upregulation of the zinc finger family 
transcriptional repressors SNAIL, SLUG, SIP1 and ZEB1, which target the E-
cadherin promoter region (Berx and van Roy., 2009; Canel et al., 2013) and alter 
4 integrin expression (Drake et al., 2010). Histone deacetylation has also been 
suggested as a negative regulator of E-cadherin expression (Mareel and Leroy., 
2003; Giehl and Menke., 2008). This reduction of E-cadherin surface expression 
and the “weakening” of the cell-cell adhesion is a crucial step in epithelial-
mesenchymal transition (EMT) process (Kalluri and Weinberg.2009; Canal et al 
2013). However; this reduction in membrane expression may simply be associated 
with the increased rate of cycling of the protein from the surface to the cytoplasm 
and back to the surface as a result of the plasticity in collective tumor migration. In 
fact, previous studies observed that reduction in E-cadherin did not cause 
dissociation of cellular clusters in Xenopus cranial neural crest cells (Huang et al., 
2016). 
E-cadherin and 6 integrin crosstalk in prostate cancer. Multiple studies showed 
the evidence of integrin and E-cadherin crosstalk in cellular adhesion, migration 
and contraction (Yano et al., 2004; de Rooij et al., 2005; Martinez-Rico et al., 
58 
 
2010).  The crosstalk between the 6 integrin and E-cadherin occurs during the 
lateral cell-cell associations in which lateral expression of 6 integrin primarily 
occurs during tissue remodeling events, such as wound healing or early embryonic 
events of organ formation involving tubulogenesis, or during the progression of 
tumors. This 6 integrin lateral association occurs with the attenuation of basal 
cells. The objective was to determine if the loss of 3 integrin would modulate 6 
integrin and E-cadherin co-distribution. To test this, anti-6 (AA6NT), anti-3 
antibody formulations in addition to a ready to use E-cadherin commercial product 
(RTD) with subsequent dilution titers were immunostained on FFPE tissues. 
CRISPR Cas9 DU145 cell lines (WT, 3KO, 6KO, 6AA) were tested with anti-6 
and E-cadherin in western blot analysis and cell line pellets were immunostained 
with anti-E-cadherin for membrane surface expression. 
The initial titrations of E-cadherin antibody were prepared by opening a ready to 
use product dispenser (0.314µg/mL) and transferring calculated amounts from the 
standard dispenser into user fillable dispensers containing calculated volume of 
RTD proprietary Avidin antibody diluent containing a B5 blocker at 1:2 and 1:4 
dilutions. The 0.314µg/mL solution was considered the baseline for E-cadherin 
immunostaining intensity and the anti-6 antibody (or AA6NT) and anti-3 
antibody (CD49c) were tested on sequential sample slides as comparators for 
protein expression. The expression of both the 6 and 3 integrin is polarized in 
the basal layer in non-neoplastic tissue while the 6 expression will transition to 
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less polarized expression in HGPIN and upregulated primary adenocarcinomas 
while 3 integrin will exhibit downregulation of expression (Goel et al., 2008). 
RESULTS 
The immunostaining procedures executed on VENTANA Benchmark ULTRA 
instrument using protocols optimized for VENTANA OptiView and ultraView IHC 
DAB Detection Kits resulted in high intensity for E-cadherin. The results for the 
initial dilutions proved to be inconclusive as the 1:2 and 1:4 dilutions proved to 
demonstrate comparable immunostaining intensity to the 0.314µg/mL 
concentration with little to no visible drop in intensity (Figure 4.1, A). This result 
prompted an increase in titer range to identify a specific extreme in which to 
determine a threshold. The next range of titers therefore were 1:100 and 1:500 
titers. The previous experimental procedures were repeated utilizing the same de-
identified sample tissues (n=4). The results of the 1:100 titer concentration 
demonstrated only a diffuse blush within the tissue while the 1:500 titer 
demonstrated a completely negative result (Figure 4.2, B). Immunostaining 
intensities were plotted in Figure 4.1, C. These results suggested that the optimal 
titer that would demonstrate any substantial information concerning the E-cadherin 
membrane of cytoplasmic distribution would not be beyond the 1:100 titer from the 
0.314µg/mL concentration. 
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Figure 4.1. E-cadherin IHC expression in prostate with titration. Images are 20x magnification. E-cadherin 
expression was observed for decrease in saturated immunostaining intensity. (A) 0.314µg/mL concentration 
expression was compared to a 1:2 and 1:4 dilution titer. (B) Dilution titers of 1:100 and 1:500 demonstrated 
decrease in immunostaining intensity. (C) Immunostain intensities scores analyzed using one-way ANOVA 
GraphPad analysis (n=4). 
This prompted the investigation of dilutions of 1:10 and 1:50 to determine if the 
range was sufficient for visible immunostaining intensity. The process was 
repeated utilizing the same tissue samples and the results indicated the 1:10 
dilution formulation titrated from the ready to use dispenser to be the appropriate 
dilution to visualize differential expression localization of E-cadherin in PCa tissues 
containing aggressive tumors compared to HGPIN and normal glands. The 1:10 
dilution of anti-E-cadherin demonstrated an observable membrane localization in 
normal glands (Figure 4.2, A) and exhibited primarily peripheral membranous 
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intensity and membranous and cytoplasmic localization in a tissue sections 
containing cribriform lesion (Figure 4.2, B). This data would support the findings 
of previous studies reporting a reduction in E-cadherin staining within aggressive 
migrating collective tumors (Bronsert et al., 2014). This would indicate plasticity of 
lateral E-cadherin localization and redistribution within aggressive migrating 
collective tumors and may be an indication of poor outcome and disease 
advancement. This will also suggest that studies reporting the dependence on β1 
integrin function for invasive migratory collective tumors were correct in their 
assumption (Hergerfedlt et al, 2002). 
The comparative sample immunostained with the anti-6 antibody exhibited the 
expected basal expression within normal glands (Figure 4.2, C) and a pattern of 
localization in the cribriform lesion similar to E-cadherin with peripheral intracellular 
membrane expression and centrally cytoplasmic expression in the within the same 
sample on sequentially cut slides. This similar expression pattern may indicate a 
complex association of the 6 integrin with the E-cadherin and potentially the 
presence of the 6p tumor specific variant within focal areas of low membrane 
expression of 6 integrin (Figure 4.2, D). The study by Bronsert et al., 2014 using 
3D melanoma explant demonstrated that budding cell clusters exhibited 
decreased membranous staining and a shift to cytoplasmic staining of E-cadherin. 
Several studies targeting Xenopus Cranial Neural Crest (CNC) migration have 
suggested that while the downregulation of E-cadherin is necessary for the 
formation and migration action of the CNC, that some E-cadherin presence is also 
necessary of migration (Schafer et al., 2014; Cousin et al., 2017). The CNC is a 
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population of early embryogenic cells that require cadherin mediate cell-cell 
contact to migrate collectively to form the head of the Xenopus embryo. 
 
Figure 4.2. Optimized detection of cell-cell distribution of E cadherin and 6 integrin in prostate normal 
and cancerous tissue. Images captured are 20x magnification. Two different prostate tissue sections are 
captured, one with normal glands and one with prostate tumor. (A) Human prostate FFPE sample with 
prominent E-cadherin membrane expression with 1:10 antibody dilution in normal prostate gland. (B) E-
cadherin cell-cell distribution and membrane staining pattern (black arrows) in PCa aggressive cribriform 
lesion (Gleason Score 4+4) and cytoplasmic localization in central regions (red arrowhead). (C) 6 Integrin 
expressed in expected basal and suprabasal pattern in normal prostate gland. (D) 6 Integrin demonstrates 
peripheral membrane associated pattern, Black arrows and central cytoplasmic localization similar to E-
cadherin in cribriform lesion. 
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Inhibition of 6 integrin cleavage by 6AAincreases E-cadherin protein expression: 
Here, the important task was to further interrogate the findings of the anti-E-
cadherin antibody titration testing. The goal was to determine if loss of 3 integrin 
surface expression would alter the 6 integrin and E-cadherin distribution.  
Previous work in experimental models had shown that depletion of α3 integrin 
expression resulted in redistribution of α6 integrin to an observed cell-cell staining 
pattern that is consistent with a suprabasal distribution observed in epidermis and 
early PIN lesions in PCa and a two-fold rate increase in internalization (Das et al., 
2017). Since others had observed a cross-talk of 6 integrin and E-cadherin 
function (reviewed in Canel et al., 2013), we performed a protein expression 
analysis with the anti-E-cadherin antibody at a 1:10 dilution with DU145 CRISPR 
Cas9 cell lines. The cell lines tested were DU145 wild type, DU145 3KO, DU145 
6KO, and DU145 6AA. Western blot analysis revealed samples with the deletion 
of the 3 gene resulted in > 2-fold reduction from the DU145 WT in the protein 
expression of E-cadherin (Figure 4.3). These data are consistent with the view 
that loss of the 3 integrin surface expression correlates with a progression toward 
the loss of E-cadherin expression.  In contrast, blocking the PTM function of the 
6 integrin (DU145AA cells) significantly increased E-cadherin expression.  These 
data are consistent with previous observations that blocking the PTM function of 
the 6 integrin will block bone metastasis progression (Ports et al., 2009; 
Landowski et al., 2014) and more recently, the muscle invasion of prostate cancer 
cells (Rubenstein et al., 2019). An 6 integrin protein assessment was also 
accomplished using the AA6NT antibody with these cell lines demonstrating the 
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deletion of 3 integrin promotes 6 integrin cleavage to 6p.  As expected, the 
6AA mutant was unable to be cleaved and only expressed the full length 6 
integrin (Figure 4.4). The increased expression of E-cadherin support our findings 
(Rubenstein et al.,2019) in which gene editing of the 6 extracellular region to 
eliminate the PTM function will generate a new biophysical phenotype of increased 
cell-cell adhesive clusters and reduced invasiveness. This may be the result of 
activation of an unknown pathway initiated by the dominant activity of the 
uncleavable full length 6 integrin.  The dramatic phenotype switch and E-cadherin 
expression suggest a major point of regulation dictated by the 6 integrin 
ectodomain.  It remains to be determined which specific integrin signal 
transduction pathways are responsible. 
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Figure 4.3. E-cadherin expression in DU145 CRISPR Cas9 prostate cancer cells. Western blot total 
protein analysis of cell lysates with anti-E-cadherin antibody at 1:10 dilution and relative expression of E-
cadherin was quantified exhibiting downregulation with 3KO and significant increase with 6AA cleavage 
inhibition. Slight recovery of E-cadherin expression observed with 6KO. 
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Figure 4.4. 6 integrin expression in DU145 CRISPR Cas9 prostate cancer cells. Western Blot total 
protein analysis of DU145 cell lysates with anti-6 (AA6NT) antibody revealed production of 6 integrin 
cleavage product in 3KO cells and inhibition of the cleavage product with 6AA. 
6AA increases E-cadherin membrane expression and cohesive tumor cell 
clustering: The objective was to determine if the increased total protein expression 
that was demonstrated in the western blot analysis because of the 6AA gene 
editing would correlate to increased tumor cell membrane expression and 
upregulated cell-cell adhesiveness in tumor cells. The observations showing 
increased E-cadherin protein expression could have potentially been the result of 
the inhibition of protein degradation pathways which could have also accounted 
for upregulated presence of E-cadherin protein. Therefore, we investigated E-
cadherin membrane expression in the matching DU145 cells. We theorized the 
6AA induced a phenotypic switch that activated unknown signaling factors that 
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promoted E-cadherin recycling to the membrane surface for stronger adherens 
junctions and tighter cell-cell associations. 
To perform this testing, single slides containing DU145 cell pellets for WT, 3KO, 
6KO, and 6AA that had been paraffin embedded and serially sectioned were 
immunostained with anti-E-cadherin.  As expected, the DU145 WT exhibited 
variable E-cadherin cell surface expression but did not appear to demonstrate 
increased cell-cell adhesion as a result of the protein expression (Figure 4.5, A). 
The DU145 3KO cells exhibited a complete lack of E-cadherin membrane 
expression, using an ultra-sensitive detection system, as mentioned earlier. This 
is significant since the western blot only detected a decrease in total protein 
expression. (Figure 4.5, B). The DU145 6KO exhibited variable E-cadherin 
membrane expression that induced some cell-cell adhesion but did not display a 
significant amount of cells forming adhesive clusters (Figure 4.5, C). This may 
indicate a potential E-cadherin association with 3 integrin, or other cell surface 
receptors such as tetraspanin CD151 at lateral cell surface (Chattopdahyay et al., 
2003). Although the role of 3 integrin has been defined in cell-ECM focal 
adhesions, results from work characterizing the PTPµ (transmembrane protein 
tyrosine phosphatase) gene expression in cadherin-mediated adhesion, suggests 
a distinct pool of 3 integrin locates to the lateral membrane in complex with 
CD151. This complex can associate with proteins of cell-cell adhesion complex 
including E-cadherin (Fitter et al., 1999; Yanez-Mo et al., 2001; Chattopdahyay et 
al., 2003). Still, it did not appear the DU145 6KO were able to facilitate a significant 
increase in cell-cell adhesive aggregates (clusters). However, as expected, the 
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DU145 cells with 6AA inhibition of the cleavage event resulted in significant 
increase in E-cadherin membrane expression (Figure 4.5, D). The tumor cells also 
demonstrated a dramatic increase in cell clusters, creating pockets of cells that 
appeared to exhibit a tight adherence to neighboring cells. Also observed, were 
spaces in between the cell clusters that further suggested increased adhesion. 
 
Figure 4.5. E-cadherin membrane expression increased with inhibition of 6 cleavage. DU145 cell 
pellets for WT, 3KO, 6KO, and 6AA cells were paraffin embedded IHC immunostained with anti-E-cadherin. 
(A) DU145 WT exhibited variable membrane expression (green arrow). (B) E-cadherin surface expression 
was relatively absent in DU145 3KO cell pellets. (C) DU145 6KO cell pellets demonstrated focal membrane 
expression (red arrows). (D) DU145 6AA cell pellets show significant membrane localization of E-cadherin 
(black arrows) and increased tumor cell clusters with increased spacing between the cell clusters (*) indicating 
tight adhesions. Images are 40x magnification. 
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Proximal detection of 6 integrin and E-cadherin in PCa prostate tissue: To test 
the theory that 6 integrin and E-cadherin were truly complexed in tissues as 
Marchio et al., 2012 suggested, an innovative proximity detection assay (PDA) was 
employed. The PDA (from RTD) utilizes a “caged hapten” proximity readout that is 
followed by IHC detection. The PLA is described in the materials and methods 
section of this dissertation. The execution of the proximity assay was accomplished 
using three human prostate FFPE tissue samples consisting of normal and tumor 
elements. The assay was designed to detect proximal protein events with 
enzymatic biochemical conformational interactions if indeed proximal association 
occurs (Figure 4.6). In the sample with normal glands, the presence of proximal 
event was demonstrated with intense immunostaining because of the proximal 
association of 6 integrin and E-cadherin. (Figure 4.7, left panel). In contrast, the 
tissue containing aggressive PNI element, the punctate immunostaining was 
evident in focal areas (Figure 4.7, right panel). These results indicate that 6 
integrin and E-cadherin form complexes in prostate tissues that is associated with 
disease progression, confirming the findings in Marchio et al., 2012. In aggressive 
PCa, cleavage of 6 integrin occurs and the invading tumor cells utilize the tumor 
variant 6p lacking the laminin binding domain to migrate along the nerve. 
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Figure 4.6. Schematic of Caged Hapten Proximity Assay for 6 integrin and E-cadherin complex. 
Proximal events, allow conformational change of secondary conjugated quinone methide precursor (NP) due 
to interaction with enzymatic alkaline phosphatase (AP) secondary to allow deposition of tertiary with anti-NP 
horseradish peroxidase (HRP) for detection (left region) (yellow and black arrows). Lack of proximity negates 
activation and results in lack of detection (right region). 
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Figure 4.7. 6 integrin and E-cadherin form complexes in prostate tissue. Proximity ligation assay using 
antibody for laminin binding region of 6 integrin and E-cadherin. Tumor clusters (Ca) invading around nerves 
(N) via perineural invasion (PNI), demonstrate low proximity expression with punctate immunostaining (black 
arrows) indicating laminin binding region of 6 integrin are unavailable (left panel). Normal prostate gland 
demonstrates intense immunostaining (black arrowhead), indicating proximal complexes of 6 integrin and E-
cadherin (right panel). [Images 10x magnification].  
DISCUSSION 
Tumor cells invading as a cohesive collective utilize activation of signaling 
pathways that control cytoskeletal dynamics and turnover of cell-matrix and cell-
cell junctions (Friedl and Alexander., 2011). In doing so, the collective adopts 
various morphological strategies to invade in to surrounding areas, although it 
depends on the cell type and environment being invaded (Friedl and Alexander., 
2011).  These multicellular collective tumors move as sheets, strands, clusters or 
ducts (Friedl and Gilmore., 2009). The collective tumors can recapitulate the types 
and mechanisms utilized by normal, non-neoplastic cell processes to migrate but 
lack the physiological “stop signals” that immobilize and anchor cells that inhibit 
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mobility (Cox et al., 2001; Friedl and Alexander., 2011). During collective migration, 
the cell-matrix integrin-mediate regulation of cell-cell adherens junction molecules, 
specifically E-cadherin, contributes to the plasticity of the collective to perpetuate 
translocation through the tissue structures. It is suggested that the alterations of 
the cell-cell and cell-matrix adhesion, through signal transduction, cytoskeletal 
signaling, cellular mechanics and protease activity determine the migration mode 
(Friedl and Wolf., 2010). 
The upregulation of 6 integrin in aggressive PCa has been well established. Our 
lab has previously defined the role that cleavage of 6 integrin to the variant 6p 
plays in progression to the invasive tumor phenotype (Demetriou and Cress., 2004; 
Demetriou et al., 2004; Pawar et al., 2007). Our group has also demonstrated that 
blocking the 6 integrin cleavage event could potentially offer a significant non-
toxic approach for to arrest progressive tumors in vivo (Ports et al., 2009; 
Landowski et al., 2014; Rubenstein et al., 2019). However, it was unknown what 
other mechanisms and molecular pathways affect the migratory capabilities of 
these tumors. 
Various groups have documented the deregulation of migratory suppressive E-
cadherin mediated cell-cell adhesion in many invasive tumor types. It is known that 
migratory cell clusters demonstrate plasticity through modulating E-cadherin 
membrane dynamics. In keratinocytes, β4 and 3 integrins stimulate E-cadherin 
hemophilic interactions that abrogated cellular motility (Hintermann and Quaranta., 
2004; Hintermann et al., 2005; Chartier et al., 2006; Martinez-Rico et al., 2010). 
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However, it has been determined that upstream signals through exposure to 
growth factors in ECM, such as TGFβ, EGF, FGF and Wnt, lead to activation of 
transcriptional repressors such as ZEB1, Snail, Slug and Twist that inhibit E-
cadherin transcription and thus protein translation (Yang et al., 2004; Friedl and 
Alexander., 2011). The aberrant signaling displayed in these tumor collectives 
underlie the mechanisms controlling the dynamic membrane and intercellular 
expressions of E-cadherin and drive these collective cohorts. Uncovering the 
mechanisms that mitigate the suppression of cell-cell adhesion regulated by E-
cadherin would be an attractive target for resolving tumor cohesive migration. 
In our results, the increased E-cadherin cell surface protein expression on the 
DU145 6AA cells was an intriguing surprise since the expected outcome was to 
phenocopy the DU145 6KO phenotype. The result indicated a potential activation 
of undetermined signaling pathways or a gain of function that initiated a cellular 
phenotypic switch phenotype as a result of expression of the 6AA uncleavable full 
length integrin. This gain of function activity may be due to induction of several 
endogenous kinases or molecular transcription factors responding to an 
unspecified transduction of integrin signaling initiated by the activation of the full-
length 6 integrin. It was previously determined by our lab that the 6AA functional 
cleavage inhibition of the 6 integrin to the tumor specific variant 6p form 
mitigating invasive chords to cohesive clusters was a reproducible outcome 
(Rubenstein et al., 2019). However, it had not been determined to an extent what 
other specific protein pathways had been surreptitiously involved. These data 
indicate that not only inhibiting the 6 integrin cleavage by uPAR can be a target 
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for impeding migratory tumors that have invaded but also that it may result in a 
phenotypic tumor switch to indolent disease.  
The results of the proximity detection assay supports the complexing of 6 integrin 
and E-cadherin role in normal prostate tissues similar to results of Marchio et al., 
2012. The result in aggressive PNI indicating only low intensity and punctate 
immunostaining would suggest increased PTM of the full-length 6 integrin to the 
6p tumor variant. This could mean the tumor variant may be constitutively 
activated to regulate E-cadherin cell-cell expression to create the plasticity 
necessary for tumor navigation through the ECM environment and along the 
nerves for dissemination. 
The next task would be to investigate what other critical factors and mechanisms 
are being activated to upregulate this cellular adhesive potential. The pathways 
and factors such as Twist activated in tumors are known antagonists of E-cadherin 
expression (Giehl and Menke., 2008; Schafer et al., 2014). These factors allow 
dissemination in most cancers and targeted therapies have been developed to 
mitigate their activity. Understanding the factors upregulating E-cadherin 
membrane expression in concert with 6 integrin cleavage inhibition leaves an 
attractive target for companion therapy that may increase the effectiveness. 
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V. Multiplex IHC detection of 6, 3 integrins and E-cadherin localization in 
PCa progression 
ABSTRACT 
The detection of protein molecules that are involved in directing specialized 
adhesions in cancer progression leading to dissemination is vital to being able to 
elucidate and target the mechanisms regulated by their co-distribution in 
aggressive transition. The development and optimization of a multiplex chromogen 
IHC detection assay interrogating the protein expression levels identified 
localization patterns of 3 integrin, 6 integrin and E-cadherin. Here, the primary 
antibodies targeting 6 integrin, E-cadherin and 3 integrin are used in a three-
color multiplex IHC panel (3-Plex) that was integral in determination of patterns on 
one sample slide associated with early disease transition in tissues. Interestingly, 
tissue regions of early progression demonstrating loss of 3 integrin, displayed co-
distribution of 6 integrin and E-cadherin. This observation, in theory, may show 
cellular response to physical stress in the attempt to maintain homeostasis and 
cell-cell and cell-ECM adherence. This multiplex panel allowed for a deployment 
of an innovative imaging analysis tool to design an algorithm to quantify regions of 
6/E-cadherin complexes to identify non-malignant regions from malignant 
regions.  In addition, this innovative assay shows capability to assess the required 
uniform protein expression levels of E-cadherin necessary for the formation of cell-
cell adhesive contacts and migratory inhibition. In addition, this assay also allows 
the identification of E-cadherin membrane levels associated with downregulation 
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in proliferative and invasive tumors. Overall, these results show that the multiplex 
detection of these protein associations in tissue allows identification of non-
malignant and malignant tumors. This may also identify a potential path to develop 
strategies mitigating the capability of aggressive prostate tumors to invade by 
activating factors that promote E-cadherin expression.  
INTRODUCTION 
The mechanisms that mediate progression from the early confined prostate cancer 
to invasive prostate tumors have remained elusive. The transition involves 
dynamic interplay between cell surface adhesion molecules that control cellular 
response to the sensing of cues from the surrounding tissue milieu that drive the 
biophysical functional activity.  The association of laminin binding integrins and 
cadherins involves a complex crosstalk driven by mechanosensing of signals from 
the microenvironment.  Mechanotransduction of these signals into intracellular 
action potentials likely regulate spatial localization of these receptors and may 
have an impact on focal adhesion traction forces, intracellular tension and cellular 
motility. The ability of tumor cells to interact with the microenvironment has a 
significant impact on behavior through cell-cell and cell-ECM adhesion (Giehl and 
Menke., 2008).  
The mechanisms associated with these tumor cell interactions involve complex 
activation or downregulation of molecular pathways and proteins that regulate 
phenotypic switch to aggressive types. Previous chapter (2) mentions the 
association of E-cadherin with inactivation the Rho family of GTPases (Rho, Rac 
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and Cdc42) to inhibit cellular migration. In addition, 6 integrin clustering requires 
Rho activation (Wei et al. 1997). Therefore, the co-distribution of 6 integrin and 
E-cadherin may regulate the Rho family activation. Other groups have reported 
that the stimulation of these factors result in adaptive remodeling of the actin 
cytoskeleton architecture in response to specific adhesions (Etienne-Manneville 
and Hall., 2002; Giehl and Menke., 2008; Watanabe et al., 2009; Parsons et al., 
2010; Mui et al., 2016). Whether the remodeling on the actin cytoskeleton results 
in increased lateral clustering of E-cadherin to reinforce cell-cell adhesion or 
activate de-polymerization depends on mechanical stresses applied. Liu et al., 
2010 demonstrated that cell-generated forces regulate the strength of cell-cell 
adhesions by inducing growth of the adherens junctions, similar to the findings of 
what occurs at focal adhesions (Maruthamuthu et al., 2011). Together, they 
provide quantitative data demonstrating an interdependence of cell-cell and cell-
ECM forces that regulate the mechanosensing, mechanotransduction that result 
in dynamic reorganization of these adhesions utilized in invasive cohesive tumors. 
Therefore, methods to detect and quantify regions of expression of 3 integrin in 
association with E-cadherin and 6 integrin are postulated to be important to 
distinguish between diagnosing confined or aggressive PCa. 
Educated decisions for stratifying patients for treatments traditionally have relied 
upon detecting biomarkers for targeting aggressive diseases. Primarily, those 
decisions have relied upon the detection of single biomarkers. Advances in 
multiplex immunostaining and multispectral imaging have allowed the 
simultaneous detection and analysis of multiple targets in FFPE that allow accurate 
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cell detection and spatial information (Gorris et al., 2017). This has given a 
potential advantage of assessment of potential aggressiveness of cancers in a 
single tissue slides as opposed to single biomarker labeling on sequential samples 
which may or may not retain the specific region of interest. 
Creating, optimizing and applying immunostaining detection protocols targeting 
multiple proteins in one sample is a complex task that some studies use primary 
antibodies (Abs) raised in separate species to prevent cross-reactivity (Gorris et 
al., 2017). However, procedures developed in this study utilized heated 
denaturation steps that may allow the use primary Abs of the same species. The 
use of tyramide signal amplification (TSA) is deployed to minimize limitations to 
detection with multiple markers in most cases but other biochemically designed 
amplifications such as Benzofuran haptenated secondaries can be employed. Still, 
careful optimization processes are still necessary to mitigate damage to epitope, 
tissue architecture or even primary antibody degradation due to exposure to 
multiple parameters during sequential immunostaining protocols.  
In prostate cancer progression, differential expression of the LBIs has been 
demonstrated (Chapter 1). The positive correlation between higher Gleason 
grades and pathological stage with the loss of cell surface expression of 3 integrin 
is an important finding (Schmelz et al., 2002).  However, the debate concerning 
the role of 3 integrin in cancer progression continues as some groups reporting 
data showing 3 integrin is involved in disease progression and promotion of 
migration (Zhou and Kramer., 2005; Zhou et al., 2014). In contrast, others have 
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demonstrated 3 integrin to be a negative suppressor of invasion, migration and 
malignant transformation (Owens and Watt., 2001; Varzavand et al., 2013; 
Varavand 2016). Results from our lab demonstrate the loss of 3 integrin coincides 
with increased expression of 6 integrin in these progressive PCa tumors that has 
been linked to reduced patient survival, and increased metastasis (Ports et al., 
2009). Increased expression of 6 integrin in PNI and PCa bone metastasis 
confirm that it is a significant factor for aggressive designation (Sroka et al., 2010; 
Landowski et al., 2014).  The 6 integrin cleavage results in the tumor specific 
variant that is has been demonstrated to be a key contributor to cancer metastasis 
(Demetriou and Cress., 2004; Demetriou et al., 2008; Ports et al., 2009; Kacsinta 
et al., 2014). Recently, it was indicated that 6 integrin and E-cadherin form a 
complex that interacts with hepatic angiopoietin-like 6 to promote aggressive liver 
metastasis (Marchio et al., 2012). This supports the work of several other groups 
indicating a specific cross talk involving the dynamic expression of integrin 
association with E-cadherin as an important factor in tumor progression, invasion 
and dissemination (Yano et al., 2004; Giehl and Menke., 2008; Martinez-Rico et 
al., 2010; Weber et al., 2011; Marchio et al., 2012; Canel et al., 2013; Mui et al., 
2016). 
RESULTS 
Four de-identified human prostate cancer FFPE tissue samples were selected and 
sectioned with initial slides stained with hematoxylin and eosin (H&E) for content 
assessment. A board-certified pathologist evaluated the H&E stained slides to 
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determine tissue architecture, morphology, histological elements and tumor 
content. The primary focus of this study was to evaluate the location of any 
elements of normal architecture, pre-malignant PIN lesions (carcinoma in-situ) and 
aggressive tumors with any notable elements of PNI (perineural invasion). 
Immunostaining protocols were initially developed utilizing each antibody 
individually with immunohistochemistry (IHC) detection with 3, 3’-diaminobinzidine 
(DAB) to maximize immunostaining intensity, sensitivity, specificity and to provide 
reproducibility. The serial sections were immunostained with the anti-6 antibody 
specific for the laminin binding region of 6 integrin, the HPA008572 antibody 
clone specific for the extracellular region of 3 integrin, and the anti-E-cadherin 
clone (36) for the transmembrane domain of E-cadherin to determine localization. 
Individual chromogen IHC detection: IHC of 6 integrin revealed cellular 
membrane localization in normal prostate glands exhibiting early progression and 
positive expression in endothelial cells of vessels (Figure 5.1, A, top left panel). 
Although, 6 integrin primarily displayed intracellular localizations with some 
membrane expression in tumors invading via PNI (Figure 5.1, A, bottom left 
panel). As expected, peripheral nerve and endothelial cells of vessels also 
exhibited membranous and cytoplasmic positive expression for 6 integrin (Figure 
5.1, A, bottom left panel). The anti-E-cadherin IHC immunostaining exhibited high 
level of intensity initially demonstrating membrane expression in samples with 
early progression (Figure 5.1, A, top middle panel) and in PNI (Figure 5.1, B, 
bottom middle panel). The 3 integrin was detected focally in the membrane and 
showed loss in prostate gland exhibiting early progression (Figure 5.1, A, top 
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right panel), and no expression was detected in the aggressive PNI (Figure 5.1, 
B, bottom right panel).  
 
Figure 5.1. 6 integrin, E-cadherin and 3 integrin expression in PCa and PNI. Individual chromogens 
were detected in human prostate tissue serial sections with anti-6 antibody (teal), anti-E-cadherin antibody 
(yellow) and anti-3 antibody (magenta). (A) Prostate gland demonstrating early progression. 6 integrin 
exhibiting membrane expression and positive intensity with vessel endothelial cells (top left panel). Anti-E-
cadherin demonstrating strong membrane intensity (top middle panel). Anti-3 demonstrating focal membrane 
expression (blue arrow) (top right panel). (B) Perineural invasion (PNI) with anti-6 exhibiting intracellular and 
some membrane expression in cancer (Ca) invading in and around nerves (N). Alteration in 6 integrin 
expression likely due to loss of epitope within in cancer cluster since normal structures exhibit immunostaining 
(bottom left panel). Anti-E-cadherin demonstrating expression in cancer (Ca) and lack of immunostaining in 
nerves (N) (bottom middle panel). Anti-3 showing lack of intensity in Cancer (Ca) or nerves (bottom right 
panel). [Images at 10x magnification]    
Chromogen multiplex IHC: The execution of the chromogen multiplex IHC detection 
yielded similar results as the individual chromogen IHC. The 3 integrin displayed focal 
immunostaining within the prostate gland with early progression features (Figure 5.2, A, 
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red arrowhead), while 6 integrin and E-cadherin demonstrate co-distribution within the 
transitioning area (Figure 5.2, A, black arrow). The co-distribution of 6 integrin and E-
cadherin likely indicates a response to increased stress. Similarly, the 3 integrin did not 
display signal in sample containing PNI. Although 6 integrin did show positive expression 
in nerves and vessels and minimal areas of co-distribution with E-cadherin, it was 
determined that the 1.5µg/mL anti-E-cadherin antibody was too high and saturated the 
intensity level reducing the ability to observe potential detail (Figure 5.2, B). Therefore, 
1.5µg/mL anti-E-cadherin antibody was optimized further to an optimal dilution of 1:10 
from 1.5µg/mL anti-E-cadherin antibody concentration (referenced from chapter IV).  
 
Figure 5.2. 6 integrin, 3 integrin and E-cadherin expression using chromogen multiplex IHC. Human 
prostate FFPE tissue immunostained with anti-3 antibody (magenta), anti-6 antibody (teal) and anti-E-
cadherin antibody (yellow). (A) Prostate gland with early cancer progression. Anti-3 demonstrates focal 
expression (red arrowhead). Anti-6 and anti-E-cadherin demonstrate co-distribution intensity (green) within 
the areas with early progression features (black arrows). (B) Perineural invasion (PNI). Anti-3 downregulated 
and showing lack of signal. Anti-6 showing positive expression in nerves (N) and endothelial cells of vessels 
(V) and demonstrates minimal area of co-distribution intensity (green) with E-cadherin in cancer cluster (black 
arrowhead). [Images at 10x magnification]. 
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Loss of 3 integrin correlates with aggressive prostate cancer: Serial sections of 
human prostate cancer tissue were immunostained with chromogen multiplex IHC 
using antibodies targeting 6, and 3 integrins and the optimized dilution of anti-
E-cadherin antibody. A difference in immunostaining pattern was observed in 
aggressive tumor samples compared to normal glands. In regions of normal 
architecture, membrane expression of 3 integrin, 6 integrin and E-cadherin were 
co-distributed. Areas of pre-malignant transition and areas of aggressive cancer 
demonstrated a loss of 3 integrin and E-cadherin while expressing 6 integrin 
(Figure 5.3, A).  
Single biomarker localization of 3 integrin, 6 integrins and E-cadherin 
expression with chromogen multiplex IHC: Image analysis was performed utilizing 
a hyperspectral research imager (HRI) capable of individual red green blue (RGB) 
wavelength channel selection. The research imager demonstrated the ability to 
detect individual colors within a chromogen multiplex array using darkfield unmixed 
absorbance images. The result demonstrated individual expression levels of 3 
integrin, 6 integrin and E-cadherin within co-distributed regions and within the 
tissue where only 6 integrin and E-cadherin were co-distributed (Figure 5.3, B). 
The co-distribution of 6 integrin and E-cadherin were distributed to pre-malignant 
lesions (area of transition) and tumor clusters within normal glands.  
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Figure 5.3. 6 integrin, 3 integrin and E-cadherin distribution in prostate cancer. Serial sections of 
human prostate cancer tissue were immunostained using chromogen multiplex assay (n=4). Normal gland 
within cancer area (Ca) with area of cellular transition representative of PIN (P) and cancer clusters within the 
lumen (**). (A) Brightfield image of antibody chromogen detection with anti-3 antibody (magenta), anti-6 
antibody (teal) and anti-E-cadherin (yellow). (B) Darkfield unmixed absorbance images of region of interest 
(ROI) at 10x magnification (green box) of 6 integrin (top left panel), E-cadherin (top middle panel) and 3 
integrin (top right panel). Bottom panel is magnified image of boxed section of ROI. [Magnification, 40x]. 
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6 integrin and E-cadherin co-distribution ratio correlate to aggressive status: 
Next, a quantitative analysis algorithm was developed to determine the ratio 
amounts of anti-6 and anti-E-cadherin antibody co-distribution within a specific 
ROI to determine stage of aggression. The ratio of antibody co-distribution would 
demonstrate the level in which 6 integrin and E-cadherin receptors co-distribute, 
indicating cellular cohesiveness. Each ROI was given an arbitrary designation of 
“PIN”, “high-grade” or “invasion” to categorize each. Absorbance wavelength 
channel selections, for 6 integrin and E-cadherin expression only, demonstrated 
co-distribution ratios of quantifiable pixel intensities in darkfield images (Figure 
5.4, A). Heat map conversions of pixel intensities indicated a greater than 40 
percent ratio of 6 integrin and E-cadherin in pre-malignant “PIN” region, less than 
40 percent ratio “high-grade” tumor cluster and low less than 20 percent ratio in 
the “invasive” cluster (Figure 5.4, B). In contrast, only intermittent ratios of low 
intensity were observed in the aggressive cancer areas outside the gland and were 
not analyzed. The analysis indicated a decreasing percent ratio of 6 integrin and 
E-cadherin co-distribution occurs as a result of cancer progression (Figure 5.4, C). 
Individual analysis showed that 6 integrin increases with tumor progression, 
whereas a decrease in overall E-cadherin surface expression occurs (Figure 5.4, 
D).  
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Figure 5.4. Percent ratio of 6 integrin and E-cadherin indicate stage of progression. Unmixed darkfield 
absorbance image of chromogen multiplex with channel selection for anti-6 antibody (teal) and anti-E-
cadherin antibody (red) only. (A) Image of 6 integrin and E-cadherin dual expression (co-distribution) in ROI 
with normal gland within cancer area (Ca) and annotated area representative of pre-malignant PIN transition 
(P) within normal gland, and annotated tumor clusters representative of high-grade (*) and invasive (**) within 
the gland. (B) Heat map of panel A depicting of pixel intensity of 6 integrin and E-cadherin co-distribution in 
annotated regions (see panel A) and cancer area (Ca). (C) Box chart analysis representative of 6 integrin 
and E-cadherin percent co-distribution ratios within ROIs. (D) Box chart analysis representative of individual 
and co-distributed 6 integrin and E-cadherin percentage of intensity level detected within each field of 
interest. 
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DISCUSSION 
Prostate cancer progression from a confined non-invasive cluster to aggressive 
and invasive cohesive phenotype requires dynamic regulatory modulation of cell-
matrix and cell-cell adhesion. The regulation necessary for generation of 
intracellular forces, signal transduction and transcriptional events for migration 
requires a coordinated crosstalk between integrins and E-cadherin (Canel et al., 
2013; Mui et al., 2016). This chapter identifies localization expression patterns of 
3 and 6 integrins in association with E-cadherin in tissues associated with PCa 
progression.  A multiplexed chromogenic assay was used to visualize these localization 
patterns and to develop a method to quantify protein co-distribution. 
The mechanotransduction of signals from the ECM to intracellular components 
drives the integrin-cadherin crosstalk, which organizes intracellular components 
for coordination of movement, transcriptional events, polarization and directional 
migration (Mui et al., 2016). Integrins are the cells signaling molecules and are a 
critical link between the ECM and the cytoskeleton of the cell (Barcyzk et al., 2009). 
The “outside-in” and “inside-out” signaling transduced by these receptors, in 
reaction to engagement of external and internal cues (respectively), affect the 
cellular physiology and activity. The regulation of integrin function is crucial for the 
formation of dynamic cell-matrix focal adhesive structures for cellular motility. The 
coordinated assembly and disassembly of these adhesive structures are required 
for cellular migration (Parsons et al., 2010). The crosstalk between integrins and 
E-cadherin is thought to be mediated by the physical disruption of cell-cell 
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adhesions that is driven by integrin-induced alterations in myosin contractility (de 
Rooij et al., 2005; Martinez-Rico et al., 2010).  
The cross talk that occurs between the dynamic interplay between cell-cell 
adhesion and cell-matrix adhesion signaling contributes to the plasticity of tumor 
cells allowing them to respond to external cues, driving optimal migration and 
invasion (Canel et al., 2013). Historically, this action is the process utilized in early 
embryogenesis and morphogenesis but is co-opted by invasive tumor collectives.  
Cell migration is complex due to the array of mechanochemical signaling events 
involving spatiotemporal coordination of cell-cell, cell-matrix and intracellular 
tension. Fine balance between substrate traction and intercellular adhesion 
controls tumor collective migration. One group described the crosstalk that occurs 
between cells, stating that an adherens junction proportional size increase due to 
increased endogenous stress (Liu et al., 2010; reviewed by Mui et al., 2016). It 
was also mentioned that increased traction forces from the ECM could affect cell-
cell adhesion and result in proportional increase in endogenous tension at cell-cell 
junctions (Maruthamuthu et al., 2011).   
Our results in PCa tissues utilizing multiplex chromogen IHC with antibodies for 3 
and 6 integrins along with an E-cadherin antibody corroborated these findings, 
which was demonstrated in the co-distribution of 6 integrin and E-cadherin in 
early progressive events. The loss of 3 integrin would appear to be a key event 
associated with early tumor progression. Since previous chapters have 
established that the loss of 3 integrin plays a role in production of 6 integrin 
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tumor variant and regulation of E-cadherin expression, it’s likely a factor in 
mediating crosstalk.  Loss of 3 integrin expression in pre-malignant lesions in 
PCa tissues may suggest increased endogenous stresses leading to signals 
upregulating 6 integrin and E-cadherin co-distribution and formation of tumor-
associated complexes, such as those found in Marchio et al., 2012. 
The development of a multiplex detection assay that is quantifiable for localization 
patterns of protein biomarkers relevant to tumor progression could be important 
for patients. This allows for detection utilizing one slide, which reduces the need 
for invasive patient tissue sampling. In addition, it allows interrogation of several 
targets at one time potentially to assess biophysical associations relevant to 
disease progression. Additionally, the development of an algorithm applied to the 
detection of multiplex images is beneficial in assigning numerical value to 
biological marker co-distribution and creating data sets to categorize tumor 
aggressiveness. Future research utilizing chromogen IHC (and quantitative 
algorithms) on proximity detection assays with antibodies for 6 integrin and the 
tumor specific variant 6p may provide more information to differentiating tumor 
aggressiveness. 
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VI. Cohesive collective tumor invasion in PCa 
ABSTRACT 
Prostate cancer is a unique disease that has two different phenotypes, a slow 
growing confined form (indolent), and an aggressive form involving invasive 
cohesive collectives of tumor cells. However, little is known as to which early 
mechanisms are responsible for initiating an indolent tumor to switch and become 
aggressive and disseminate. Using gene edited DU145 prostate cancer cell lines 
in mouse models, we investigated how these tumor collectives invade through the 
muscle of the diaphragm to model the environment of the ECM. We demonstrated 
the deletion of 3 integrin results in increased invasion, suggesting the removal of 
3 integrin plays a role in initiating a more efficient invasive subclass of aggressive 
tumor collective. We also showed that the deletion of 3 integrin promotes 
production of 6 integrin cleavage product 6p with altered biophysical adhesive 
properties. The perturbation of the 6 cleavage integrin, by creating an 
uncleavable product (6AA) with the substitution of arginine for alanine (R594A-
595A) using CRISPR Cas 9 gene editing, reduced tumor collective invasion 
through the muscle. Interestingly, the inability to cleave the integrin also promoted 
an increase of E-cadherin protein expression, suggesting a gain of phenotype 
switch that activates pathways to increase cell-cell adhesion. Together, these data 
suggest that loss of 3 integrin in human tumors will promote a metastatic 
phenotype of cohesive tumor collectives. These collectives utilize the 6 integrin 
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cleavage product that enhances migration, but can be inhibited by a function block 
of the 6 cleavage that in turn, increases cell-cell adhesion to block invasion. 
INTRODUCTION 
Prostate cancer is a neurotrophic disease that arises from the peripheral zone of 
the prostate gland (reviewed by Harryman et al., 2016). These cohesive tumor-cell 
clusters develop as intraepithelial neoplasia that migrate through muscle and 
escape the gland via perineural invasion for hematogenous spread to distant 
tissues (Harryman et al., 2016). The intratumoral heterogeneity of prostate cancers 
makes it extremely difficult to identify which tumors may switch and develop the 
propensity to invade as a cohesive collective. Previous chapters have shown that 
6 and 3 integrins play a critical role in progression of these invasive tumor 
clusters. Invasive prostate cancer clusters uniformly express 6 integrin, and 
laimnin-10, which is the predominant laminin form in muscle and nerve 
microenvironments (Harryman et al., 2016). The 6 integrin primarily associates 
with laimin-10, which is utilized for focal adhesions during cellular migration. 
Depletion of the 3 integrin significantly increased dissemination of cohesive tumor 
clusters to distant tissue.  
The current strategies for early stage detection and diagnosis of disease have 
improved the 5-year survival rate to ~100% and has resulted in a 40% decrease 
in mortality rates for those with localized prostate cancer. However, the 5-year 
survival rate of patients presenting with extracapsular escape remains at less than 
30% (Siegel et al., 2019). In addition, statistics show that the incidence of 
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metastatic PCa disease increased 72% between 2004 and 2013 in a sample of 
more than 700,000 men diagnosed with prostate cancer (Weiner et al., 2016; 
Harryman et al., 2016).  Therefore, in spite of improvements in detection, the 
incidence of metastatic disease remains a significant issue. The principle modes 
of tumor dissemination that have long been the focus study of researchers for 
decades are single cell and collective tumor migration. Single cell migration is the 
best studied mechanism for cell movement in vitro and contributes to in vivo 
physiological motility processes such as tissue development, immune surveillance 
and cancer invasion and metastasis (Ridley et al., 2003; Friedl and Gilmore., 
2009). However, collective cell migration is prevalent in many cancer types and is 
emerging as a major driver of embryonic development, organogenesis, tissue 
homeostasis and tumor dissemination (Friedl and Gilmore., 2009; Mishra et al., 
2019).  
Most research models suggest that metastases are seeded by single cells that 
have originated from the primary tumor, but increasing evidence is demonstrating 
that collective tumors traveling together is required for successful seeding (Chueng 
and Ewald., 2016). Collective cell migration is considered the second mode of 
cellular movement (Vaughn et al.,1966; Friedl, Hergefedlt and Tusch., 2004; Friedl 
and Gilmore., 2009). The migration of cohesive cell collectives is an event that 
occurs in early embryonic development that is necessary for development of 
complex tissues and organic systems. This early morphogenetic event is the 
hallmark of tissue remodeling and development.  It is this mechanism of the normal 
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developmental process that is co-opted by aggressive tumors and is a focus of this 
study. 
One of the most popular hypotheses of tumor cellular invasion and migration 
postulates the involvement of cellular epithelial-mesenchymal transition or EMT. 
The concept maintains single cells that are undergoing EMT detach from the 
primary tumor and disseminate to metastatic sites (Friedl and Wolf., 2010; Bronsert 
et al., 2014). According to some researchers, metastasis by EMT may primarily 
occur in epithelial carcinomas, however; this has not been observed among clinical 
pathologists studying human material (Talmadge and Filder., 2010) and 
metastasis has been proposed in prostate cancers to occur by tubulogenesis 
(Nagle and Cress., 2011). EMT is associated with the loss of E-cadherin from the 
adherens junction and involves the switch from keratin to vimentin, a mesenchymal 
filament (Hurst and Welch., 2011; Nagle and Cress., 2011). However, it is 
recognized that the reduction of E-cadherin is not uniform in carcinomas. This was 
due to findings in a study in which complete deficiency of E-cadherin was found in 
some cancers whereas only the membranous localization is lost in the 
dedifferentiated region of the invasive front of tumors (Giehl and Menke., 2008). In 
addition, some models state that when EMT inducing signals are lost, tumor cells 
may reverse the process and elicit a mesenchymal to epithelial transition (MET) 
(Chaffer et al., 2006; Hugo et al., 2007; Nagle and Cress., 2011). Invasive prostate 
cancer collectives remain epithelial and do not require the transition to an epithelial 
phenotype making it an EMT-independent event (Nagle and Cress., 2011). 
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Collective tumor migration requires integrin signaling for migration of cells while 
simultaneously cell-cell adhesion is necessary for motile cells (Yano et al., 2004). 
This cell-cell based collective adhesion is necessary for cohesive tumor invasion 
through the prostate muscle. Friedl and Gilmore have described three key hallmark 
properties of collective cell migration that are considered basics of the mechanism: 
(1) cell clusters remain physically connected and cell-cell junctions are preserved; 
(2) multicellular polarity along with cytoskeleton organization producing adhesive 
friction and protrusion of the crawling edge of the cluster while preserving cell-cell 
junctions; (3) cohesive collectives of cells modify the tissue structures of vessels 
by which they travel, clearing a pathway or by the deposition of elements of the 
basement membrane (reviewed in Friedl and Gilmore., 2009; Harryman et al., 
2016).  
These cohesive cellular units are bound together laterally by maintaining what 
Friedl and Gilmore describe as ‘supracellular properties’ fostered by the cell-cell 
protein adhesions at the adherens junctions. These properties offer the tumor 
cohesive unit the pliability to transverse the extracellular milieu with the use of 
cellular polarization, directionality and modification. Cellular cues and biochemical 
signals from the surrounding stromal environment are transduced into action 
potential that induce cell state plasticity. The cell-ECM presence of β4 and 3 
integrins supports stronger cell-cell affinity in normal cells. However, these 
receptors are downregulated in cohesive tumor collectives. This leads to increased 
expression of 6 integrin and co-distribution with E-cadherin, which involves 
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“receptor crosstalk” that modulates the cell-cell adherens junctions that allows 
migration of these cohesive collectives.  
Here the loss of 3 integrin is identified as a key event that leads to the 
development and exacerbates dissemination of PCa cohesive tumor collectives 
through muscle. This relies on increased production of the 6 integrin tumor variant 
6p and modulation of E-cadherin surface expression. Interestingly, this pinpoints 
a detectable occurrence of that may define a subclass indicating metastatic 
potential. While there are several biomarkers available to identify aggressive 
clusters that have already invaded, there has yet to be specific biomarkers 
characterized to differentiate between those that remain static and those that 
present with early invasive potential.  Detection of this early event may be critical 
to diagnose those that are at risk for invasive disease and allow objective decisions 
for appropriate therapy. 
RESULTS 
Tumor Muscle Invasion Assay: The initial objective of this research was to 
investigate the ability of the 6AA to inhibit the onset of cohesive collective tumor 
muscle invasion and to elucidate the significance the role 3 integrin loss plays in 
tumor invasion and extravasation through muscle. According to previous 
publications, tumor onset is independent of the presence of 3 integrin but 
depletion results in reduced survival and increased tumor growth and 
vascularization (Ramovs et al., 2019). Similar results were reported with a PCa 
study in Varzvand et al., 2013 in which 3 integrin was silenced in prostate 
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carcinoma cell lines.  In order to facilitate a model for collective prostate cancer 
muscle invasion, DU145 cells were utilized. A CRISPR Cas9 3 integrin gene 
deletion was performed to generate a DU145 cell line lacking 3 integrin surface 
expression. In addition, a non-cleavable 6 integrin (6AA) mutant cell line was 
generated and transfected into DU145 cells to inhibit cleavage of the 6 integrin 
at amino acid (aa) region 594A-595A (alanine residues). These cell lines were 
allowed to culture and were harvested for injection into severe combined 
immunodeficient (SCID) mice for tumor dissemination.   
SCID mouse xenograft models: To demonstrate the role that the loss of 3 integrin 
and the cleavage of 6 integrin plays in the formation of tumor colonies and 
collective tumor muscle invasion, we injected DU145 CRISPR Cas9 prostate tumor 
cultured cell lines into SCID mice. According to previous testing, DU145 cells 
introduced into male SCID mice will readily produce tumors (Rubenstein et al., 
2019). The purpose was to generate invasive tumors targeting diaphragm 
invasion. The murine diaphragm mimics the muscle stroma of the prostate, 
containing an ample vascular supply, sensory and motor nerve endings, stromal 
fibroblasts and muscle cells and contains both smooth and skeletal muscle 
features (McCandless et al., 1997; Rubenstein et al., 2019).  These mice contain 
a loss of function homozygous mutation on the PRKDC gene that results in 
absence of mature T and B lymphocytes, as well as natural killer (NK) cells, and a 
Null mutation in the allele of the IL2 gamma chain (ILR2γ) to eliminate cytokine 
signaling pathways. Therefore, these mice are severely immunocompromised and 
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unable to mount a sufficient immune response making them a prime candidate for 
model tumor invasion assays. 
Three tumor cell lines, along with a normal cell line, were selected for the study. 
The tumor cell lines were DU145 6WT, DU145 3 knockout (3KO) and the 
DU145 6AA mutant representing the non-cleavable full-length 6 integrin. Five 
mice from each were selected to represent the cell line category for observation. 
The DU145 cell cultures were administered via injection through the peritoneum. 
The time point for sample harvest was 8 weeks. However, some of the animals 
began to exhibit ascites at 5 weeks indicating distress due to tumor burden in which 
a fluid drain was accomplished and the subjects were allowed to continue to reach 
a 6-week and 8-week interval before harvest. All the cell lines demonstrated tumor 
colonies on the diaphragm surface at the end of the 8-week period. At each target 
time point, subjects from each category were sacrificed and portions of the small 
bowel were removed and placed into 50ml vials containing 10% Neutral Buffered 
Formalin (NBF) and stored for a twenty-four-hour period to allow tissue fixation. 
After removal of the small bowel sections, the subjects were placed with open 
peritoneal cavities into a container with approximately 20mls 10% NBF for twenty-
four hour to allow tissue fixation. 
After completion of the twenty-four-hour tissue fixation, the fixed diaphragm 
samples were removed from the 10% NBF and placed in laminar flow hood. The 
diaphragms samples were excised from the subjects and the superior (top) side 
was blotted with cotton tipped swabs to remove excess moisture for application of 
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India ink to demarcate superior from inferior (bottom) side of the diaphragm. 
Samples were then placed into separately labeled 50ml vials containing 70% 
ethanol (EtOH) for overnight incubation. For each subject, the 10% NBF fixed 
sections of the small bowel were removed and also placed into separately labeled 
50mL vials containing 70% EtOH for potential tumor dissemination and genomic 
testing. Images of the sample diaphragms were captured to demonstrate the 
amount of tumor burden and any potential evidence of superior side dissemination. 
Both the DU145 6WT and DU145 3KO samples were observed to exhibit high 
amount of tumor burden throughout the peritoneal cavity whereas the DU145 6AA 
mutant samples demonstrated a lower amount of burden (Figure 6.1). 
 
Figure 6.1. DU145 diaphragm tumor burden. Gross images of diaphragm sample harvest. (IP side) 
Intraperitoneal side (diaphragm side) showing tumor burden for DU145 WT, 3KO, and 6AA. (Lung side) 
(Superior side) evaluating tumor invasion through the diaphragm to the lung side. DU145 WT and DU145 3KO 
demonstrate substantial amount of tumor burden (black arrows) on IP side compared to DU145 6AA exhibiting 
minute tumor burden amount (black arrows). 
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After 70% EtOH storage, each sample tissue (small bowel and diaphragm) were 
sliced into approximately 3-4 sections (strips) and paraffin embedded for serial 
sectioning. The sample diaphragms were each placed on the side to orient the 
samples with the superior side (with India ink) in the same direction. Unstained 
FFPE serial section slides were prepared for immunostaining. The sectioned slides 
were allowed to dry in a laminar flow hood for a 24-hour period and afterwards the 
first slide of the series in each sample category was stained with hematoxylin and 
eosin (H&E). H&E stained slide images of 1x, 4x, 10x and 20x were captured to 
evaluate any tumor invasion through the diaphragm.  
The H&E stained slides demonstrated visual evidence of tumor burden for each 
category of cell line with the DU145 6WT and DU145 3KO displaying an increased 
incidence of collective tumor muscle invasion with more frequency compared to 
the DU145 6AA (Figure 6.2).  The 6-week incidence of tumor invasion sites was 
counted and the total amount was tabulated for each 4mm sample diaphragm strip 
for each test category, both diaphragm (Table 2) and small bowel (Table 3). The 
6-week sample mice tested with DU145 6WT resulted in approximately forty-nine 
invasion sites on the diaphragm strips, this totaled to be an average of 
approximately four invasion sites per section of diaphragm with the maximum 
depth of penetration exhibited at 604 units. The DU145 3KO 6-week specimens 
resulted in an approximate thirty-nine tumor invasion sites averaging 
approximately three per section of diaphragm with the maximum depth of invasion 
presenting at 363 units. In contrast, the DU145 6AA sample mutants exhibited 
only five invasion sites averaging less than one invasion site per section of 
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diaphragm with the maximum depth of penetrant muscle invasion recoded at 270 
units.  
 
Figure 6.2. Hematoxylin and eosin stained xenograft PCa tissue slides. Sample slides with collective 
tumor invasion through muscle diaphragm indicated by dotted white line. DU145 WT tissue slides 
demonstrating collective tumor invasion through each muscle diaphragm (Top row). DU145 3KO tissue slides 
demonstrating collective tumor invasion through each muscle diaphragm (middle row). DU145 6AA tissue 
slides demonstrating tumor colonies remaining on the surface of muscle diaphragm (bottom left and middle 
panel) and tumor chord invasion through muscle diaphragm (bottom right panel). [Images, 10x magnification] 
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The average number of invasion sites for each cell line was tabulated and analyzed 
for comparisons for any significant differences or parallels. The data indicates no 
significant difference in amount of tumor sites between the DU145 WT and the 
DU145 3KO, but significant difference between DU145 6AA and DU145 WT and 
DU45 3KO (Figure 6.3). Suggesting significant inhibition of invasion by the 6AA.  
The depth of tumor invasion on the H&E stained slides was measured (in µm) 
utilizing the Aperio AT2 software and analyzed with GraphPad analysis to 
determine the maximum depth per each sample type. The analysis of the 6-week 
DU145 samples indicated that a slightly significant difference existed between the 
DU145 WT and 3KO but did not indicate a significant difference in depth of 
invasion between the DU145 3 and 6 samples (Figure 6.4, A and B). However, 
this may be an artifact of the diaphragm size and shape since each diaphragm 
exhibited variable thicknesses even within each sample.  It must also be noted that 
there were fewer sites of diaphragm invasion for the 6AA, which may have also 
skewed the average. The DU145 WT 8-week specimen demonstrated 
approximately forty-five tumor invasion sites within the diaphragm sections and 
incurred a maximum depth of approximately 518 units (supplemental data, 
Figure S1). 
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Figure 6.3. Inhibition of 6 integrin cleavage reduces tumor invasion sites. (A) Average number of tumor 
invasion sites per diaphragm section charted for DU145 WT, 3, and 6 integrin xenografts. (B)  Comparison 
of invasion sites across each xenograft cell line. Statistical significance calculated for mean differential 
between each cell line as two-way ANOVA GraphPAD analysis, (n=4). 
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Loss of 3 integrin results in highly metastatic phenotype. Interestingly, at 6 weeks, 
the mice injected with the DU145 3KO tumor cells displayed the highest incidence 
of tumor dissemination to the small bowel with a total of fifteen sites compared to 
five totaled for the DU145 6WT and just one tumor incidence with mice burdened 
with DU145 6AA mutant tumors (Figure 6.4). However, visual evidence suggests 
that the tumor clusters did not invade through the muscle of the small bowel but 
only colonized on the muscle surface. Nevertheless, the tumors did exhibit 
invasion through the pancreatic space (Figure 6.5.). This was intriguing result and 
appeared similar to the results in previous experiments accomplished by other 
groups utilizing WT, 3 integrin silenced (3si), 6 integrin-silenced (6si) and 3 
and 6 integrin silenced (3/6si) GS689.Li prostate carcinoma cell lines 
inoculated via tail vein into SCID BALB-c mice (Varzavand et al., 2013).  Their 
bioluminescence imaging (BLI) results showed after 5 weeks, the tumor burden 
caused by 3si cell dissemination to the lungs appeared greater than burden 
caused by the WT. 
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Figure 6.4. Maximum depth of tumor invasion in mouse diaphragms. (A) Average of maximum tumor 
invasion depth for observed diaphragm charted for DU145 WT, 3KO, 6AA xenografts. (B) H&E stained slide 
images with maximum tumor depth measurement for DU145 WT (left panel), DU145 3KO (middle panel), and 
DU145 6AA (right panel). (C) Comparison of maximum tumor depths across each xenograft cell line. 
Statistical mean difference calculated as two-way ANOVA GraphPAD analysis, (n =3) 
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Figure 6.5. Loss of 3 integrin increases tumor dissemination to the small bowel and 6AA reduces 
dissemination. (A) Table containing number of tumor sites per observed disseminated to the small bowel. 
(B) Charted number of tumor sites to the small bowel per DU145 cell type. (C) H&E stained slide of DU145 
3KO collective tumor colonization on the small bowel infiltrating the pancreas. [Image, 10x magnification]. 
6 integrin and E-cadherin co-distribute in cohesive tumor collectives: 
Immunostaining with antibodies for 6 integrin and E-cadherin demonstrated 
specific regions in the invading tumor clusters that exhibited similar expression 
patterns for both proteins (Figure 6.6, A). However, the tumors displayed 
heterogeneity such that the biomarkers exhibited various localization patterns in 
areas of invasion. In regions indicative of migration both membrane and 
intracellular (cytoplasmic) localization of 6 integrin and E-cadherin was observed 
(Figure 6.6, B). This observation corroborates the theory of integrin and E-
cadherin crosstalk mediating tumor invasive migration through the muscle stroma. 
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Figure 6.6. DU145 3KO xenograft 6 and E-cadherin IHC expression. Xenograft serial sections were 
immunostained with IHC DAB for antibodies for 3 integrin, 6 integrin and E-cadherin. (A) Images 
demonstrating lack of 3 integrin with deletion of gene (top left panel), expression of 6 integrin in tumor 
clusters (*) invading through muscle diaphragm (dotted line) (top middle panel), and expression of E-cadherin 
in tumor clusters (*) invading through muscle diaphragm (dotted line) top right panel). [Images 10x 
magnification]. (B) Image magnification of annotated region of tumor showing heterogeneous localization with 
membrane (black arrows) and cytoplasmic (red arrows) expression of 6 integrin and E-cadherin in co-
distributed region in which 3 integrin is lost. [Magnification, 40x].  
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DISCUSSION 
Tumors invading as a cohesive collective have been observed in various types of 
aggressive cancers including prostate. Aggressive prostate cancers initiate 
invasion with the budding of clusters of cohesive cells from pre-malignant HGPIN 
lesions (as seen in chapter 2). These observations challenge the prevalent theory 
that invasion into the surrounding stromal environment primarily occurs as single 
tumor cells. We have demonstrated earlier that aberrant events leading the loss of 
β4 and 3 integrins indicate the early stages of oncogenesis. We further 
demonstrated that the absence of the 3 integrin expression increases both 
production of the tumor specific cleavage form of 6 integrin, (6p), and results in 
decreased cell surface expression of E-cadherin. 
The tumor burden with the loss of 3 integrin was comparable to the WT, but 
interestingly resulted in a 3-fold increase in collective tumor dissemination sites to 
distant tissue compared to the WT. We suggest that loss of the 3 integrin 
promotes a phenotypic switch to a subclass of tumor with a more aggressive 
migratory capability with the potential to metastasize.  This may be a direct result 
of the increase in 6p production in conjunction with the downregulation of the 
surface expression of E-cadherin, which exacerbates the pliability of the tumor 
collective through the stroma.  
The IHC detection with antibodies specific for 6 integrin and E-cadherin 
demonstrated similar regions of localization in the DU145 3KO sample diaphragm 
invasion but also exhibited areas on heterogenous expression in which the E-
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cadherin demonstrated cytoplasmic localization. The co-distribution of these 
proteins in specific regions would support previous studies that indicate an 6/E-
cadherin complex in association with aggressive tumor dissemination (Marchio et 
al., 2012). This would also suggest that 6 integrin crosstalk with E-cadherin plays 
a role in regulating the cell surface or cytoplasmic expression. 
Also as expected, the inhibition of the 6 integrin cleavage (with 6AA) proved a 
benefit with a reduction of invasive cohesive tumor collectives in almost 60% (7/12) 
of DU145 6AA sample diaphragms at the 6-week time period. Although it did not 
completely mitigate the formation of tumors, it reduced the number of invasive sites 
and dramatically inhibited cohesive dissemination to distant tissue (one site) 
compared to the DU145 WT (five sites) and DU145 3KO (fifteen sites). The most 
intriguing result observed was the increased E-cadherin total protein expression 
as a result of the cleavage inhibition by the 6AA. We demonstrated the increase 
in total protein expression corresponded to an increase in E-cadherin membrane 
localization and thus increase in tight cell-cell junctions creating cohesive clusters.  
It is possible that the abrogation of the 6 integrin cleavage induces a constitutive 
activation state in the 6 integrin that enacts signal transduction to a positive 
transcription pathway for E-cadherin upregulation. This result may indicate that a 
specific switch in phenotypic functionality may occur leading to decreased plasticity 
and therefore reduced migratory capability.  Future testing to identify the specific 
factors or pathways that are directly involved in upregulating E-cadherin will be an 
important endeavor to possibly designing therapeutics possibly targeting tumor 
clusters before they invade. 
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VII. 6 integrin correlative localization with PTEN and ERG expression 
ABSTRACT 
The phosphatase and tensin homolog (PTEN) tumor suppressor is frequently 
found mutated or deregulated in various cancers. The inhibition of the PI3K/AKT 
pathway by PTEN modulates downstream cellular signaling molecules that have 
roles in regulating the cell cycle, cell survival and invasion such as mammalian 
target of rapamycin (mTOR). Over the past decade, the loss of PTEN expression 
has been an indicator of prostate cancers associated with poor prognosis and high-
risk metastatic disease. In human prostate cancers PTEN loss is also associated 
with increased intracellular expression of 6 integrin. Recently, there has also 
been increased correlation of aggressive prostatic disease with extracapsular 
escape relating to PTEN status with the ETS-related gene (ERG) overexpression. 
This chapter investigates the potential to correlate 6 integrin membrane or 
cytoplasmic localization to PTEN/ERG positive or negative expression in 
aggressive prostate cancer. Here, we immunostained FFPE human prostate core 
needle biopsies (CNBs) with anti-HMWCK+p63 antibody to identify normal regions 
of prostate and anti-PTEN, anti-ERG and anti-6 for assessment of aggressive 
disease. We utilized an innovative image capture platform to develop a novel 
quantitative algorithm by employing the QuPATH image analysis tool to evaluate 
and quantify immunostain localization patterns to correlate with aggressiveness. 
In the CNBs tested, we establish a relationship in which a shift in 6 integrin 
localization, identified within samples evaluated for PTEN and ERG status, could 
allow categorization of tumors as aggressive or non-aggressive. 
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INTRODUCTION 
PTEN loss has been shown to be a critical pathway involved to disease 
progression in specific tumor types (Hollander et al., 2011). Multiple studies have 
concluded that PTEN loss is a major contributing event in prostate cancer 
progression. For instance, PTEN is demonstrated to be lost in 40% of metastatic 
prostate cancer (Suzuki et al., 1998, Han et al., 2009; Taylor et al., 2010), and is 
critical in progression to castration-resistant prostate cancer (CRPC) 
(Jamaspishvili et al., 2018). PTEN acts as a lipid phosphatase converting 
phosphatidylinositol 3, 4, 5-triphosphate (PtdIns 3, 4, 5 or PIP3) into 
phosphatidylinositol 4, 5-biphosphate (PIP2) regulating membrane 
phosphoinositide composition (Sun et al., 1999). This function occurs by 
antagonizing PI3K activity by dephosphorylating FAK and Shc adaptor proteins 
involved in integrin-mediated signaling. Both FAK and Shc are involved in integrin 
clustering in focal adhesions during cellular migration (Gillmore and Romer., 1996). 
In epithelial cells, E-cadherin-mediated cell-cell interaction (and possibly integrin-
mediated cell-matrix interaction) lead to PIP3 production, which involve 
downstream Rho GTPases, actin rearrangements and changes in membrane 
traffic (Gassama-Diagne et al., 2006). 
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PTEN can facilitate direct interaction with these adaptors resulting in their 
dephosphorylation suppressing downstream effectors that mitigate the cell cycle, 
apoptosis, differentiation, cellular architecture and invasion (Gu et al., 1998; 
Tamura et al., 1998; Tamura et al., 1999; Lee et al., 1999; Yamada and Araki., 2001; 
Song et al., 2012; Nagle et al., 2013; Jamasphili et al., 2018) (Figure 7.1).  In 
polarized cells, PTEN localizes to the apical membrane where the function as a 
phosphatase prevents PIP3 accumulation by converting it to PIP2 (Martin-Belmonte 
et al., 2007). By restricting PIP3 localization to the basolateral membrane, PTEN 
plays a role in regulating cellular polarity (Gassama-Diagne et al., 2006).  
 
Figure 7.1. PTEN regulates PIP3, FAK and Shc. Schematic representation of PTEN regulation of cellular 
survival, proliferation and migration through inhibition of PIP3 activation of the Akt pathway. In addition, PTEN 
phosphatase domain (red) dephosphorylates and inhibits Shc and FAK which may mediate integrin membrane 
expression modulating adhesion and migration (Adapted from Yamada and Araki., 2001). 
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The Rab11 family of small GTPases play a role in directing lipid, receptor and 
transporter traffic from endocytic vesicles to the plasma membrane (Lindsey and 
McCaffery., 2004; Campa and Hirsh., 2017).  A Rab11 family of interacting proteins 
(FIPs) contain a C2 phospholipid-binding domain that serves as a docking site to 
target phosphoinositide in the cell membrane for membrane translocation (Lindsey 
and McCaffery., 2017). In theory, the PTEN regulation of PIP3 may influence the 
trafficking 6 integrin to cell surface and thus impact the capability of tumor 
aggressiveness and mobility. Integrin trafficking to the surface promotes tumor cell 
invasion and metastasis through laminin-rich matrices (Bridgewater et al., 2012), 
and this may be mediated by PTEN and Rab11 function.   
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The TMPRSS2/ERG fusion gene (which is associated with the protein expression 
of ERG) is shown to be present in approximately 50% of PCa and promotes 
progression in vivo (Ayala et al., 2015). It is hypothesized that PCa negative for 
these gene fusions may still harbor rearrangements of other ETS family members 
(Tomilins et al., 2006).  Studies have demonstrated the TMPRSS2/ERG fusion 
gene can enhance prostate epithelial cell proliferation, motility and invasion (Wang 
et al., 2008).  Multiple proteins and pathways involved in prostate oncogenesis are 
activated in response to ERG expression including SOX2, EZH2, TGFβ, Wnt 
pathway and SOX9 (Tomlins et al., 2008; Brase et al., 2011., Wu et al., 2013; Ayala 
et al., 2015). This links ERG to pathways mediating invasive properties (Becker-
Santos et al., 2012). Interestingly, in human prostate cancer development, 
TMPRSS/ERG fusions are stated to occur in context of early lesions such as with 
the loss of single NKX3-1 and/or PTEN alleles (Tomlins et al., 2008). In theory, this 
could mean the presence of ERG in prostate cancer development, indicates 
invasive potential. 
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The presence of ERG along with PTEN expression status (positive or negative), 
has been demonstrated in various types of aggressive cancers. The 
overexpression of the ERG protein in prostate tumors is considered by some a 
hallmark of advanced disease and relates to poor prognosis (Yoshimoto et al., 
2008; King et al., 2009; Nagle et al., 2011; Leinonen et al 2013; Ayala et al., 2015). 
However, some found that ERG expression associates with prostate cancers that 
demonstrate lower stage and longer progression free survival (Petrovics et al., 
2005; Saramaki et al., 2008). Other studies measuring biochemical recurrence 
demonstrated that regardless of ERG status the patients did poorly when PTEN 
was lost (Khron et al., 2012; Lotan et al., 2016). The variability of results shown by 
different groups highlight the difficulty that the heterogeneity of aggressive PCa 
poses in determination of aggressive phenotypes.  
The heterogeneity within these tumors results in shifting phenotypes that 
contribute to diverse patterns and mechanisms (Geraschenko et al., 2019). These 
phenotypes present with variable expression of cell surface molecules that make 
it problematic to identify molecules that may be utilized as predictive biomarkers. 
This uncertainty creates an obstacle in the identification and treatment of patients 
at risk for tumors capable of invasion and metastatic dissemination. Previous 
chapters showed the ability to quantitate the 6 integrin co-distribution with uPAR 
and E-cadherin in human prostate tissues to the categorize tumors with invasive 
and aggressive potential. The hypothesis tested in this chapter is that the 
membrane and cytoplasmic localization status of 6 integrin correlates with PTEN 
and ERG expression in human prostate characterizations.  
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This chapter investigates if 6 integrin localization (membrane, cytoplasmic or 
both) correlates with PTEN and ERG expression status in prostate tumor cells and 
could be quantified with an image analysis algorithm. The combination of IHC 
along with a quantitative image analysis was used in the identification and 
stratification of aggressive PCa. The results reported here indicate the ability to 
associate the 6 integrin expression with PTEN and ERG status in human prostate 
FFPE tissue samples. 
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RESULTS 
6 integrin localizes to the membrane with PTEN loss and ERG expression: 
Human prostate cancer FFPE tissue CNBs (~435) were serial sectioned and 
immunostained with antibodies specific for PTEN, ERG, 6 integrin and HMWCK 
+ p63. H&E stained slides were prepared with the first slides of the series. The 
H&E stained slides were then evaluated by a board-certified pathologist (RBN) for 
tissue morphology, architecture, normal elements and tumor content (Figure 7.2, 
A). Serial sections of evaluated CNB samples were immunostained with the 
specified antibodies previously mentioned and assessed for positive or negative, 
Gleason grades, and localization of 6 integrin (membrane, cytoplasmic or both). 
Sample observations revealed very interesting protein localization patterns of 
expression. The first observation occurred with samples containing tumors with the 
loss of basal cells (identified by the lack of HMWCK+p63 expression) (Figure 7.2, 
B and C, lower right panel). Region of tumor with negative PTEN expression 
demonstrated ERG positive expression within the identical region of the sequential 
slide, even at the cellular level (Figure 7.2, B and C, left and right top panels). 
Secondly, PTEN negative and ERG positive cancer exhibited 6 integrin 
membrane expression in a cell-cell membranous pattern resembling a “fish net” 
(Figure 7.2, B and C, left bottom panels). Interestingly this was repeated in 
specific tumor regions in five samples demonstrating this specific pattern (PTEN 
negative and ERG positive) (supplemental data, Figure S2-S4). PTEN positive 
and ERG negative tumors demonstrated either cytoplasmic 6 integrin localization 
or a combination of cytoplasmic and membranous expression (supplemental 
117 
 
data, Figure S2-S4).   
 
Figure 7.2. PTEN, ERG, 6 integrin and HMWCK+p63 protein expression in prostate cancer. Serial 
sections of human prostate cancer CNBs were immunostained for PTEN, ERG, 6 integrin and HMWCK+p63 
(n=435). (A) H&E stained slide of FFPE prostate tissue. (B) FFPE IHC DAB detection with antibodies for 
PTEN (top left panel), ERG (top right panel), 6 integrin (left bottom panel), and HMWCK+p63 (right bottom 
panel). Regions with positive PTEN expression (green arrows) with identical region in sequential slides with 
negative ERG result (red arrows). PTEN negative tumor (**), demonstrates positive ERG expression (red 
arrowhead). The 6 Integrin in PTEN negative/ERG positive region demonstrates membrane expression 
(black arrows) (Images are 10x magnification). (C) Enlarged images of indicated immunostained regions (20x 
magnification).  
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Quantitative analysis of 6 integrin expression: To evaluate if a correlation 
between 6 integrin localization with PTEN and ERG expression status could 
determine sample category (benign, low grade or high grade), a quantitative 
machine-learning algorithm was applied to the scanned images of 6 integrin 
immunostained slides using QuPATH™ image analysis tool. The algorithm 
employed a classifier to detect cells positive or negative for DAB immunostaining. 
A set of measurements were made for each detected cell and a filter is 
incorporated that allowed selection of positive DAB immunostained cells from 
negative cells. The algorithm differentiated between cytoplasmic and membrane 
immunostaining by utilizing an arbitrary distance ratio (2µm) from the nuclei of each 
cell detected to annotate individual cells. The results ratios were obtained by 
calculating the cytoplasmic optical density (OD) mean divided by membrane OD 
mean of the 4656 positive DAB cells detected from the annotated region of interest 
(ROI) (Figure 7.3, A). The ratios were plotted on a histogram with membrane OD 
mean of 0.823 and cytoplasmic OD mean of 0.659 calculated (Figure 7.3, B).  The 
OD mean ratios plotted indicated the initial ROI tested contained a more 
membrane expression of 6 integrin. The determination of cytoplasmic vs 
membrane distribution status depended on how far the mean ratio shifts from the 
standard of one (Figure 7.3, C). 
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Figure 7.3. 6 integrin localization is quantifiable on immunostained human prostate FFPE slides. A 
scanned prostate CNB IHC DAB slide immunostained with anti-6 antibody was quantified with QuPATH 
image analysis. (A) Image of annotated prostate CNB (top panel) and magnified ROI with individual cells 
identified by algorithm (bottom panel). (B) Histogram plot of calculated ratios cytoplasmic DAB OD mean to 
membrane DAB OD mean in total cells detected in ROI. (C) Table of cells detected with positive DAB 
immunostaining in ROI and total averages OD mean of cells with cytoplasmic and membrane expression of 
6 integrin. (D) Box and whisker plot of cellular distribution in the ROI with cytoplasmic OD mean over 
membrane OD mean (dots are outliers that are more than 1.5 standard deviations from the mean). 
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6 integrin membrane and cytoplasmic staining correlates with aggressive tumors: 
After the preliminary evaluation of the algorithm on the test sample, we next 
analyzed nine prostate samples immunostained with anti-6 representing two PNI 
samples, two high-grade tumor (Gleason 3+4), three low grade (Gleason 3+3) and 
one PIN lesion. To accomplish this testing, one core from each CNB was selected 
for annotation and analysis of the entire core. The results with the two high-grade 
tumors demonstrating cytoplasmic to membrane OD mean (C/M OD mean) of 0.92 
showed a distribution shift to membranous. One sample exhibited PTEN negative 
tumor with positive ERG expression and the other with PTEN and ERG negative 
expression. The three Gleason 3+3 tumor samples demonstrated slight variability 
in PTEN and ERG expression and C/M OD mean. One tested core presented 
tumor with negative PTEN and ERG expression with C/M OD mean of 0.91. 
Another sample exhibited both PTEN and ERG positive immunostaining with C/M 
OD mean of 0.86 (rounded). The final Gleason 3+3 sample demonstrated positive 
PTEN immunostaining and had negative expression of ERG with C/M OD mean 
of 0.90. Interestingly, the samples with PNI displayed variable PTEN expression. 
One sample expressed positive PTEN and negative ERG intensity with PNI 
(Figure 7.4, A) and demonstrated a C/M OD mean of 0.91 (rounded) (Figure 7.4, 
D, left panel), while the other exhibited a lack of PTEN expression and displayed 
weak ERG positive expression (Figure 7.4, B) demonstrating a C/M OD mean of 
0.80 (Figure 7.4, D, middle panel). This result would suggest the distribution 
indicated a shift to membranous expression while showing some cytoplasmic 
expression in this sample.  The sample with PIN lesion that demonstrated positive 
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PTEN expression and negative ERG expression. (Figure 7.4, B) As expected, PIN 
sample displayed a C/M OD mean of 0.84 (Figure 7.4, C, right panel).  The 
distribution results from the PIN sample would indicate more cells exhibited 
membrane staining.   
Overall, these results suggest that 6 integrin membrane localization in aggressive 
cancers is associated with the loss or mutation of PTEN in concert with 
overexpression of ERG. Prostate cancer presenting with positive PTEN 
expression and negative ERG appears to result in cytoplasmic with some 
membrane expression of 6 integrin, whereas prostate tumors with both PTEN 
and ERG Negative expression displays 6 integrin cytoplasmic localization.   
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Figure 7.4. 6 integrin cytoplasmic and membrane IHC expression in PNI and PIN. Human prostate CNB 
serial sections were immunostained with antibodies specific for PTEN, ERG, 6 integrin for presence of tumor 
and HMWCK+p63 for normal element comparison. (A) 6 integrin exhibits cytoplasmic (*) and membrane 
expression (black arrow) in cancer cells (Ca) invading the perineurium (P and red arrow) of nerves (N) in PNI 
sample with positive PTEN and negative ERG and HMWCK+p63 expression. (B) Membrane expression of 
6 integrin (black arrow) and cytoplasmic (*) observed in PNI sample with negative PTEN and HMWCK+p63 
intensity and weak ERG expression. (C) 6 integrin demonstrates mostly membrane and some cytoplasmic 
expression in PIN lesion with positive PTEN, negative ERG and discontinuous HMWCK+p63 expression. (D) 
Histogram plots of QuPATH algorithm ratio analysis of cytoplasmic to membrane OD mean in PNI (left panel), 
(middle panel) and PIN lesion (right panel). (Images are 10x Magnification). 
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DISCUSSION 
The detection of PTEN with ERG expression status in prostate cancers has 
become an intriguing discussion in the attempt to investigate reliable biomarkers 
to identify tumors with propensity for invasion. These tumors express a high degree 
of variability in protein expression associated with aggressive potential. Although 
our understanding of the downstream effector pathways directly or indirectly 
related to PTEN function has improved, it still has not definitively led to a signature 
of invasive potential. This current chapter associates the localization of 6 integrin 
with PTEN and ERG protein expression status to identify prostate cancers with 
aggressive capacity. 
Human prostate cancers demonstrate multiple proteins that display upregulated or 
downregulated expression status, variable localization pattern within the tumor 
cells and variable co-distribution patterns, even within one tumor. Many of the 
observed prostate cancers and some PIN lesions with PTEN loss and ERG 
expression presented with an 6 integrin membranous “fish net” immunostaining 
pattern. Tumors with PTEN positive and ERG negative expression displayed 
mostly cytoplasmic but some membrane 6 integrin immunostaining. Tumors with 
both PTEN and ERG positive expression (although rare) exhibited slightly more 
membrane localization of 6 integrin. Prostate cancer demonstrating a lack of 
PTEN and ERG expression presented with mostly diffuse cytoplasmic localization.  
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Studies have shown that PTEN can inhibit cellular invasion, migration and growth 
by negatively regulating integrin function (Gu et al., 1998; Tamura et al., 1998; 
Tamura et al., 1999). Although the PTEN phosphatase function modulates 
PIP3/PI3K pathway activity and phosphoinositide composition regulating vesicular 
membrane trafficking, the activation of other kinase mediated effector proteins may 
also be able to perform this function. For instance, other groups have shown that 
PTEN negatively regulates ERK1/2 signaling (although indirectly) in prostate 
cancer (Bouali et al., 2008; Chetram et al., 2011; Chetram and Hinton., 2012). 
Studies have shown ERG as a specific target of ERK for phosphorylation and 
activation in prostate cancers (Selvaraj et al., 2015; Kedage et al., 2017). This may 
explain the specific membrane localization patterns with 6 integrin with PTEN 
loss and ERG expression. This also suggests that further investigation of non-
canonical pathways influenced by alterations in PTEN/PI3K status associated 6 
integrin regulation is critical in assessing tumor aggressiveness. 
Prostate cancer is an extremely heterogeneous type of cancer that displays an 
indolent and aggressive phenotype. During progression, these tumors exhibit 
phenotypic transitions that enhances cellular plasticity and exacerbates the 
inability to identify tumors that will acquire invasive capability. Alterations and 
mutations in specific gene and proteins have long been designated as focal points 
for initiation of oncogenesis; here the alterations in PTEN with respect ERG 
functionality have come to the forefront. 
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PTEN loss and ERG status in relevance to aggressive PCa behavior has been a 
debate for some time. The variable expression for both (or either) within PCa 
tumors is an evident display of tumor intratumoral heterogeneity. The fact that 
these tumors can exhibit varying status of these protein expressions indicates the 
potential existence of subclasses of tumor within just one primary region. Here, we 
have determined a relevance in the detection of specific 6 integrin localization in 
PCa tissues in correlation with PTEN and ERG expression status. The patterns 
displayed have indicated a potential connection with deregulation of PTEN and 
increased expression of 6 integrin. The membrane presence of 6 integrin in 
concert with PTEN negative and ERG positive expression may indicate a transition 
to an aggressive tumor subtype. Previous chapters have established the 
upregulation of 6 integrin (specifically to the cell-cell region) results in interaction 
with uPAR and PTM to the tumor specific variant form associated with invasion. In 
addition, our results demonstrate inhibition of the 6 integrin cleavage activates 
unknown pathways to upregulate E-cadherin expression and mitigate tumor cell 
migration. It will be critical to determine if inhibition of the PTM of 6 integrin will 
also activate pathways re-establishing PTEN expression in tumor with mutation of 
inactivation. 
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ABSTRACT 
The potential to reuse archived Hematoxylin and Eosin (H&E) stained slides with 
various immunostaining detection strategies present a unique opportunity for not 
only for interrogating past tissues with new biomarkers but also as an alternative 
for samples with limited tissue availability. Archived Hematoxylin and Eosin (H&E) 
stained pathology slides are routinely stored to index FFPE sample tissue blocks. 
The FFPE blocks are clinically annotated human tumor specimens that can be 
valuable in studies decades after the tissue was collected. If stored properly they 
have the potential to yield a valuable number of serial sectioned slides for 
diagnostic or research purposes. However, some retrospective studies are limited 
in scope because the tissue samples have been depleted or not enough material 
is available in stored blocks for serial sections. The goal of these studies was to 
determine if archived H&E-stained slides can be directly reutilized by optimizing 
methods to de-stain and then re-stain the H&E stained slides to allow detection of 
several biomarkers of interest using a conjugated antibody with chromogen 
multiplex immunohistochemistry procedure. This simple but innovative procedure, 
combined with image analysis techniques, demonstrates the ability to perform 
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precise detection of relevant markers correlated to disease progression in initially 
identified tumor regions in tissue. This may add clinical value in retaining H&E 
slides for further use. 
INTRODUCTION 
In immunohistochemistry several types of tissue immunostains are utilized to 
analyze morphological features, cellular structures, cell type, and presence or 
absence of microorganisms. The most popular of the staining methods for 
diagnostic potential is the utilization of hematoxylin and eosin (H&E) staining 
(Bancroft and Layton., 2013). H&E stains reveal structural information, with 
specific functional implications. H&E staining of tissue is used to assess cellular 
and morphological structures, identify type of tissue, morphological variability, cell 
type, and pathological changes. The use of H&E staining has been the most 
effective and utilized procedure for pathological diagnosis of patient neoplasia for 
over a century (Fischer et al., 2008; Chan., 2014) It has allowed pathologists to 
pinpoint focal areas of a specimen containing aggressive tissue and foster a proper 
diagnosis (Titford., 2005). Therefore, developing procedures to re-utilize these 
archived samples to determine individual biomarker expression levels (and 
potential protein-protein association) could assist in determining disease 
progression and directions for appropriate treatments. 
H&E staining is used in conjunction with a variety of tissue fixatives and allows the 
display of various cellular and tissue components including the extracellular matrix, 
the cellular cytoplasm, and the nuclear structures (Fischer et al., 2008). The 
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hematoxylin is converted into its oxidization product hematein, which is a basic dye 
that stains acidic (basophilic) tissue components (ribosomes, nuclei, and rough 
endoplasmic reticulum) a darker purple color while the acidic eosin dye stains other 
protein structures of the tissue (stroma, cytoplasm, muscle fibers) a pink color 
(Chan., 2014; Titford., 2005; Feldman and Wolfe., 2014). They are also valuable 
in distinguishing normal structural components from neoplastic regions. However, 
with current procedures, H&E staining is utilized along with sequential sections 
stained with antibody. Serial sectioning may cut through the region of intent and 
may result in loss of regions necessary for critical diagnosis. This is particularly an 
issue with smaller core needle biopsies (CNBs), that are of limited size and 
number. These samples are considered “precious” in regard to availability and 
require the utmost accuracy in testing procedures to result in proper diagnoses. 
A major advantage of a method that allows reuse of the H&E-stained slide is that 
it will alleviate the need for additional sequentially-sectioned slides, particularly 
with the diminutive CNBs. Due to the of size of CNBs, they are also subject to 
tissue sample exhaustion with loss of the diagnostic lesion. This method would 
present a major practicality when a particular region of interest is no longer 
available in the sample block due to sequential cuts. The ability to resuse the initial 
H&E containing the lesion could be critical. De-staining these H&E-stained tissue 
slides could also potentially reduce the need for re-biopsy. 
Another advantage for restaining archived H&E-stained slides is due the rapidly 
expanding use of whole-slide imaging (WSI), also known as digital pathology (DP) 
or virtual pathology. DP is a technology that involves high-speed, high-resolution 
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digital acquistion of images representing entire stained tissue sections from glass 
slides in a format that allows them to be viewed by a pathologist on a computer 
monitor (Mukhopadhyay et al., 2018). This streamlines the ability of surgical 
pathologist to make a primary diagnosis utilizing digitized images of the H&E-
stained slide, allowing digital preservation while the H&E and other stains are fresh 
(Zarella et al., 2018). As the validation of this technology becomes widespread, the 
method reported here could be used for analysis of stored H&E-stained slides for 
subsequent diagnosis of tumor subtypes within a patient sample or future 
discovery of novel target proteins. 
For our research, prostate cancer was initially chosen due to frequent limitations 
of tissue in sample biopsies and the requirement for biomarker study. PCa is also 
known to express variable levels of several markers associated with disease 
progression, such as PTEN ERG, making it a viable target for testing this 
procedure. A link between the PTEN pathway and ERG protein expression has 
previously been evaluated in previous chapters and various prostate cancer 
studies [Yoshimoto et al., 2008; Han et al., 2009; Leinonen et al., 2013; Nagle et 
al., 2013; Ayala et al., 2015; Jamaspishvili et al., 2018). In studies investigating the 
trend of PTEN loss in tumors of prostatectomies and locally recurring castrate-
resistant prostate cancers (CRCPs) with ERG overexpression, the data showed 
that the loss of PTEN was significantly associated with ERG positivity (Leinonen 
et al., 2013). Another study indicated that the combination of ERG overexpression 
and PTEN deletion is common in aggressive capsular penetrating lesions (Ports 
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et al., 2009). Therefore, we decided that using antibodies targeting PTEN and ERG 
would be the validated markers in this study. 
RESULTS 
Archived H&E stained slides from PCa resections or CNBs stored for at least one 
year (with film coverslips) were initially used to demonstrate proof that the H&Es 
could be reutilized for biomarker stain using an H&E de-staining procedure with 
standard equipment and reagents. De-identified patient tissue samples were 
provided with no link to information that can be used to identify patients. FFPE 
prostate tissue multi-array (TMA), adenocarcinoma, lung, colon, and skin tissue 
slide samples were used (Table 5). The initial antibodies chosen for the proof-of-
concept testing were ready to use products from Ventana/RTD such as anti-p40 
(B28) mouse monoclonal antibody (data not shown), anti-cytokeratin 5/14 
(CK5/14) (EP1601Y/LL002) rabbit and mouse monoclonal antibody cocktail from 
Cell Marque (Figure 8.1). In addition, the rabbit polyclonal antibody against the 
laminin-binding extracellular domain of 6 integrin (CD49f) was also tested. 
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Figure 8.1. Malignant primary prostate adenocarcinoma tissue sample. The first image shows the 
prostate tissue stained with H&E (A). The areas with tumor and normal prostate gland tissue are labeled. The 
H&E stained tissue slide was de-stained and anti-CK5/14 mouse monoclonal antibody cocktail was applied to 
determine feasibility of the proposed protocol (B). A sequential sample slide was stained with the same anti-
CK5/14 marker using a standard protocol procedure (right panel), for comparison of stain intensity to initial 
de-stain/re-stain procedure results (C). [10x magnification] 
The method described in this study utilized forty-nine sample H&E-stained 
resection and CNB slides that were analyzed and commented on by a board-
certified pathologist (Dr. Ray Nagle) for normal or neoplastic status, Gleason 
grade, preservation status, and any distinguishing features for categorization of 
potential aggressiveness (Table 4). The initial testing was accomplished using 
DAB IHC detection kits to determine retention of marker stain intensity. During the 
initial stages of this study, multiple test samples demonstrated lower intensities as 
a result of utilizing an un-optimized protocol (data not shown). However, continued 
editing and updates to the initial procedure on re-utilized H&E index slides resulted 
in viable stain intensity demonstrating the feasibility of the procedure and potential 
for optimization to culminate in stain intensity comparable to that of sequential 
slides utilizing standard procedures (Figure 8.2). 
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Figure 8.2. Sequential slides of human prostate tissue exhibiting cancer (Ca) invading into normal 
glands and high-grade prostatic intraepithelial neoplasia (HGPIN).  There is an aggressive carcinoma 
invading glandular structures that have retained normal basal cells. The retained basal cells are positive for 
HMWCK + p63 (A) [grey arrowheads], positive for PTEN (B) [black arrows], and negative for ERG (C) [green 
arrowheads]. The cancer is negative for HMWCK + p63 (A) [red arrowheads], PTEN (B) [red arrows], but 
positive for ERG (C) [black arrowheads]. [Images, 10x magnification]. 
The initial testing procedures resulted in moderate but visible stain intensity 
providing proof-of-concept. At this stage, further optimization and repeat testing 
was warranted to increase the stain intensity to comparable levels of those 
occurring using the standard antibody staining methods and to ensure 
reproducibility. The procedure methods were improved by four steps: 1. Applying 
timed reagent rinse procedures at the xylene, ethanol (EtOH), and Ventana/RTD 
proprietary reaction buffer steps (1-minute rinse times between each hold); 2. 
Increasing EtOH and reaction buffer reagent rinses from 1 rinse to 5-6 and 3-4 
manual rinses respectively for optimal efficiency; 3.  Including an approximate 5-
minute drying step after the reaction buffer rinse to limit residual excess reagent 
interference in the online application of biomarkers; and 4. Editing online cell 
conditioning steps (for heat induced antigen retrieval) to reduce potential epitope 
destruction. 
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This procedure optimization was considered the standard when applied to any 
H&E-stained slide stored up to 2 years but needed further optimization for tissues 
stored for periods 2 years or longer. The subsequent experimentation steps 
employed the use of antibodies targeting PTEN and ERG biomarkers, VENTANA 
anti-PTEN (SP218) mouse monoclonal antibody, and anti-ERG (EPR3864) rabbit 
monoclonal antibody respectively. These validated markers were used since they 
demonstrate 1. the heterogeneous variability of aggressive prostate cancer and 2. 
the comparative expression of PTEN loss and ERG expression in aggressive 
tumors. In this procedure, steps (1-8) represent the optimized H&E de-staining 
procedures. However, during the testing, unforeseen scheduling resulted in slight 
deviations (extended reagent HOLD times) in steps 4 and 7 that lead to 
determination that certain steps, which were the xylene and reaction buffer HOLD 
times, could be amended without incurring damage to samples. The updated 
procedure, which only involved an extended xylene hold time and is essentially the 
same optimized procedure, resulted in comparable stain intensity to the standard 
protocol and allowed the ability of distinct determination of aggressive tumor areas 
(Figure 8.3). After the successful completion of a sequential round of 
experimentation using IHC DAB, we tested if antibodies targeting multiple 
biomarkers could be applied for detection with the use of chromogenic detection 
reagents. Again, prostate adenocarcinoma CNBs were used as experimental 
specimens for the de-stain and re-stain procedure. The antibodies chosen were 
specific for the 6 integrin laminin-binding domain and HMWCK + p63. These 
markers were chosen due to known membranous expression levels (CD49f) and 
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cytoplasmic and nuclear (HMWCK + p63 respectively) positive expression levels 
in non-neoplastic basal cells of prostate tissue. In PCa, 6 integrin expression is 
membranous and aggressive and invasive disease exhibits an intracellular 
expression pattern (Ports etal., 2009; Sroka et al., 2010; Sroka et al., 2016; 
Harryman et al., 2016; Das et al., 2017).  It is also associated with poor patient 
prognosis, reduced survival, and increased metastasis (Friedrichs et al., 1995; 
Landowski et al., 2014; Stewart et al., 2016). These markers were not expected to 
colocalize but to demonstrate the expression pattern of both non-neoplastic and 
neoplastic structures and focal areas in tissue after marker application, following 
the de-stain procedure. 
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Figure 8.3. Prostate cancer CNBs sample H&E slides with PTEN and ERG IHC DAB stained slides. The 
first slide for each sample was H&E-stained (A) Each sample H&E was de-stained and re-stained with either 
PTEN or ERG antibody depending on the pathologist analysis for biomarker loss or positivity to demonstrate 
tumor heterogeneity (B) The additional sequential slides for each sample were stained with anti-PTEN 
antibody or anti-ERG antibody (C) Each sample H&E was de-stained and re-stained with either PTEN or ERG 
antibody depending on the pathologist analysis for biomarker loss or positivity to demonstrate tumor 
heterogeneity [10x magnification]. 
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The expected outcome was to demonstrate definitive areas of non-neoplastic vs. 
tumor regions with the application of antibodies and chromogen detection. This 
would allow the simultaneous detection of normal and aggressive structures in one 
tissue sample after pathologist analysis of the H&E-stained slide, allowing for the 
potential utilization of one slide. The results demonstrated strong stain intensities 
for both targets and well-defined areas of demarcation of non-neoplastic vs tumor 
structures. As expected, both markers are visible in normal basal cells of normal 
prostate glands (although the HMWCK + p63 stain intensity primarily masks the 
6 integrin signal in those areas), but anti-6 antibody displays an intracellular and 
cytoplasmic expression in the areas of budding tumor (Figure 4). 
 
Figure 8.4. Prostate adenocarcinoma sample CNB H&E and Chromogen IHC. The initial H&E-stained 
slide with dotted line indicating prostatic intraepithelial neoplasia (PIN) lesion and tumor area (left panel) (A) 
The de-stained H&E that was stained with HMWCK + p63 mouse monoclonal antibody cocktail and anti-CD49f 
rabbit polyclonal antibodies using Dual Chromogen detection (right panel) (B) The anti-HMWCK + p63 
antibody cocktail (purple) stains the basal cells of normal prostatic glands, and the anti-CD49f (teal) antibody 
stains normal basal cell membranes (masked by the HMWCK + p63) but demonstrates an intracellular and 
137 
 
cytoplasmic expression in aggressive tumors (area demonstrating budding tumor outlined in H&E-stained slide 
in left panel and right panel). [Images, 20x magnification with 60x instep]. 
These positive results from testing samples archived up to 2 years warranted the 
evaluation of the potential ability of this procedure to be utilized with other tissue 
types, for H&E stained slides archived 2 years or more, and samples archived 
utilizing glass coverslips. Therefore, five archived PCa CNBs (2 years 11 months), 
a normal colon (2 years 1 month), liver and lung samples (4 years) along with 4-
plus year (4+) PCa resection (4 years 11 months) H&E stained sample slides 
sealed with thin film coverslip were tested. For the testing of H&E stained slides 
sealed with glass coverslips, archived PCa CNBs (2 years 11 months), skin 
samples (5 years) and a PCa TMA sample (12 years) were tested. During the 
execution of this procedure the removal of the coverslip was determined to be a 
limiting factor therefore the parameters involved with the removal was tracked and 
recorded in this report (Table 5). After the removal of the H&E stain, the sample 
slides were re-stained with selected antibodies utilizing optimized protocols 
adapted for IHC on de-stained H&E slides (Table 6). 
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The testing of the H&E stained slide samples archived 2 years or more involved 
extended coverslip removal and reagent rinse times (2+, 4, 4+, 5, and 12-year 
archived samples) which indicated that archival time, storage condition and 
coverslip type may play a factor in slide processing with the procedure. The 
processing of 2-year archived H&E stained slides sealed with thin film (all PCa 
CNBs) only required minimal extension time of coverslip removal (to ~ 60 minutes) 
but resulted in H&E stain removal and comparable antibody immunostaining 
intensities compared to the corresponding sequential slides (Figure 8.5, A-6E). 
The reused H&E and corresponding sequential slides were evaluated by a board-
certified pathologist in a side by side comparison for immunostaining intensity 
(Table 7). The histopathologic analysis focused on any present tumor or normal 
regions for intensity. The data analysis indicates that there was a significant 
matching in the immunostaining intensities between the reused H&E stained slides 
and sequential comparator slides immunostained with the various antibodies 
(Figure 8.5, F). 
The processing of the 4 and 4+ year archived H&E stained slides (PCa resections) 
sealed with thin film coverslip required extended time of coverslip removal (~38 
and 47 hours) but resulted in H&E stain removal.  The archived H&E stained slides 
sealed with glass coverslip for 2+, 5 and 12-year (PCa resection, two skin and PCa 
TMA) required 1-2 days and 4-5 days for coverslip removal. The 4+ year archived 
sample resulted in comparable intensity (CK 8 &18) to the sequential comparator 
slide (Figure 6). The reused 12-year archived PCa TMA H&E stained slide 
immunostained with Ventana anti-ERG resulted in immunostaining but intensity 
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was variable across different cores but demonstrated feasibility (data not shown). 
The reused 5-year archived H&E stained slides (skin resections) sealed with glass 
coverslips also required extended time for coverslip removal and reagent rinses. 
The resulting H&E stain removal exhibited residual H&E stain on the slides 
resulting in incomplete immunostaining (ERG) (data not shown). The resulting 
retention of the hematoxylin and eosin on the slides may have potentially impacted 
the results and will need further inquiry on storage conditions to ascertain steps to 
mitigate any issue. We have found that storage conditions of older H&E stained 
slides (particularly with glass coverslips) causes extensive adhesion of the 
coverslip to the tissue slide due to the extended time in storage, requiring a slight 
extension of extraction procedures. Also, we observed that pre-analytics will 
impact H&E removal resulting in some residual retention. Unfortunately, due to age 
of the slide, pre-analytical data was not available. 
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Figure 8.5. H&E stained slide image and reused H&E slide selected antibody immunostain comparison 
with sequential slides in PCa CNBs. (A through 6E). H&E stained Slides. (A-E) Antibodies: HMWCK+p63 
(1A-5A), [Note: uneven data points for Sequential slide 5 due to lack of immunostain for HMWCK+p63]; CK 8 
&18 (1B-6B); CD49f (1C-6C); E-cadherin (1D-6D); ERG (1E-6E). Scatter plot assessment of side by side 
comparison of pathologist analysis scores and comments for sequential slide and reused H&E antibody 
immunostaining. Note: red inverted triangles represent ERG internal controls and open inverted triangles with 
black outline represent CD49f internal controls (F). Data presented as SEM with Chi square, df (18.12, 1). The 
results determined by RM one-way ANOVA matching across rows (see Table 5) showing significant matching 
with p value (<0.0001). Analysis performed using GraphPad Prism version 8.2.1. [Images 4x Magnification] 
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Figure 8.6. H&E stained slide archived 4+ years subjected to de-stain and re-stain procedure compared 
to sequential sample slide. Initial H&E stained slide containing region of tumor (A). CK 8 &18 antibody re-
stained slide retaining region of interest and exact architecture (B). Sequential slide comparison immunostain 
with CK 8 &18 exhibiting comparable stain intensity. [Images, 10x Magnification]. 
DISCUSSION 
When patients are suspected of having PCa, a tissue sample is required for 
diagnosis. The sampling of the potentially neoplastic area may be assisted through 
means of ultrasound (US) or multiparametric magnetic resonance imaging 
(mpMRI) guided techniques. Sample resections and needle biopsies are routinely 
formalin-fixed and processed and embedded for histological sampling then stained 
for H&E and IHC, allowing pathologists to analyze an excised patient tissue sample 
from the affected area after diagnosis to differentiate between cancer and non-
neoplastic events, such as benign prostatic hyperplasia. The H&E-stained slide 
plays a critical role in assisting the diagnosis of the pathologist in corroborating the 
initial findings with MRI and US procedures. Traditionally, after pathologist analysis 
and diagnosis, the samples can then be processed with biomarkers targeting 
detection of epitopes that are overexpressed in aggressive tumors. Currently this 
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is the standard procedure deployed in companion diagnostics that allows for the 
stratification of patients who may benefit from a specific therapeutic intervention. 
The accurate evaluation of biomarkers with these samples is critical for patient 
diagnosis, particularly with smaller samples, such as CNBs, fine needle aspirates, 
and potentially transurethral resection of prostate samples (TURPS). The smaller 
size of these tissue samples limits tissue availability and requires precise testing 
for important results. Loss of available tissue slides is a risk that could be mitigated 
with the use of H&E slide de-stain and re-stain procedures. The potential to detect 
multiple markers using chromogenic multiplexing on a single indexed tissue slide 
that had been analyzed and diagnosed by a pathologist to definitively contain 
aggressive tumor, leaves open the possibility of predictive companion diagnostics 
with minimal sampling. This may provide the opportunity for a one sample/one 
result diagnosis limiting the invasive nature of tissue specimen collection, which 
benefits the patient greatly. 
There are few reports that provide instructions for removal of the H&E staining that 
leaves the target epitopes intact for potential reuse of the slide for selective 
biomarkers. Current existing protocols (and forums) only discuss de-stain 
procedures for slides that have stained inadequately, or have been stained with 
excessive hematoxylin and have lengthy protocol steps that may extend the 
procedure hours to days. Others may require the use of more corrosive reagents 
(% HCL solutions). Procedures utilizing either beta-mercaptoethanol/sodium 
dodecyl sulfate (2ME/SDS),  6 guanidinium hydrochloride (GnHCL)  or 6 M Urea 
have been demonstrated to elute antibodies from immunostained tissues on 
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positively charged glass slides (or glass coverslips) for sequential antibody re-stain 
(Gendusa et al., 2014;  Bolognesi et al., 2017). However, these methods focused 
on the removal of the bound primary antibody and the reagents used were not 
indended to remove the H&E stain.  For this report, an innovative method utilizing 
non-corrosive reagents was created and applied in a particular procedure using 
these reagents in sequence that optimized the H&E slide de-stain. This procedure 
removed the majority of the visible stain while retaining tissue integrity and 
morphology and allowed preparation of specified IHC protcol to restain the sample 
sides. The primary tissue sample used for initial testing was prostate 
adenocarcinoma, however, this will translate to other tissues. 
This study utilized liver, colon, skin and PCa resections and CNB samples for 
procedure testing. The study included the addition of antibodies detecting clinically 
relevant biomarkers such as PTEN, ERG, E-cadherin, Racemase (p504s), 
cytokeratin 8 &18 and the CD49f protein for potential indication of aggressiveness 
and antibodies against HMWCK cocktailed with a p63 marker (a p53 homologue 
containing the N-terminal transactivation domain) as well as the variant p40 marker 
(lacking the N-terminal domain), that will detect the presence of normal basal cells 
of prostatic glands. These antibodies were critical in detection of differentiating 
prostatic adenocarcinomas vs detection of non-neoplastic prostatic tissue, as well 
as determination of intracellular marker activity and basal cell attenuation, 
respectively.  Also, during this study the positive outcome from testing various 
tissue samples archived beyond 4 years utilizing thin film and 12 years with glass 
coverslips yielded promising results indicating tissue epitopes remain stable on 
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H&E stained slides archived at a minimum of 4 years. This indicates that the 
procedure may be useful for interrogating other clinically relevant proteins in 
tissues other than prostate and for H&E-stained slides stored for longer periods of 
time. However, the conditions of the slide storage and the type of adhesives 
applied to seal the slide may have an impact on results. Another factor may be the 
specific antibody selected for each specific study. The antibodies used for this 
study yielded promising results but each antibody demonstrates various qualities, 
therefore continued optimization may be warranted for this procedure. 
Further experimentation will be repeated involving archived specimen slides 
utilizing film coverslips that have been stored for 4 years and more, as well as 
continued interrogation of samples sealed with glass coverslips. This will 
determine the robustness of the procedure to encompass reproducible testing of 
samples from decades past to incorporate newly discovered targets to test protein 
expression that may offer answers to questions that may have remained unsolved. 
Also, with the development of newer chromogen dyes, the possibility of utilizing 
one slide for multiple markers may now become a distinct possibility saving 
valuable time and resources. The results demonstrated in this report can be 
considered the first step towards a more extensive study incorporating much larger 
cohorts that may ultimately utilize this procedure as a viable tool in cancer 
diagnosis and treatments. 
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IX. Concluding statements and future research 
 
Prostate cancer (PCa) progression to metastatic disease involves a complex 
process of cascading steps. The first steps begin with development of 
premalignant PIN lesions with continuity gaps in basal cell layer. Next, a malignant 
cluster of tumor cells invade through continuity gaps into surrounding tissues. 
These clusters then escape via laminin-expressing peripheral nerves, migrate into 
and survive the circulatory system, enter and colonize distant tissue causing death. 
The cleavage of 6 integrin by the uPA facilitates the altered adhesive status, 
increasing the cellular rate of migration on laminin. This uPA-mediated cleavage 
of 6 integrin is regulated by the uPA receptor (uPAR) through direct co-distributive 
interaction as confirmed in previous co-immunoprecipitation experiments 
(Rubenstein et al., 2019). The co-distribution of 6 integrin with uPAR was found 
to be dependent on the expression of 3 integrin. A deletion of the 3 integrin gene 
produced increased levels of the cleavage product 6p. This result indicates the 
loss of 3 integrin is a critical event that occurs in early PCa and promotes 
progression to aggressive disease. In addition to influencing the cleavage of 6 
integrin, the loss of 3 integrin also promoted the reduced expression of the cell-
cell adhesion protein E-cadherin. The lost surface expression of E-cadherin 
reduces stable connectivity and promotes cellular plasticity. Taken in concert with 
the 6 integrin cleavage, this creates progressive tumors with the ability to 
disseminate as highly motile collectives.  The ability to detect these cascading 
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events early in disease progression could potentially lead to a preventative 
measure that would prove beneficial to patients at risk for aggressive cancer.  
Advancements in diagnostic strategies and early screening for detection of 
aggressive disease have lowered the prostate cancer mortality rate 40% and 
increased the 5-year survival rate for confined disease to nearly 100%. The 
primary tests are direct rectal examination and PSA serum tests for evidence of 
cancer. Current tests target newer molecular and protein biomarkers, such as 
PTEN and ERG, for expression status in patient samples relevant to aggressive 
disease. However, multiple proteins and other molecular determinants are 
involved in processes that occur simultaneously that promote progression from low 
risk to aggressive tumors. This results in patient misdiagnosis and overtreatment 
of low risk cancers that lack invasive capability and has still yet to curtail the <30% 
5-year survival rate of patients with tumors presenting extracapsular invasion.  
Consequently, the characterization of more a reliable detection signature 
indicating the early transition to invasive disease will provide the crucial information 
for objective decisions for patients truly at risk. Therefore, this research aimed to 
develop and utilize multiple strategies to characterize various protein associations 
related to early invasive disease transition. Based on the detection and quantitative 
analysis of human PCa tissues, it can be concluded that when the loss of 3 
integrin is observed, the increased production of 6p associated with enhanced 
migration. In addition, there is increased coincidence of 6 integrin with E-cadherin 
and a correlation to PTEN and ERG status that is an important signature 
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determining early invasiveness. The results suggest that together, the associations 
of these surface protein molecules indicate a signature of phenotypical aggressive 
tumors that are initiating the first steps of invasion. 
The research here utilized primary antibody detection strategies on patient tissues 
and cell lines to target proteins of interest relating to disease progression. The use 
of antibodies to detect proteins involved in early stage progression of prostate 
cancer has been a problematic due to the unique and heterogeneous nature of 
tumors. During different stages of cancer progression, proteins will demonstrate 
variable expression within a tumor. Furthermore, proteins will also show variable 
expression within the same focal regions of the same tumors. This means that a 
cancer can exhibit different subtypes and demonstrate the ability to perform a 
phenotypic switch from non-aggressive to invasive. It is within this switch to 
invasive cancer that protein localization patterns and associations can determine 
a precursor to metastatic potential. Another issue is that tumor regions of interest 
can be lost due to serial sampling. A viable method to reuse H&E stained slides 
was developed and tested to mitigate this. The resulting data indicated that the 
method demonstrated comparable intensities to standard IHC and can be used 
with multiple targets and allow quantitation.  
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The optimization of multiplex IHC antibody assays for multiple biomarkers in 
patient tissue samples resulted in observable patterns of protein localizations 
indicative of such associations. First, the dual chromogenic detection of 6 integrin 
and uPAR exhibited increased co-distribution in increasing Gleason grade tumor 
samples compared to normal and aggressive. In theory, the resulting pattern would 
be an early signature of potential invasion. However, discontinuation of the uPAR 
antibody did not allow further testing. Therefore, E-cadherin became a viable 
option to test co-distribution. Additional chromogen multiplex detection 
demonstrated distinct co-distribution patterns of 6 integrin and E-cadherin with 
focal loss of 3 integrin. Furthermore, a quantitative analysis of separate nodes 
expressing 6 integrin and E-cadherin co-distribution exhibited distinct ratios 
percentages that could coincide with potential invasive capability. Although the 
analysis of the 6 and E-cadherin co-distribution was accomplished by comparing 
mappings of chromogen expression in unmixed images, the analysis of the pixels 
relative to the chromogen intensities were an approximation of protein expression. 
The process of PCa cell invasion and migration is a co-opted embryonic 
developmental process that incorporates cell-matrix and cell-cell adhesion. 
Cohesive collective migration is a mechanism of cellular mobilization utilized in 
differentiation of tissues and tissue repair. Adhesive interactions among cells, 
between cells and the ECM are important during this morphogenetic process 
(Burdsal et al., 1993). 6 Integrin and E-cadherin are key cell-matrix and cell-cell 
factors (respectively) involved in collective cell migration. They are also necessary 
for the dynamic dissemination of these cohesive clusters through adjacent tissues. 
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The co-association of these two receptors in early cancer progression and 
migrating clusters indicate the coordination of signaling pathways that control 
cytoskeletal dynamics in tumor cells regulating the turnover of cell-cell and cell-
matrix adhesions allowing tumor plasticity throughout migration. In previous work, 
we have shown that inhibition of 6 integrin cleavage prevents invasive cord 
networks and cellular migration (Rubenstein et al., 2019). However, it was 
unknown how the inhibition promoted adhesion and what specific pathway was 
mediated by the loss of 3 integrin that promoted the invasive process.  
Results described in Chapter VI showed that tumor cells expressing a deletion in 
3 integrin demonstrated significant collective migration through muscle and 
greatly increased dissemination to distant tissue. The collective migration was 
slightly comparable to the tumor cells expressing endogenous wild type receptors 
but the dissemination was increased 3-fold. In addition, this exhibited stark contrast 
with tumor cells expressing an uncleavable full-length 6 integrin, which 
demonstrated reduced collective invasion sites and minor dissemination. 
Interestingly, the results indicate that deletion of 3 integrin not only promotes the 
production of the tumor variant 6p, but also increases E-cadherin cell membrane 
localization. This would play a significant role in the regulating the plasticity of 
invading tumor collectives through tissues. The most profound discovery was that 
the inhibition of 6 integrin cleavage not only mitigated production of 6p, but also 
significantly increased E-cadherin protein expression and cell membrane 
localization on tumor cell pellets. Proximity detection assay confirmed the 
formation of 6 integrin an E-cadherin dynamic complexes in human prostate 
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tissues. The comparison between normal tissues and aggressive PNI lesions 
demonstrated differential localization patterns that would indicate the 6 integrin 
cleavage event in aggressive samples and stable, intact 6 integrin, complexes in 
normal. Therefore, inhibiting the 6 integrin PTM has revealed a pathway 
regulating a phenotypic switch to inhibit tumor migration by promoting E-cadherin 
surface expression. Future experiments to elucidate the unknown activated factors 
promoting E-cadherin expression will provide a promising development for 
potential intervention of metastatic disease. 
The localization of 6 integrin was also associated with status of PTEN and ERG 
in human PCa specimens. PTEN is a regulator of intracellular vesicular trafficking 
that inhibits integrin mediated cell migration. ERG, which is associated with the 
TMPRSS2: ERG gene fusion, is expressed in ~50% of prostate cancers and 
correlates with prostate cancer progression. Correlative studies have shown a 
relationship between PTEN loss and ERG expression in promoting prostate cancer 
progression (Yoshimoto et al., 2008; King et al., 2009; Carver et al. 2009; Guedes 
et al., 2017). Integrins internalize and sort through the intracellular pathway system 
and then recycle to the surface membrane in focal adhesions for cellular migration. 
The results in this research showed that a number of tumor sample specimens 
with focal PTEN loss and ERG expression demonstrated membrane expression of 
6 integrin. This suggested that loss of PTEN promotes increased recycling of the 
6 integrin to the surface in more aggressive tumors. This notion was tested with 
the development of a quantitative algorithm to determine if the membrane or 
cytoplasmic positive localization of 6 integrin in PCa CNB samples (n=9) 
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correlated to aggressiveness.  The results showed that tumors with negative PTEN 
and positive ERG expression exhibited shift to more membranous localization of 
6 integrin whereas cytoplasmic localization was observed in samples PTEN 
negative and ERG negative.  
Overall, the results observed in this research demonstrate the heterogenetic 
nature of tumor progression.  While relying on the detection of relevant proteins to 
identify tumors initiating aggressive events, it does elucidate the genomic causal 
determinants of invasive transition. This research demonstrates several protein 
associations either mediate or are indicative of transition from non-aggressive to 
aggressive disease. The expression of 3 integrin regulates the expression and 
cleavage of 6 integrin and the expression of E-cadherin. The status of PTEN and 
ERG correlate with low risk or aggressive disease. Hence, either the loss or co-
incidence of these in association with 6 integrin localization in a sample can be 
predictive of tumor invasiveness in patients. Our ability to detect these protein 
associations in patient tissue samples have given the capability to stratify tumors 
with aggressive potential. Therefore, it has predictive value and brings further 
insight into evaluating other protein associations in other aggressive cancers for 
interventional means of therapeutics. Further evaluations of cellular adhesion 
factors, such as these described in this study, may lead to understanding how 
these factors relate to clinical progression of disease and metastasis across 
various cancer types including prostate, colorectal and breast cancers. 
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X. Tables 
 
Table 1. List of antibody diluents 
Diluent Buffer, pH 
95119 Tris, 7.7 
90039  
Phosphate, 7.3 95028 
90040 
90103 Tris, 7.5 
 
 
 
Table 2. 6-week diaphragm invasion sites 
 
DU145 
Diaphragm ID 
Tumor invasion sites-strip number  
 
Overall total 
1 2 3 4 Total 
WT Diaphragm 1 1 6 3 6 16  
49 WT Diaphragm 2 4 5 3 2 14 
WT Diaphragm 3 3 5 7 4 19 
3KO Diaphragm 1 1 3 5 3 12  
39 3KO Diaphragm 2 1 4 5 5 15 
3KO Diaphragm 3 4 3 3 2 12 
6AA Diaphragm 1 1 1 1 0 3  
5 6AA Diaphragm 2 1 0 0 0 1 
6AA Diaphragm 3 0 0 0 1 1 
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Table 3. 6-week small bowel tumor incidence 
 
Small Bowel DU145 ID 
Tumor incidence-
specimen number 
 
Overall Total 
1 2 3 Total 
WT Sm. Bowel 1  0 0 0 0  
 
5 
WT Sm. Bowel 2 0 0 0 0 
WT Sm. Bowel 3 0 0 0 0 
WT Sm. Bowel 4 0 1 2 3 
WT Sm. Bowel 5 1 0 1 2 
3KO Sm. Bowel 1 0 2 1 3  
 
15 
3KO Sm. Bowel 2 0 1 1 2 
3KO Sm. Bowel 3 1 0 0 1 
3KO Sm. Bowel 4 1 6 0 7 
3KO Sm. Bowel 5 1 1 0 2 
6AA Sm. Bowel 1  0 0 0 0  
 
1 
6AA Sm. Bowel 2 0 0 0 0 
6AA Sm. Bowel 3 0 0 0 0 
6AA Sm. Bowel 4 0 0 0 0 
6AA Sm. Bowel 5 0 0 1 1 
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Table 4. List of initially assessed sample H&E stained slides with specimen 
parameters, de-stain results and antibodies tested. 
 
Tissue Specimen H&E De-
stain 
result 
Antibodies used Initial H&E Analysis 
Prostate 
Resection + p40 
Malignant Primary_Adenocarcinoma, Gleason 
3+3 = 6 
Prostate Resectiona + CK5/14: PTEN NA 
Prostate Resectiona + CK5/14: p504s 
Malignant Primary_Adenocarcinoma, Gleason 
3+3 = 6 
Liver (Pancreas 
Met)* 
CNBa + PTEN/p504s/CK5/14 Mock CNBs (due to the cut) 
Liver Resection +/- HMWCK+p63 NA 
Lung Resection +/- HMWCK+p63 NA 
N. colon Resection + HMWCK+p63 NA 
Skin Resection - E-cadherin NA 
Skin Resection - E-cadherin NA 
Prostate TMA + ERG NA 
Prostate CNB + CD49f 3+3 
Prostate CNB + CD49f no cancer 
Prostate CNB + CD49f no cancer 
Prostate CNB + PTEN/ERGb High grade growing into normal glands 3+3 
Prostate CNB + PTEN/ERGb little bit of tumor grade 3+3 
Prostate CNB + PTEN/ERGb 3+3, area of tumor, fragmented tumor 
Prostate CNB + PTEN/ERGb no tumor 
Prostate CNB + PTEN/ERGb grade 4 and 5 cancer, High grade 
Prostate CNB + PTEN/ERGb low grade 3, Lot of PIN 
Prostate CNB + PTEN/ERGb atrophy, inflammation 
Prostate CNB + PTEN/ERGb no cancer, small nerve area 
Prostate CNB + PTEN/ERGb a little fragment tumor 
Prostate CNB + PTEN/ERGb HGPIN, few basal cells left, some cancer 
Prostate CNB + PTEN/ERGb 
Atypical adenomatous hyperplasia and 
atrophic glands, Central zone lesion 
Prostate CNB + PTEN/ERGb 1 mm grade 3 tumor 
Prostate CNB + PTEN/ERGb small tumor area 
Prostate CNB + PTEN/ERGb small tumor area 
Prostate CNB + CD49f/HMWCKb 
high grade cancer 4 and 5 trying to make 
glands invading into norm glands 
Prostate CNB + CD49f/HMWCKb grade 5 cancer (high grade), PIN 
Prostate CNB + CD49f/HMWCKb small amount of tumor no basal cells 
Prostate Resection + CK 8 &18 NA 
Prostate CNB + CD49f little bit of tumor grade 3+3 
Prostate CNB + HMWCK+p63 grade 4 and 5 cancer, High grade 
Prostate CNB + p504s low grade 3, Lot of PIN 
Prostate CNB + CK 8 &18 cancer (3+3 with normal) 
Prostate CNB + PTEN 3+3 ERG positive, tumor folded over 
Prostate CNB + CD49f 3+3 lesion: 3 cores 
Prostate CNB + ERG 3+3 involving 2/2 cores 
Prostate CNB + CD49f 2 cores: 3+3 involving 2/2 cores 
Prostate CNB + CK 8 & 18 
3+3 lesion in one frag 1mm heterogeneous 
chromatin 
Prostate CNB + HMWCK+p63 tumor 3+3 Atrophic glands, edge normal 
Prostate CNB + HMWCK+p63 no tumor 
Prostate CNB + HMWCK+p63 atrophy inflammation 
Prostate CNB + CK 8&18 atrophy, inflammation 
Prostate CNB + CD49f no cancer 
Prostate CNB + ERG 3+3 fragmented tumor lost basal cells 
Abbreviations: Met, Metastasis; CNB, Core needle biopsy: NA, Not applicable: a Multiple H&Es prepared. b Dual chromogen 
immunostaining. *Mock needle cores: Appropriate H&E de-stain, (+); Moderate de-stain, (+/-); retention of H&E, (-). 
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Table 5. Time tracking and coverslip parameters 
 
Sample Archive 
time 
Coverslip removal 
time 
Type of Coverslip 
1 month 10 min Thin film 
1 year  10 min Thin film 
2 year 10 min-60min Thin film 
4 year ~38 hrs Thin film 
4+ year** ~47 hrs Thin film 
2+ year# 1-2 days Glass 
5 year 4-5 days Glass 
5 year 4-5 days Glass 
12 year 4-5 days Glass 
Abbreviations: hrs, hours; ** Sample Archived 4 years 11 months; # 
Samples Archived 2 years 11 months ~Approximation due to time 
at removal 
 
 
Table 6. Immunohistochemistry (IHC) Antibodies and Adapted Staining Protocols 
 
Antibody 
(clone) 
HMWCK+p63 
(34βE12) 
p504s 
(SP116) 
CK 8 &18 
(B22.1 
&B23.1) 
PTEN 
(SP218) 
E-
cadherin 
(36) 
CD49f 
ERG 
(EPR3864) 
Species 
mouse 
monoclonal  
rabbit 
monoclonal 
mouse 
monoclonal 
rabbit 
monoclonal 
mouse 
monoclonal 
rabbit 
polyclonal 
rabbit 
monoclonal 
Antibody 
Vendor 
Ventana 
Medical 
Systems, 
Inc., Tucson, 
Arizona 
Cell-
Marque, 
Rocklin, 
California 
Ventana Medical Systems, Inc., 
Tucson, Arizona 
N/A 
Ventana 
Medical 
Systems, 
Inc., 
Tucson, 
Arizona 
De-stained H&E slide Immunohistochemistry adapted protocol 
IHC 
platform 
Ventana Benchmark ULTRA 
Detection 
Kit 
Ventana OptiView DAB IHC 
Ventana 
UltraView 
DAB IHC 
Ventana OptiView DAB IHC 
Deparaffin none 
HIER 
64 min CC1 
(pH 8.5) 
32 min 
CC1 (pH 
8.5) 
36 min 
CC1 (pH 
8.5) 
56 min 
CC1 (pH 
8.5) 
63 min 
CC1 (pH 
8.5) 
64 min 
CC1 (pH 
8.5) 
32 min 
CC1 (pH 
8.5)  
Blocking  Peroxidase block 
Ab 
incubation 
parameters 
36oC, 16 min 
36oC, 32 
min 
37oC, 16 
min 
37oC, 16 
min 
36oC, 24 
min 
36oC, 24 
min 
36oC, 32 
min 
Abbreviations: Ab, antibody; CC, cell conditioning; DAB, 3, 3’- diaminobenzidine HIER, heat-induced epitope 
retrieval; min, minutes, N/A, Not Applicable. 
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Table 7. Comparison of H&E re-used and sequential comparator immunostaining 
intensity scores 
 
Marker Re-used 
H&E 
stain 
intensity 
Sequential stain intensity: 0-3 
(int ctrl) 
 
Initial H&E 
assessment 
 
HMWCK+p63 3 2 2 2 0 3 atrophy inflammation 
CK8&18 
3 3 3 3 3 3 
Atrophy + inflammation: 
whole glands 
CD49f 
3(2) 3 (1) 3 (1) 3 (1) 
3 
(1) 
3 (2) 
no cancer, int ctrls 
E-cadherin 
3 3 3 3 3 3 
not much cancer but 
weird well differentiated 
ERG 
3 (3) 0 (3) 0 (3) 0 (0) 
1 
(3) 
0 (3) 
lots of infiltrating 
lymphocytes, grade 3+3 
fragmented tumor lost 
basal cells, int ctrls 
Abbreviation: int ctrls, internal controls. 
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XI. Materials and methods 
Cell culture: A human prostate DU145 cell line was obtained from the American 
Tissue Type Collection (ATCC, Manassas, VA).  The cell line was cultured in 
Iscove’s modified Dulbecco’s medium (IMDM) from Invitrogen (Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS) Hyclone Laboratories (Novato, 
CA) and incubated at 37° in a 5% CO2 humidified chamber.  Non-enzymatic 
Cellstripper (CelGro, Manassas, VA) was used for cell harvesting.  
 
Whole cell lysate and cell pellet preparation. The DU145 cell lines were washed 
in a saline buffer and cell lysis was performed with CHAPS lysis buffer (50 mmol/L 
Tris HCL, 110 mmol/NaCl, 5 mmol L EDTA, 1% CHAPS) with a complete mini 
protease inhibitor and phosphatase 1 and 2 inhibitor additives from Roche and 
Sigma, respectively.  
 
Gene editing. Homozygous knock-out cell lines for ITGA6 gene (6KO), ITGA3 
gene (DU145 3KO) and homozygous amino acid substitutions for the ITGA6 
R594A and 596A (DU145 6AA) were created using CRISPR/Cas9 technologies in 
the University of Arizona Cancer Center (UACC) Genome Editing Facility.  For the 
production of DU145 6AA the facility produced double strand breaks on either side 
of exon 4 of ITGA6 transcription unit at predicted sites 2: 172,466,252 and 2: 
172,468,987 with the guide RNAs corresponding to the sequences 5’-
TAGACCGAACATATCAAACG-3’ and 5’-ATATTTGCTGGTCTGGGATC-3’. 
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Colonies were screened by an AA-specific polymerase chain reaction (PCR) 
primer and agarose gel electrophoresis. Clones positive for the AA amplification 
were sent for sequencing.  
Parental prostate cancer cells DU145 were transfected with Cas 9 protein, 
crRNAs, and tracrRNA (Integrated DNA Technologies) using the Lipofectamine 
RNAiMAX reagent (Thermo Fisher Scientific).  Two days after transfection, cutting 
efficiency was estimated based on DNA prepared from a portion of the transfected 
cell population using a T7 endonuclease assay (New England BioLabs) employing 
PCR primers flanking the predicted ligation-junction product (5’-
GTTCTGCAGGAGGTTGTGGA-3’ and 5’-TCGCCCATCACAAAAGCTCC-3’).  
Single cells were deposited in ten 96-well plates by UACC Flow Cytometry Shared 
Resource.  Colonies were expanded and screened by PCR and agarose gel 
electrophoresis.  Clones that were negative for fragment internal to the targeted 
deletion (5’-ACTCAGAGTCGAGGCCATTTG-3’) and 5’-
TAGGTTGTGTGATTGCTTCTAAGT-3’) but positive for ligation-junction fragment 
were potentially homozygous for the deletion.  Absence of 6 integrin or presence 
of 6 integrin AA mutant was confirmed by flow cytometry and western-blot 
analysis.  All cells were authenticated by the University of Arizona Genetics Core 
(UAGC). 
SCID Mouse Muscle Invasion Model. For the mouse xenograft muscle invasion 
assay, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (or NOD-scid IL2Rgamma) (3 mice 
per group) from Dr. Leonard D. Shultz from The Jackson Laboratory, were 
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interperitoneally (IP) implanted with human DU145 wildtype (WT), 3KO, 6KO or 
6AA tumor cells (1 X 107). Tumor colonies were allowed to grow on the diaphragm 
and within the peritoneal cavity for 6 and 8 weeks (formation of ascites dictated 
harvest at 6 weeks). Diaphragm samples from each subject was harvested, fixed 
and embedded in a lateral manner to orient the tumor colony on top of the muscle. 
Sequential transverse sectioning will demonstrate tumor displacement of the 
myoepithelium and invasion into and through the muscle to the superior side of the 
diaphragm.  
The experimental mouse studies were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC), Protocol Number: 07029. The protocol 
was conducted in accordance with all applicable federal and institutional policies, 
procedures and regulations, including PHS policy on Human Care and Use of 
Laboratory Animals, USDA regulations (9 CFR parts 1, 2, 3), the Federal Animal 
Welfare Act (7 USC 2131 et Seq.), the Guide for the Care and Use of Laboratory 
Animals, and all institutional regulations and policies regarding animal care and 
use at the University of Arizona. The mice were anesthetized by placement into a 
CO2 chamber. 
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Advanced staining and detection platforms:  Processing of FFPE tissue sample 
slides was performed on either the Roche Tissue Diagnostics/ Ventana 
BenchMark ULTRA (BenchMark ULTRA) IHC/ISH system or DISCOVERY Ultra 
(DISCVERY) automated system platform. The optimization of initial antibody 
protocols was accomplished on the BenchMark ULTRA. The migration of these 
procedures for antibody Chromogenic Multiplex, and protein biomarker proximity 
detection assays was performed using the DISCOVERY platform.   
Reagent Detection Kits: The reagent detection kits utilized for these studies were 
all acquired from Roche Tissue Diagnostics. The kits used where Ventana 
OptiView DAB IHC Detection Kit, ultraView IHC DAB Detection Kit and 
DISCOVERY Chromomap Detection kits. The proximity detection assay is a 
research use only, in research development detection system applied to samples 
on the DISCOVERY ULTRA platform for interrogation of protein co-distribution.  
Ready to use Antibodies. The ready to use antibodies used for this study 
included anti-high molecular weight cytokeratin  (HMWCK) + p63 mouse 
monoclonal Basal Cell Cocktail (Ventana, clone 34βE12+4A4), anti-E-cadherin 
mouse monoclonal antibody (mAb) (0.314µg/mL, Ventana, clone 36), anti-E-
cadherin rabbit mAB (Cell-Marque, EP700Y), anti-p120 Catenin muse mAb 
(Ventana,  clone 98), anti-PTEN rabbit mAb (1:300, Ventana, clone SP218), anti-
ERG mouse mAb (Ventana, clone EPR3864). The ready to use antibodies used 
sparingly in this study were anti-p40 (BC28), CK 5/14 and anti-Desmin mouse mAb 
(DER). These antibodies were used primarily for IHC of de-identified archived 
FFPE tissues.  
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E-cadherin antibody titration: It had been determined the antibody dilution of ready 
to use anti-E-cadherin resulted in saturated immunostaining intensity. Therefore, 
it was decided to formulate dilution titers of E-cadherin from a ready to use 
dispenser. The standard concentration of ready to use dispensers is 0.314 µg/ml. 
A 1:10 dilution of the standard dispenser concentration was optimal and also 
utilized in chromogen multiplex IHC and protein gels. 
Experimental Research Antibodies: The anti-6 (CD49f) or AA6NT rabbit 
polyclonal antibody (pAb) was characterized by our lab and used at a dilution of 
1:800. The anti-3 (CD49c) rabbit pAb (Sigma Aldrich, clone HPA008572) was 
used at 1:200. The anti-β4 integrin rat monoclonal antibody (BD Pharmingen, clone 
439.9B) was used at 1:100. The anti-uPAR mouse monoclonal (Sekisui 
Diagnostics, clone ABG3937) was used at 1:100. Each of these were used in the 
analysis of protein expression in FFPE tissues and the AA6NT was also used in 
western blot. Each primary antibody was initially formulated at 1:100 dilution in 
various RTD proprietary Tris or Phosphate based antibody diluents (Table 1) to 
determine specificity of epitope binding, non-specific binding of endogenous 
proteins and background deposition. A dilution “guard-banding” was performed to 
determine the appropriate antibody dilution for optimal immunostaining intensity.  
Two titrations above and below the 1:100 dilution was tested with each research 
antibody and the dilution exhibiting appropriate immunostaining intensity was 
selected.  
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Human Prostate Tissue Immunohistochemistry. Prostate tissue resections 
from various vendors that had been formalin fixed and embedded in paraffin were 
acquired from Ventana Medical Systems, Inc. / Roche Tissue Diagnostics (RTD). 
In addition, ~435 prostate core needle biopsies (CNBs) were obtained from the 
University of Arizona Medical Imaging Department with permission from Dr. Hina-
Arif Tawari. Prostate resection samples slides were micro-sectioned at 4µm 
thickness and mounted to positively charged Matsunami TOMO or superfrost 
(Thermo Fischer Scientific) glass slides for hematoxylin and eosin staining (H&E) 
and immunohistochemistry by RTD integrated (iCORE) services 
histotechnologists. The University of Arizona TACMASR department prepared the 
prostate CNB sample slide sections. H&E stained slides were prepared from the 
initial sectioning of each sample tissues and evaluated for content by a pathologist 
(Dr. Ray Nagle). Immunohistochemical (IHC) staining was conducted manually or 
with automated protocols on the VENTANA BenchMark ULTRA or DISCOVERY 
ULTRA platforms following antibody package insert protocols for publicly released 
(on market) antibodies or optimized protocols for experimental antibodies. The IHC 
staining protocols performed for each antibody used is listed in Table 5. 
Chromogen Multiplex Assays: To perform chromogen multiplex IHC (cmIHC) 
using brightfield microscopy, anti-species secondary and tertiary antibodies 
conjugated with hydroxy quinazoline (HQ), horseradish peroxidase (HRP), 
nitropyrazole (NP) and alkaline phosphatase (AP) were acquired from RTD. All 
chromogen multiplex IHC assays were performed on the DISCOVERY ULTRA 
platform. 
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Proximity Detection Assay: The Proximity Detection Assay (PDA) is a 
proprietary, in research development detection system of RTD. Execution of the 
PDA was performed on the DISCOVERY ULTRA. Antibodies for 6 integrin and 
E-cadherin were utilized with the PDA for the proximal detection of protein 
complexes.  
Imaging Platforms and Image Analysis: Tissue slide imaging was performed 
using the following imaging platforms: the Aperio AT2 slide scanner (Leica 
Biosystems), VENTANA DP200 slide scanner, a hyperspectral research imager 
(HRI) and Axio Scan 2.1™ (Axio™) slide scanner. The Aperio AT2 and DP200 
imagers were utilized for IHC DAB and chromogen multiplex IHC detection. The 
HRI was utilized for image un-mixing and quantitative image analysis of individual 
chromogen intensities and protein co-distribution quantitative values after 
chromogenic multiplexing. The Aperio AT2 image software was used for image 
analysis for measurements of tumor invasion depth. The Axio™ was used with 
QuPath™ image analysis software for quantitative analysis of 6 integrin protein 
localization on slide images. 
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Statistical Analysis: GraphPad Prism 8.2.1 was utilized to perform Two-way 
ANOVA and RM one-way ANOVA analysis throughout. MATLab analysis software 
was used to develop a quantitative image analysis for HRI imaging. QuPath™ 
image analysis software was used in development of membrane/ cytoplasmic 
localization algorithm with the Axio™ scanner. For muscle invasion assays, two-
way ANOVA statistical significance was tested for differences in number of tumor 
sites and invasion depth. For H&E de-stain and re-stain, RM one-way ANOVA 
statistical significance was tested for differences in matching intensities assuming 
equal variance. P-values lower than 0.05 were considered statistically significant. 
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XII. Supplemental figures 
 
 
Figure S1. H&E stained slide of DU145 WT 8-week mouse diaphragm. Sample slide images with maximum 
tumor cluster depth measurement showing invasion to the lung side (left panel, 4x). Image magnification of 
the annotated region (right panel, 10x). 
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Figure S2. 6 integrin localization with PTEN and ERG expression. Prostate cancer immunostained with 
antibodies for PTEN, ERG, 6 integrin and HMWCK+p63 (HMWCK). Cancer region with PTEN loss (*) (top 
left panel). ERG positive (top right panel), 6 integrin membrane expression (black arrow) (bottom left panel) 
and lack of HMWCK intensity (bottom right panel). 
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Figure S3. 6 integrin localization with PTEN and ERG expression. Prostate cancer immunostained with 
antibodies for PTEN, ERG, 6 integrin and HMWCK+p63 (HMWCK). Cancer region with PTEN loss (*) (top 
left panel), ERG positive (top right panel), 6 integrin membrane expression (black arrow) (bottom left panel) 
and lack of HMWCK intensity (bottom right panel). 
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Figure S4. 6 integrin localization with PTEN and ERG expression. Prostate cancer immunostained with 
antibodies for PTEN, ERG, 6 integrin and HMWCK+p63 (HMWCK). Tumor invading into normal glands with 
PTEN loss (*) (top left panel), ERG positive (top right panel), 6 integrin membrane expression (black arrow) 
(bottom left panel) and positive expression of HMWCK in normal basal cells of the glands (bottom right panel). 
 
 
 
 
 
169 
 
Appendix A: Manuscripts 
 
1. William L. Harryman, James P. Hinton, Cynthia P. Rubenstein, Parminder 
Singh, M.D., Raymond B. Nagle, M.D., Ph.D., Sarah J. Parker, Ph.D., 
Beatrice S. Knudsen, M.D., Ph.D., Anne E. Cress, Ph.D. “The Cohesive 
Metastasis Phenotype in Human Prostate Cancer.” Biochimica et 
Biophysica Acta (BBA) – Reviews on Cancer 1866 (2016): 221-31. 
 
2. Cynthia S. Rubenstein, Jamie M.C. Gard, Mengdie Wang, Julei E. McGrath, 
Nadia Ingabire, James P. Hinton, Kendra D. Marr, Skyler J. Simpson, 
Raymond B. Nagle, Cindy K. Miranti, Noel A. Warfel, Joe G.N. Garcia, Hina 
Arif-Tiwari and Cress, Anne E. Cress. “Gene Editing of 6 Integrin Inhibits 
Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties 
in Prostate Cancer.” Cancer Research (2019); 79: 4703-14. 
 
3. Mengdie Wang, James P. Hinton, Joe G.N. Garcia, Beatrice S. Knudsen, 
Raymond B. Nagle, and Anne E. Cress. “Integrin 6β4E variant is 
associated with actin and CD9 structures and modifies the biophysical 
properties of cell-cell and cell-extracellular matrix interactions.” Molecular 
Biology of the Cell (2019): 838-850. 
 
4. James P. Hinton, Katerina Dvorak, Esteban Roberts, Wendy J. French, 
Jon C. Grubbs, Anne E. Cress, Hina-Arif Tawari, Raymond B. Nagle. “A 
Method to Reuse Archived H&E Stained Histology Slides for a Multiplex 
Protein Biomarker Analysis.” Methods and Protocols. (2019); 2: 4, 86. 
 
 
 
 
 
 
 
170 
 
REFERENCES 
A. Sakr, Wael, David J. Grignon, Gabriel P. Haas, Lance K. Heilbrun, J. Edson 
Pontes, and John D. Crissmana. 1996. “Age and Racial Distribution of 
Prostatic Intraepithelial Neoplasia.” European Urology 30 (2): 138–44. 
https://doi.org/10.1159/000474163. 
Ayala, Gustavo, Anna Frolov, Deyali Chatterjee, Dandan He, Susan Hilsenbeck, 
and Michael Ittmann. 2015. “Expression of ERG Protein in Prostate Cancer: 
Variability and Biological Correlates.” Endocrine-Related Cancer 22 (3):  
277–87. https://doi.org/10.1530/ERC-14-0586. 
Barczyk, Malgorzata, Sergio Carracedo, and Donald Gullberg. 2010. “Integrins.” 
Cell and Tissue Research 339 (1): 269–80. https://doi.org/10.1007/s00441-
009-0834-6. 
Becker-Santos, Daiana D, Yubin Guo, Mazyar Ghaffari, Elaine D Vickers, Melanie 
Lehman, Manuel Altamirano-Dimas, Arusha Oloumi, et al. 2012. “Integrin-
Linked Kinase as a Target for ERG-Mediated Invasive Properties in Prostate 
Cancer Models.” Carcinogenesis 33 (12): 2558-67.  
https://doi.org/10.1093/carcin/bgs285. 
Berx, G., and F. van Roy. 2009. “Involvement of Members of the Cadherin 
Superfamily in Cancer.” Cold Spring Harbor Perspectives in Biology 1 (6): 
a003129–a003129. https://doi.org/10.1101/cshperspect.a003129. 
Birchmeier, W, and J Behrens. 1994. “Cadherin Expression in Carcinomas: Role 
in the Formation of Cell Junctions and the Prevention of Invasiveness.” 
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1198 (1):  
11–26. https://doi.org/10.1016/0304-419X(94)90003-5. 
Bolognesi, Maddalena Maria, Marco Manzoni, Carla Rossana Scalia, Stefano 
Zannella, Francesca Maria Bosisio, Mario Faretta, and Giorgio Cattoretti. 
2017. “Multiplex Staining by Sequential Immunostaining and Antibody 
Removal on Routine Tissue Sections.” The Journal of Histochemistry and 
Cytochemistry : Official Journal of the Histochemistry Society 65 (8):  
431–44. https://doi.org/10.1369/0022155417719419. 
Bonkhoff, H., and K. Remberger. 1995. “Morphogenetic Aspects of Normal and 
Abnormal Prostatic Growth,.” Pathology - Research and Practice 191 (9): 
833-35. https://doi.org/10.1016/S0344-0338(11)80963-5. 
Borghi, N., M. Lowndes, V. Maruthamuthu, M. L. Gardel, and W. J. Nelson. 2010. 
“Regulation of Cell Motile Behavior by Crosstalk between Cadherin- and 
Integrin-Mediated Adhesions.” Proceedings of the National Academy of 
Sciences 107 (30): 13324–29. https://doi.org/10.1073/pnas.1002662107. 
Bostwick, David G., and Joseph W. Aquilina. 1996. “Prostatic Intraepithelial 
Neoplasia (PIN) and Other Prostatic Lesions as Risk Factors and Surrogate 
Endpoints for Cancer Chemoprevention Trials.” Journal of Cellular 
Biochemistry 63 (S25): 156–64. https://doi.org/10.1002/(SICI)1097-
4644(1996)25+<156. 
Bostwick, David G, Lina Liu, Michael K Brawer, and Junqi Qian. 2004. “High-Grade 
Prostatic Intraepithelial Neoplasia.” Reviews in Urology 6 (4): 171–79. 
171 
 
Bouali, S., Chrétien, A., Ramacci, C., Rouyer, M., Becuwe, P., Merlin, J."PTEN 
expression controls cellular response to cetuximab by mediating PI3K/AKT 
and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone 
refractory prostate cancer cells". Oncology Reports 21, no. 3 (2009): 731-
735.  https://doi.org/10.3892/or_00000278 
Brase, Jan C, Marc Johannes, Heiko Mannsperger, Maria Fälth, Jennifer Metzger, 
Lukasz A Kacprzyk, Tatjana Andrasiuk, et al. 2011. “TMPRSS2-ERG -
Specific Transcriptional Modulation Is Associated with Prostate Cancer 
Biomarkers and TGF-β Signaling.” BMC Cancer 11 (1).  
https://doi.org/10.1186/1471-2407-11-507. 
Bridgewater, R. E., J. C. Norman, and P. T. Caswell. 2012. “Integrin Trafficking at 
a Glance.” Journal of Cell Science 125 (16): 3695-3701.   
https://doi.org/10.1242/jcs.095810. 
Bronsert, P, K Enderle-Ammour, M Bader, S Timme, M Kuehs, A Csanadi, G 
Kayser, et al. 2014. “Cancer Cell Invasion and EMT Marker Expression: A 
Three-Dimensional Study of the Human Cancer-Host Interface: 3D Cancer-
Host Interface.” The Journal of Pathology 234 (3): 410-22.   
https://doi.org/10.1002/path.4416. 
Burdsal, C.A., C.H. Damsky, and R.A. Pedersen. 1993. “The Role of E-Cadherin 
and Integrins in Mesoderm Differentiation and Migration at the Mammalian 
Primitive Streak.” Development 118 (3): 829. 
Busso, N. 1994. “Induction of Cell Migration by Pro-Urokinase Binding to Its 
Receptor: Possible Mechanism for Signal Transduction in Human Epithelial 
Cells.” The Journal of Cell Biology 126 (1): 259-70.   
https://doi.org/10.1083/jcb.126.1.259. 
Campa, Carlo Cosimo, and Emilio Hirsch. 2017. “Rab11 and Phosphoinositides: A 
Synergy of Signal Transducers in the Control of Vesicular Trafficking.” 
Advances in Biological Regulation 63 (January): 132-39.   
https://doi.org/10.1016/j.jbior.2016.09.002. 
Canel, M., A. Serrels, M. C. Frame, and V. G. Brunton. 2013. “E-Cadherin-Integrin 
Crosstalk in Cancer Invasion and Metastasis.” Journal of Cell Science 126 
(2): 393–401. https://doi.org/10.1242/jcs.100115. 
Carter, W G, P Kaur, S G Gil, P J Gahr, and E A Wayner. 1990. “Distinct Functions 
for Integrins Alpha 3 Beta 1 in Focal Adhesions and Alpha 6 Beta 4/Bullous 
Pemphigoid Antigen in a New Stable Anchoring Contact (SAC) of 
Keratinocytes: Relation to Hemidesmosomes.” The Journal of Cell Biology 
111 (6 Pt 2): 3141–54. https://doi.org/10.1083/jcb.111.6.3141. 
Carver, Brett S, Jennifer Tran, Anuradha Gopalan, Zhenbang Chen, Safa Shaikh, 
Arkaitz Carracedo, Andrea Alimonti, et al. 2009. “Aberrant ERG Expression 
Cooperates with Loss of PTEN to Promote Cancer Progression in the 
Prostate.” Nature Genetics 41 (5): 619–24. https://doi.org/10.1038/ng.370. 
Chaffer, C. L., J. P. Brennan, J. L. Slavin, T. Blick, E. W. Thompson, and E. D. 
Williams. 2006. “Mesenchymal-to-Epithelial Transition Facilitates Bladder 
Cancer Metastasis: Role of Fibroblast Growth Factor Receptor-2.” Cancer 
Research 66 (23): 11271–78. https://doi.org/10.1158/0008-5472.CAN-06-
2044. 
172 
 
Chan, John K. C. 2014. “The Wonderful Colors of the Hematoxylin–Eosin Stain in 
Diagnostic Surgical Pathology.” International Journal of Surgical Pathology 
22 (1): 12–32. https://doi.org/10.1177/1066896913517939. 
Chang, A C, D R Salomon, S Wadsworth, M J Hong, C F Mojcik, S Otto, E M 
Shevach, and J E Coligan. 1995. “Alpha 3 Beta 1 and Alpha 6 Beta 1 
Integrins Mediate Laminin/Merosin Binding and Function as Costimulatory 
Molecules for Human Thymocyte Proliferation.” The Journal of Immunology 
154 (2): 500. 
Chartier, N. T. 2006. “Laminin-5-Integrin Interaction Signals through PI 3-Kinase 
and Rac1b to Promote Assembly of Adherens Junctions in HT-29 Cells.” 
Journal of Cell Science 119 (1): 31–46. https://doi.org/10.1242/jcs.02698. 
Chattopadhyay, Nibedita, Zemin Wang, Leonie K. Ashman, Susann M. Brady-
Kalnay, and Jordan A. Kreidberg. 2003. “Α3β1 Integrin–CD151, a 
Component of the Cadherin–Catenin Complex, Regulates PTPμ 
Expression and Cell–Cell Adhesion.” The Journal of Cell Biology 163 (6): 
1351–62. https://doi.org/10.1083/jcb.200306067. 
Chen, Yih-Tai, Daniel B Stewart, and W James Nelson. 1999. “Coupling Assembly 
of the E-Cadherin/β-Catenin Complex to Efficient Endoplasmic Reticulum 
Exit and Basal-Lateral Membrane Targeting of E-Cadherin in Polarized 
MDCK Cells.” The Journal of Cell Biology 144: 13. 
Chetram, M. A., V. Odero-Marah, and C. V. Hinton. 2011. “Loss of PTEN Permits 
CXCR4-Mediated Tumorigenesis through ERK1/2 in Prostate Cancer 
Cells.” Molecular Cancer Research 9 (1): 90-102.   
https://doi.org/10.1158/1541-7786.MCR-10-0235. 
Chetram, Mahandranauth A., and Cimona V. Hinton. 2012. “PTEN Regulation of 
ERK1/2 Signaling in Cancer.” Journal of Receptors and Signal Transduction 
32 (4): 190–95. https://doi.org/10.3109/10799893.2012.695798. 
Cheung, K. J., and A. J. Ewald. 2016. “A Collective Route to Metastasis: Seeding 
by Tumor Cell Clusters.” Science 352 (6282):167-69  
https://doi.org/10.1126/science.aaf6546. 
Cousin, Hélène. 2017. “Cadherins Function during the Collective Cell Migration of 
Xenopus Cranial Neural Crest Cells: Revisiting the Role of E-Cadherin.” 
Mechanisms of Development 148 (December):  79–88. 
https://doi.org/10.1016/j.mod.2017.04.006. 
Cox, Elisabeth A, Sarita K Sastry, and Anna Huttenlocher. 2001. “Integrin-Mediated 
Adhesion Regulates Cell Polarity and Membrane Protrusion through the 
Rho Family of GTPases□V.” Molecular Biology of the Cell 12: 13. 
Cress, Anne E., Manolis C. Demetriou, Kevin A. Kwei, Marianne B. Powell, 
Raymond B. Nagle, and G. Tim Bowden. 2008a. “Integrin A6 Cleavage in 
Mouse Skin Tumors.” The Open Cancer Journal 2 (1): 1-4.  
https://doi.org/10.2174/1874079000802010001. 
———. 2008b. “Integrin A6 Cleavage in Mouse Skin Tumors.” The Open Cancer 
Journal 2 (1): 1–4. https://doi.org/10.2174/1874079000802010001. 
173 
 
Cress, Anne E., Isaac Rabinovitz, Weiguo Zhu, and Ray B. Nagle. 1995. “The 
Α6β1 and Α6β4 Integrins in Human Prostate Cancer Progression.” Cancer 
and Metastasis Reviews 14 (3): 219-28.   
https://doi.org/10.1007/BF00690293. 
Cunningham, O. 2003. “Dimerization Controls the Lipid Raft Partitioning of 
UPAR/CD87 and Regulates Its Biological Functions.” The EMBO Journal 
22 (22): 5994–6003. https://doi.org/10.1093/emboj/cdg588. 
Das, Lipsa, Todd A. Anderson, Jaime M.C. Gard, Isis C. Sroka, Stephanie R. 
Strautman, Raymond B. Nagle, Colm Morrissey, Beatrice S. Knudsen, and 
Anne E. Cress. 2017. “Characterization of Laminin Binding Integrin 
Internalization in Prostate Cancer Cells: LAMININ BINDING INTEGRIN 
INTERNALIZATION.” Journal of Cellular Biochemistry 118 (5): 1038–49. 
https://doi.org/10.1002/jcb.25673. 
Davis, Michael A., Renee C. Ireton, and Albert B. Reynolds. 2003. “A Core Function 
for P120-Catenin in Cadherin Turnover.” The Journal of Cell Biology 163 
(3): 525–34. https://doi.org/10.1083/jcb.200307111. 
Davis, Tracy L., Isaac Rabinovitz, Bernard W. Futscher, Martina Schnölzer, 
Friederike Burger, Yuangang Liu, Molly Kulesz-Martin, and Anne E. Cress. 
2001. “Identification of a Novel Structural Variant of the α 6 Integrin.” Journal 
of Biological Chemistry 276 (28): 26099-106.   
https://doi.org/10.1074/jbc.M102811200. 
De Calisto, J. 2005. “Essential Role of Non-Canonical Wnt Signalling in Neural 
Crest Migration.” Development 132 (11):  2587–97. 
https://doi.org/10.1242/dev.01857. 
De Melker, A. Annemieke, Duco Kramer, Ingrid Kuikman, and Arnoud Sonnenberg. 
1997. “The Two Phenylalanines in the GFFKR Motif of the Integrin Α6A 
Subunit Are Essential for Heterodimerization.” Biochemical Journal 328 (2): 
529–37. https://doi.org/10.1042/bj3280529. 
Dedhar, Shoukat, Ronald Saulnier, Raymond Nagle, and Christopher M. Overall. 
1993. “Specific Alterations in the Expression of Α3β1 and Α6β4 Integrins in 
Highly Invasive and Metastatic Variants of Human Prostate Carcinoma Cells 
Selected by in Vitro Invasion through Reconstituted Basement Membrane.” 
Clinical & Experimental Metastasis 11 (5): 391-400.  
https://doi.org/10.1007/BF00132982. 
Delwel, Gepke O., Ingrid Kuikman, and Arnoud Sonnenberg. 1995. “An 
Alternatively Spliced Exon in the Extracellular Domain of the Human Α6 
Integrin Subunit-Functional Analysis of the Α6 Integrin Variants.” Cell 
Adhesion and Communication 3 (2): 143-61.  
https://doi.org/10.3109/15419069509081283. 
Demetriou, Manolis C., and Anne E. Cress. 2004. “Integrin Clipping: A Novel 
Adhesion Switch?” Journal of Cellular Biochemistry 91 (1): 26-35.  
https://doi.org/10.1002/jcb.10675. 
Demetriou, Manolis C, Michael E Pennington, Raymond B Nagle, and Anne E 
Cress. 2004. “Extracellular Alpha 6 Integrin Cleavage by Urokinase-Type 
Plasminogen Activator in Human Prostate Cancer.” Experimental Cell 
Research 294 (2): 550–58. https://doi.org/10.1016/j.yexcr.2003.11.023. 
174 
 
Desgrosellier, Jay S., and David A. Cheresh. 2010. “Integrins in Cancer: Biological 
Implications and Therapeutic Opportunities.” Nature Reviews Cancer 10 
(1): 9–22. https://doi.org/10.1038/nrc2748. 
DiPersio, C. Michael, Kairbaan M. Hodivala-Dilke, Rudolf Jaenisch, Jordan A. 
Kreidberg, and Richard O. Hynes. 1997. “Α3β1 Integrin Is Required for 
Normal Development of the Epidermal Basement Membrane.” The Journal 
of Cell Biology 137 (3): 729–42. https://doi.org/10.1083/jcb.137.3.729. 
DiPersio, C.M., S. Shah, and R.O. Hynes. 1995. “Alpha 3A Beta 1 Integrin 
Localizes to Focal Contacts in Response to Diverse Extracellular Matrix 
Proteins.” Journal of Cell Science 108 (6): 2321. 
Drake, Justin M., J. Matthew Barnes, Joshua M. Madsen, Frederick E. Domann, 
Christopher S. Stipp, and Michael D. Henry. 2010. “ZEB1 Coordinately 
Regulates Laminin-332 and Β4 Integrin Expression Altering the Invasive 
Phenotype of Prostate Cancer Cells.” Journal of Biological Chemistry 285 
(44): 33940–48. https://doi.org/10.1074/jbc.M110.136044. 
D’Souza-Schorey, Crislyn. 2005. “Disassembling Adherens Junctions: Breaking up 
Is Hard to Do.” Trends in Cell Biology 15 (1): 19-26.  
https://doi.org/10.1016/j.tcb.2004.11.002. 
Durbeej, Madeleine. 2010. “Laminins.” Cell and Tissue Research 339 (1): 259–68. 
https://doi.org/10.1007/s00441-009-0838-2. 
Etienne-Manneville, Sandrine, and Alan Hall. 2002. “Rho GTPases in Cell Biology.” 
Nature 420 (6916): 629–35. https://doi.org/10.1038/nature01148. 
Felding-Habermann, Brunhilde. 2003. “Integrin Adhesion Receptors in Tumor 
Metastasis.” Clinical & Experimental Metastasis 20 (3): 203-13.   
https://doi.org/10.1023/A:1022983000355. 
Fitter, S, P M Sincock, C N Jolliffe, and L K Ashman. 1999. “Transmembrane 4 
Superfamily Protein CD151 (PETA-3) Associates with Beta 1 and Alpha IIb 
Beta 3 Integrins in Haemopoietic Cell Lines and Modulates Cell-Cell 
Adhesion.” The Biochemical Journal 338 (Pt 1) (Pt 1): 61–70. 
Fischer, A. H., K. A. Jacobson, J. Rose, and R. Zeller. 2008. “Hematoxylin and 
Eosin Staining of Tissue and Cell Sections.” Cold Spring Harbor Protocols 
2008 (6): pdb.prot4986-pdb.prot4986.  
https://doi.org/10.1101/pdb.prot4986. 
Fleshner, Katherine, Melissa Assel, Nicole Benfante, Justin Lee, Andrew Vickers, 
Samson Fine, Sigrid Carlsson, and James Eastham. 2016. “Clinical 
Findings and Treatment Outcomes in Patients with Extraprostatic Extension 
Identified on Prostate Biopsy.” Journal of Urology 196 (3): 703-8.  
.https://doi.org/10.1016/j.juro.2016.03.152. 
Flier, Arjan van der, and Arnoud Sonnenberg. 2001. “Function and Interactions of 
Integrins.” Cell and Tissue Research 305 (3): 285-98.   
https://doi.org/10.1007/s004410100417. 
Fornaro, Mara, Thomas Manes, and Lucia R. Languino. 2002. “Integrins and 
Prostate Cancer Metastases.” In Prostate Cancer: New Horizons in 
Research and Treatment, edited by Michael L. Cher, Avraham Raz, and 
Kenneth V. Honn, 81:185–95. Boston: Kluwer Academic Publishers. 
https://doi.org/10.1007/0-306-48143-X_12. 
175 
 
Friedl, Peter. 2004. “Prespecification and Plasticity: Shifting Mechanisms of Cell 
Migration.” Current Opinion in Cell Biology 16 (1): 14-23.   
https://doi.org/10.1016/j.ceb.2003.11.001. 
Friedl, Peter, and Stephanie Alexander. 2011. “Cancer Invasion and the 
Microenvironment: Plasticity and Reciprocity.” Cell 147 (5): 992-1009.  
.https://doi.org/10.1016/j.cell.2011.11.016. 
Friedl, Peter, and Darren Gilmour. 2009. “Collective Cell Migration in 
Morphogenesis, Regeneration and Cancer.” Nature Reviews Molecular Cell 
Biology 10 (7): 445–57. https://doi.org/10.1038/nrm2720. 
Friedl, Peter, Yael Hegerfeldt, and Miriam Tusch. 2004. “Collective Cell Migration 
in Morphogenesis and Cancer.” The International Journal of Developmental 
Biology 48 (5–6): 441–49. https://doi.org/10.1387/ijdb.041821pf. 
Friedl, Peter, and Katarina Wolf. 2010. “Plasticity of Cell Migration: A Multiscale 
Tuning Model.” The Journal of Cell Biology 188 (1): 11-19.  
https://doi.org/10.1083/jcb.200909003. 
Friedrichs, Kay, Patricia Ruiz, Folker Franke, Ingbert Gille, Hans-Joachim Terpe, 
and Beat A. Imhof. 1995. “High Expression Level of Α6 Integrin in Human 
Breast Carcinoma Is Correlated with Reduced Survival.” Cancer Research 
55 (4): 901. 
Gassama-Diagne, Ama, Wei Yu, Martin ter Beest, Fernando Martin-Belmonte, 
Arlinet Kierbel, Joanne Engel, and Keith Mostov. 2006   
“Phosphatidylinositol-3,4,5-Trisphosphate Regulates the Formation of the 
Basolateral Plasma Membrane in Epithelial Cells.” Nature Cell Biology 8 (9): 
963-70. https://doi.org/10.1038/ncb1461. 
Gendusa, Rossella, Carla Rossana Scalia, Serena Buscone, and Giorgio 
Cattoretti. 2014. “Elution of High-Affinity (>10 -9 K D ) Antibodies from Tissue 
Sections: Clues to the Molecular Mechanism and Use in Sequential 
Immunostaining.” Journal of Histochemistry & Cytochemistry 62 (7):  519–
31. https://doi.org/10.1369/0022155414536732 
Gerashchenko, Tatiana S., Nikita M. Novikov, Nadezhda V. Krakhmal, Sofia Y. 
Zolotaryova, Marina V. Zavyalova, Nadezhda V. Cherdyntseva, Evgeny V. 
Denisov, and Vladimir M. Perelmuter. 2019. “Markers of Cancer Cell 
Invasion: Are They Good Enough?” Journal of Clinical Medicine 8 (8): 1092.
  https://doi.org/10.3390/jcm8081092. 
Ghadimi, B.M, J Behrens, I Hoffmann, W Haensch, W Birchmeier, and P.M Schlag. 
1999. “Immunohistological Analysis of E-Cadherin, α-, β- and γ-Catenin 
Expression in Colorectal Cancer: Implications for Cell Adhesion and 
Signaling.” European Journal of Cancer 35 (1):  60–65. 
https://doi.org/10.1016/S0959-8049(98)00344-X. 
Giehl, Klaudia. 2008. “Microenvironmental Regulation of E-Cadherin-Mediated 
Adherens Junctions.” Frontiers in Bioscience Volume (13): 3975.  
https://doi.org/10.2741/2985. 
Gilmore, A P, and L H Romer. 1996. “Inhibition of Focal Adhesion Kinase (FAK) 
Signaling in Focal Adhesions Decreases Cell Motility and Proliferation.” 
Molecular Biology of the Cell 7 (8): 1209-24.  
https://doi.org/10.1091/mbc.7.8.1209. 
176 
 
Goel, H. L., J. Li, S. Kogan, and L. R Languino. 2008. “Integrins in Prostate Cancer 
Progression.” Endocrine Related Cancer 15 (3): 657-64.  
https://doi.org/10.1677/ERC-08-0019. 
Goel, Hira Lal, Naved Alam, Isaac N S Johnson, and Lucia R Languino. 2009. 
“Integrin Signaling Aberrations in Prostate Cancer.” American Journal of 
Translational Research 1 (3): 211–20. 
Gorris, Mark A. J., Altuna Halilovic, Katrin Rabold, Anne van Duffelen, Iresha N. 
Wickramasinghe, Dagmar Verweij, Inge M. N. Wortel, Johannes C. Textor, 
I. Jolanda M. de Vries, and Carl G. Figdor. 2018. “Eight-Color Multiplex 
Immunohistochemistry for Simultaneous Detection of Multiple Immune 
Checkpoint Molecules within the Tumor Microenvironment.” The Journal of 
Immunology 200 (1): 347–54. https://doi.org/10.4049/jimmunol.1701262. 
Grignon, David J. 2018. “Prostate Cancer Reporting and Staging: Needle Biopsy 
and Radical Prostatectomy Specimens.” Modern Pathology 31 (S1): 96-
109.  https://doi.org/10.1038/modpathol.2017.167. 
Gu, Jianguo, Masahito Tamura, and Kenneth M. Yamada. 1998. “Tumor 
Suppressor PTEN Inhibits Integrin- and Growth Factor–Mediated Mitogen-
Activated Protein (MAP) Kinase Signaling Pathways.” The Journal of Cell 
Biology 143 (5): 1375–83. https://doi.org/10.1083/jcb.143.5.1375. 
Guedes, Liana B., Jeffrey J. Tosoian, Jessica Hicks, Ashley E. Ross, and Tamara 
L. Lotan. 2017. “PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies 
Is Associated with Nonorgan Confined Disease at Radical Prostatectomy.” 
Journal of Urology 197 (4):  1054–59. 
https://doi.org/10.1016/j.juro.2016.09.084. 
Han, Bo, Rohit Mehra, Robert J Lonigro, Lei Wang, Khalid Suleman, Anjana 
Menon, Nallasivam Palanisamy, Scott A Tomlins, Arul M Chinnaiyan, and 
Rajal B Shah. 2009. “Fluorescence in Situ Hybridization Study Shows 
Association of PTEN Deletion with ERG Rearrangement during Prostate 
Cancer Progression.” Modern Pathology 22 (8): 1083-93.   
https://doi.org/10.1038/modpathol.2009.69. 
Harryman, William L., James P. Hinton, Cynthia P. Rubenstein, Parminder Singh, 
Raymond B. Nagle, Sarah J. Parker, Beatrice S. Knudsen, and Anne E. 
Cress. 2016. “The Cohesive Metastasis Phenotype in Human Prostate 
Cancer.” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1866 
(2): 221–31. https://doi.org/10.1016/j.bbcan.2016.09.005. 
Harryman, William L., Noel A. Warfel, Raymond B. Nagle, and Anne E. Cress. 
2019. “Tumor Microenvironments of Lethal Prostate Cancer.” In Advances 
in Experimental Medicine and Biology edited by Scott M. Dehm and Donald 
J. Tindall, 978-030-32655-5. Cham, Switzerland: Springer International 
Publishing, 2nd ed. 2019. https://doi.org/10.1007/978-3-030-32656-2. 
Hegerfeldt, Yael, Miriam Tusch, Eva-B. Bröcker, and Peter Friedl. 2002. “Collective 
Cell Movement in Primary Melanoma Explants.” Cancer Research 62 (7): 
2125. 
177 
 
Hintermann, Edith, and Vito Quaranta. 2004. “Epithelial Cell Motility on Laminin-5: 
Regulation by Matrix Assembly, Proteolysis, Integrins and ErbB Receptors.” 
Matrix Biology 23 (2): 75–85. https://doi.org/10.1016/j.matbio.2004.03.001. 
Hintermann, Edith, Neng Yang, Deirdre O’Sullivan, Jonathan M. G. Higgins, and 
Vito Quaranta. 2005. “Integrin Α6β4-ErbB2 Complex Inhibits Haptotaxis by 
Up-Regulating E-Cadherin Cell-Cell Junctions in Keratinocytes.” Journal of 
Biological Chemistry 280 (9): 8004-15.   
https://doi.org/10.1074/jbc.M406301200. 
Hogervorst, F, L G Admiraal, C Niessen, I Kuikman, H Janssen, H Daams, and A 
Sonnenberg. 1993. “Biochemical Characterization and Tissue Distribution 
of the A and B Variants of the Integrin Alpha 6 Subunit.” The Journal of Cell 
Biology 121 (1): 179–91. https://doi.org/10.1083/jcb.121.1.179. 
Hogervorst, Frans, Ingrid Kuikman, Ad Geurts Kessel, and Arnoud Sonnenberg. 
1991. “Molecular Cloning of the Human Alpha6 Integrin Subunit. Alternative 
Splicing of Alpha6 MRNA and Chromosomal Localization of the Alpha6 and 
Beta4 Genes.” European Journal of Biochemistry 199 (2): 425-33.  
https://doi.org/10.1111/j.1432-1033.1991.tb16140.x. 
Hollander, M. Christine, Gideon M. Blumenthal, and Phillip A. Dennis. 2011. “PTEN 
Loss in the Continuum of Common Cancers, Rare Syndromes and Mouse 
Models.” Nature Reviews Cancer 11 (4):  289–301. 
https://doi.org/10.1038/nrc3037. 
Huang, Chaolie, Marie-Claire Kratzer, Doris Wedlich, and Jubin Kashef. 2016. “E-
Cadherin Is Required for Cranial Neural Crest Migration in Xenopus Laevis.” 
Developmental Biology 411 (2): 159-71.  
https://doi.org/10.1016/j.ydbio.2016.02.007. 
Hugo, Honor, M. Leigh Ackland, Tony Blick, Mitchell G. Lawrence, Judith A. 
Clements, Elizabeth D. Williams, and Erik W. Thompson. 2007. “Epithelial—
Mesenchymal and Mesenchymal—Epithelial Transitions in Carcinoma 
Progression.” Journal of Cellular Physiology 213 (2): 374–83. 
https://doi.org/10.1002/jcp.21223. 
Hurst, Douglas R., and Danny R. Welch. 2011. “Metastasis Suppressor Genes.” In 
International Review of Cell and Molecular Biology, 286:107–80. Elsevier. 
https://doi.org/10.1016/B978-0-12-385859-7.00003-3. 
Hwang, Soonyean, Noah P. Zimmerman, Kimberle A. Agle, Jerrold R. Turner, 
Suresh N. Kumar, and Michael B. Dwinell. 2012. “E-Cadherin Is Critical for 
Collective Sheet Migration and Is Regulated by the Chemokine CXCL12 
Protein During Restitution.” Journal of Biological Chemistry 287 (26): 
22227-40. https://doi.org/10.1074/jbc.M112.367979. 
Hynes, Richard O. 2002. “Integrins: Bidirectional, Allosteric Signaling Machines.” 
Cell 110 (6): 673–87. https://doi.org/10.1016/S0092-8674 (02)00971-6. 
Ireton, Reneé C., Michael A. Davis, Jolanda van Hengel, Deborah J. Mariner, Kirk 
Barnes, Molly A. Thoreson, Panos Z. Anastasiadis, et al. 2002. “A Novel 
Role for P120 Catenin in E-Cadherin Function.” The Journal of Cell Biology 
159 (3): 465–76. https://doi.org/10.1083/jcb.200205115. 
178 
 
Itoh, M, A Nagafuchi, S Moroi, and S Tsukita. 1997. “Involvement of ZO-1 in 
Cadherin-Based Cell Adhesion through Its Direct Binding to Alpha Catenin 
and Actin Filaments.” The Journal of Cell Biology 138 (1): 181-92.  
https://doi.org/10.1083/jcb.138.1.181. 
Jamaspishvili, Tamara, David M. Berman, Ashley E. Ross, Howard I. Scher, Angelo 
M. De Marzo, Jeremy A. Squire, and Tamara L. Lotan. 2018. “Clinical 
Implications of PTEN Loss in Prostate Cancer.” Nature Reviews Urology 15 
(4): 222–34. https://doi.org/10.1038/nrurol.2018.9. 
Johnson, Randy, and Georg Halder. 2014. “The Two Faces of Hippo: Targeting the 
Hippo Pathway for Regenerative Medicine and Cancer Treatment.” Nature 
Reviews Drug Discovery 13 (1): 63–79. https://doi.org/10.1038/nrd4161. 
Jones, J C, M A Kurpakus, H M Cooper, and V Quaranta. 1991. “A Function for the 
Integrin Alpha 6 Beta 4 in the Hemidesmosome.” Cell Regulation 2 (6): 427–
38. https://doi.org/10.1091/mbc.2.6.427. 
Kacsinta, Apollo D., Cynthia S. Rubenstein, Isis C. Sroka, Sangita Pawar, Jaime 
M. Gard, Raymond B. Nagle, and Anne E. Cress. 2014. “Intracellular 
Modifiers of Integrin Alpha 6p Production in Aggressive Prostate and Breast 
Cancer Cell Lines.” Biochemical and Biophysical Research 
Communications 454 (2): 335-40.  335–40. 
https://doi.org/10.1016/j.bbrc.2014.10.073. 
Kalluri, Raghu, and Robert A. Weinberg. 2009. “The Basics of Epithelial-
Mesenchymal Transition.” Journal of Clinical Investigation 119 (6): 1420-28.
  https://doi.org/10.1172/JCI39104. 
Karantanos, T, P G Corn, and T C Thompson. 2013. “Prostate Cancer Progression 
after Androgen Deprivation Therapy: Mechanisms of Castrate Resistance 
and Novel Therapeutic Approaches.” Oncogene 32 (49): 5501-11.  
https://doi.org/10.1038/onc.2013.206. 
Kedage, Vivekananda, Brady G. Strittmatter, Paige B. Dausinas, and Peter C. 
Hollenhorst. 2017. “Phosphorylation of the Oncogenic Transcription Factor 
ERG in Prostate Cells Dissociates Polycomb Repressive Complex 2, 
Allowing Target Gene Activation.” Journal of Biological Chemistry 292 (42): 
17225-35.  https://doi.org/10.1074/jbc.M117.796458. 
Kikkawa, Y., N. Sanzen, H. Fujiwara, A. Sonnenberg, and K. Sekiguchi. 2000. 
“Integrin Binding Specificity of Laminin-10/11: Laminin-10/11 Are 
Recognized by Alpha 3 Beta 1, Alpha 6 Beta 1 and Alpha 6 Beta 4 Integrins.” 
Journal of Cell Science 113 (5): 869. 
Kim, Janice P., Ken Zhang, Randall H. Kramer, Thomas J. Schall, and David T. 
Woodley. 1992. “Integrin Receptors and RGD Sequences in Human 
Keratinocyte Migration: Unique Anti-Migratory: Unique Anti-Migratory 
Function of Α3β1 Epiligrin Receptor.” Journal of Investigative Dermatology 
98 (5): 764–70. https://doi.org/10.1111/1523-1747.ep12499947. 
179 
 
King, Jennifer C, Jin Xu, John Wongvipat, Haley Hieronymus, Brett S Carver, David 
H Leung, Barry S Taylor, et al. 2009. “Cooperativity of TMPRSS2-ERG with 
PI3-Kinase Pathway Activation in Prostate Oncogenesis.” Nature Genetics 
41 (5): 524–26. https://doi.org/10.1038/ng.371. 
Krohn, Antje, Tobias Diedler, Lia Burkhardt, Pascale-Sophie Mayer, Colin De Silva, 
Marie Meyer-Kornblum, Darja Kötschau, et al. 2012. “Genomic Deletion of 
PTEN Is Associated with Tumor Progression and Early PSA Recurrence in 
ERG Fusion-Positive and Fusion-Negative Prostate Cancer.” The American 
Journal of Pathology 181 (2): 401-12.  
https://doi.org/10.1016/j.ajpath.2012.04.026. 
Kurpakus, Michelle A, Vito Quaranta, and Jonathan C R Jones. 1991. “Surface 
Relocation OfA1pha6Beta4 Integrins and Assembly of Hemidesmosomes 
in an In Vitro Model of Wound Healing.” The Journal of Cell Biology 115: 14. 
Landowski, T. H., J. Gard, E. Pond, G. D. Pond, R. B. Nagle, C. P. Geffre, and A. 
E. Cress. 2014. “Targeting Integrin 6 Stimulates Curative-Type Bone 
Metastasis Lesions in a Xenograft Model.” Molecular Cancer Therapeutics 
13 (6): 1558–66. https://doi.org/10.1158/1535-7163.MCT-13-0962. 
LeBeau, Aaron M., Natalia Sevillano, Kate Markham, Michael B. Winter, Stephanie 
T. Murphy, Daniel R. Hostetter, James West, Henry Lowman, Charles S. 
Craik, and Henry F. VanBrocklin. 2015. “Imaging Active Urokinase 
Plasminogen Activator in Prostate Cancer.” Cancer Research 75 (7): 1225–
35. https://doi.org/10.1158/0008-5472.CAN-14-2185. 
Lee, Jie-Oh, Haijuan Yang, Maria-Magdalena Georgescu, Antonio Di Cristofano, 
Tomohiko Maehama, Yigong Shi, Jack E Dixon, Pier Pandolfi, and Nikola P 
Pavletich. 1999. “Crystal Structure of the PTEN Tumor Suppressor: 
Implications for Its Phosphoinositide Phosphatase Activity and Membrane 
Association.” Cell 99 (3): 323-34. https://doi.org/10.1016/S0092-
8674(00)81663-3. 
Leinonen, K. A., O. R. Saramaki, B. Furusato, T. Kimura, H. Takahashi, S. Egawa, 
H. Suzuki, et al. 2013. “Loss of PTEN Is Associated with Aggressive 
Behavior in ERG-Positive Prostate Cancer.” Cancer Epidemiology 
Biomarkers & Prevention 22 (12): 2333–44. https://doi.org/10.1158/1055-
9965.EPI-13-0333-T. 
Li, Y., and P.J. Cozzi. 2007. “Targeting UPA/UPAR in Prostate Cancer.” Cancer 
Treatment Reviews 33 (6):  521–27. 
https://doi.org/10.1016/j.ctrv.2007.06.003. 
Lindsay, A. J. 2004. “The C2 Domains of the Class I Rab11 Family of Interacting 
Proteins Target Recycling Vesicles to the Plasma Membrane.” Journal of 
Cell Science 117 (19): 4365–75. https://doi.org/10.1242/jcs.01280. 
Lindsay, Andrew J., and Mary W. McCaffrey. 2017. “Rab Coupling Protein 
Mediated Endosomal Recycling of N-Cadherin Influences Cell Motility.” 
Oncotarget 8 (62). https://doi.org/10.18632/oncotarget.10513. 
180 
 
Lippert, Solvej, Kasper D Berg, Gunilla Høyer-Hansen, Ida K Lund, Peter Iversen, 
Ib J Christensen, Klaus Brasso, and Martin A Røder. 2016. “Copenhagen 
UPAR Prostate Cancer (CuPCa) Database: Protocol and Early Results.” 
Biomarkers in Medicine 10 (2): 209-16.   
https://doi.org/10.2217/bmm.15.114. 
Liu, Z., J. L. Tan, D. M. Cohen, M. T. Yang, N. J. Sniadecki, S. A. Ruiz, C. M. 
Nelson, and C. S. Chen. 2010. “Mechanical Tugging Force Regulates the 
Size of Cell-Cell Junctions.” Proceedings of the National Academy of 
Sciences 107 (22): 9944–49. https://doi.org/10.1073/pnas.0914547107. 
Llense, Flora, and Enrique Martín-Blanco. 2008. “JNK Signaling Controls Border 
Cell Cluster Integrity and Collective Cell Migration.” Current Biology 18 (7): 
538–44. https://doi.org/10.1016/j.cub.2008.03.029. 
llić, Duško, Yasuhide Furuta, Satoshi Kanazawa, Naoki Takeda, Kenji Sobue, 
Norio Nakatsuji, Shintaro Nomura, et al. 1995. “Reduced Cell Motility and 
Enhanced Focal Adhesion Contact Formation in Cells from FAK-Deficient 
Mice.” Nature 377 (6549): 539–44. https://doi.org/10.1038/377539a0. 
Lokman, Utku, Andrew M. Erickson, Hanna Vasarainen, Antti S. Rannikko, and 
Tuomas Mirtti. 2018. “PTEN Loss but Not ERG Expression in Diagnostic 
Biopsies Is Associated with Increased Risk of Progression and Adverse 
Surgical Findings in Men with Prostate Cancer on Active Surveillance.” 
European Urology Focus 4 (6): 867-73.  
https://doi.org/10.1016/j.euf.2017.03.004. 
Lotan, Tamara L, Wei Wei, Olga Ludkovski, Carlos L Morais, Liana B Guedes, 
Tamara Jamaspishvili, Karen Lopez, et al. 2016. “Analytic Validation of a 
Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by 
Comparison with PTEN FISH.” Modern Pathology 29 (8): 904-14.  
https://doi.org/10.1038/modpathol.2016.88. 
Ma, Zhong, Donna J. Webb, Minji Jo, and Steven L. Gonias. 2001. “Endogenously 
Produced Urokinase-Type Plasminogen Activator Is a Major Determinant of 
the Basal Level of Activated ERK/MAP Kinase and Prevents Apoptosis in 
MDA-MB-231 Breast Cancer Cells.” Journal of Cell Science 114 (18): 3387. 
Mahmood, Niaz, Catalin Mihalcioiu, and Shafaat A. Rabbani. 2018. “Multifaceted 
Role of the Urokinase-Type Plasminogen Activator (UPA) and Its Receptor 
(UPAR): Diagnostic, Prognostic, and Therapeutic Applications.” Frontiers in 
Oncology 8 (February). https://doi.org/10.3389/fonc.2018.00024. 
Makrilia, Nektaria, Anastasios Kollias, Leonidas Manolopoulos, and Kostas 
Syrigos. 2009. “Cell Adhesion Molecules: Role and Clinical Significance in 
Cancer.” Cancer Investigation 27 (10): 1023-37.  
https://doi.org/10.3109/07357900902769749. 
181 
 
Marchiò, Serena, Marco Soster, Sabrina Cardaci, Andrea Muratore, Alice Bartolini, 
Vanessa Barone, Dario Ribero, et al. 2012. “A Complex of α 6 Integrin and 
E‐cadherin Drives Liver Metastasis of Colorectal Cancer Cells through 
Hepatic Angiopoietin‐like 6.” EMBO Molecular Medicine 4 (11):   
1156–75. https://doi.org/10.1002/emmm.201101164. 
Mareel, Marc, and Ancy Leroy. 2003. “Clinical, Cellular, and Molecular Aspects of 
Cancer Invasion.” Physiological Reviews 83 (2): 337-76.  
https://doi.org/10.1152/physrev.00024.2002. 
Margadant, C., K. Raymond, M. Kreft, N. Sachs, H. Janssen, and A. Sonnenberg. 
2009. “Integrin 3β1 Inhibits Directional Migration and Wound Re-
Epithelialization in the Skin.” Journal of Cell Science 122 (2): 278–88. 
https://doi.org/10.1242/jcs.029108. 
Marques, Rute B., Natasja F. Dits, Sigrun Erkens-Schulze, Wytske M. van 
Weerden, and Guido Jenster. 2010. “Bypass Mechanisms of the Androgen 
Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models.” 
Edited by Chad Creighton. PLoS ONE 5 (10): e13500.  
https://doi.org/10.1371/journal.pone.0013500. 
Martin-Belmonte, Fernando, Ama Gassama, Anirban Datta, Wei Yu, Ursula 
Rescher, Volker Gerke, and Keith Mostov. 2007. “PTEN-Mediated Apical 
Segregation of Phosphoinositides Controls Epithelial Morphogenesis 
through Cdc42.” Cell 128 (2): 383-97.   
https://doi.org/10.1016/j.cell.2006.11.051. 
Martinez-Rico, C., F. Pincet, J.-P. Thiery, and S. Dufour. 2010. “Integrins Stimulate 
E-Cadherin-Mediated Intercellular Adhesion by Regulating Src-Kinase 
Activation and Actomyosin Contractility.” Journal of Cell Science 123 (5):  
712–22. https://doi.org/10.1242/jcs.047878. 
Maruthamuthu, V., B. Sabass, U. S. Schwarz, and M. L. Gardel. 2011. “Cell-ECM 
Traction Force Modulates Endogenous Tension at Cell-Cell Contacts.” 
Proceedings of the National Academy of Sciences 108 (12):  4708–13. 
https://doi.org/10.1073/pnas.1011123108. 
Mayor, Roberto, and Sandrine Etienne-Manneville. 2016. “The Front and Rear of 
Collective Cell Migration.” Nature Reviews Molecular Cell Biology 17 (2): 
97–109. https://doi.org/10.1038/nrm.2015.14. 
McCandless, J, A Cress, I Rabinovitz, C Payne, G Bowden, J Knox, and R Nagle. 
1997. “A Human Xenograft Model for Testing Early Events of Epithelial 
Neoplastic Invasion.” International Journal of Oncology, February.  
https://doi.org/10.3892/ijo.10.2.279. 
Melker, Anneinieke A., and Arnoud Sonnenberg. 1996. “The Role of the 
Cytoplasmic Domain of Alpha6 Integrin in the Assembly and Function of 
Alpha6beta1 and Alpha6beta4.” European Journal of Biochemistry 241 (1):
  254–64. https://doi.org/10.1111/j.1432-1033.1996.0254t.x. 
Mishra, Abhinava, James Mondo, Joseph Campanale, and Denise Montell. 2019. 
“Coordination of Protrusion Dynamics within and between Collectively 
Migrating Border Cells by Myosin II.” Molecular Biology of the Cell 30 
(August): mbc.E19-02. https://doi.org/10.1091/mbc.E19-02-0124. 
182 
 
Miyake, H, I Hara, K Yamanaka, S Arakawa, and S Kamidono. 1999. “Elevation of 
Urokinase-Type Plasminogen Activator and Its Receptor Densities as New 
Predictors of Disease Progression and Prognosis in Men with Prostate 
Cancer.” International Journal of Oncology, March.  
https://doi.org/10.3892/ijo.14.3.535.  
Miyazaki, Takamichi, Sugiko Futaki, Kouichi Hasegawa, Miwa Kawasaki, Noriko 
Sanzen, Maria Hayashi, Eihachiro Kawase, Kiyotoshi Sekiguchi, Norio 
Nakatsuji, and Hirofumi Suemori. 2008. “Recombinant Human Laminin 
Isoforms Can Support the Undifferentiated Growth of Human Embryonic 
Stem Cells.” Biochemical and Biophysical Research Communications 375 
(1): 27-32.  https://doi.org/10.1016/j.bbrc.2008.07.111. 
Mondino, Anna, and Francesco Blasi. 2004. “UPA and UPAR in Fibrinolysis, 
Immunity and Pathology.” Trends in Immunology 25 (8): 450-55.   
https://doi.org/10.1016/j.it.2004.06.004. 
Montironi, Rodolfo, Roberta Mazzucchelli, and Marina Scarpelli. 2006. 
“Precancerous Lesions and Conditions of the Prostate: From Morphological 
and Biological Characterization to Chemoprevention.” Annals of the New 
York Academy of Sciences 963 (1): 169–84. https://doi.org/10.1111/j.1749-
6632.2002.tb04108.x. 
Mui, Keeley L., Christopher S. Chen, and Richard K. Assoian. 2016. “The 
Mechanical Regulation of Integrin–Cadherin Crosstalk Organizes Cells, 
Signaling and Forces.” Journal of Cell Science 129 (6): 1093–1100. 
https://doi.org/10.1242/jcs.183699. 
Mukhopadhyay, Sanjay, Michael D. Feldman, Esther Abels, Raheela Ashfaq, 
Senda Beltaifa, Nicolas G. Cacciabeve, Helen P. Cathro, et al. 2017. “Whole 
Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical 
Pathology: A Multicenter Blinded Randomized Noninferiority Study of 1992 
Cases (Pivotal Study).” The American Journal of Surgical Pathology, 
September 1. https://doi.org/10.1097/PAS.0000000000000948. 
Nagle, Ray B, Junshan Hao, J David Knox, Bruce L Dalkin, and Anne E Cress. 
1995. “Expression of Hemidesmosomal and Extracellular Matrix Proteins by 
Normal and Malignant Human Prostate Tissue” 146 (6): 10. 
Nagle, Raymond B., and Anne E. Cress. 2011. “Metastasis Update: Human 
Prostate Carcinoma Invasion via Tubulogenesis.” Prostate Cancer 2011:  
1–10. https://doi.org/10.1155/2011/249290. 
Nagle, Raymond B., Amit M. Algotar, Connie C. Cortez, Katherine Smith, Carol 
Jones, Ubaradka G. Sathyanarayana, Steven Yun, et al. 2013. “ERG 
Overexpression and PTEN Status Predict Capsular Penetration in Prostate 
Carcinoma: ERG & PTEN Predict Capsular Penetration.” The Prostate 73 
(11): 1233-40.  https://doi.org/10.1002/pros.22675.   
183 
 
Nguyen, Beth P., Xiang-Dong Ren, Martin A. Schwartz, and William G. Carter. 
2001. “Ligation of Integrin α 3 β 1 by Laminin 5 at the Wound Edge Activates 
Rho-Dependent Adhesion of Leading Keratinocytes on Collagen.” Journal 
of Biological Chemistry 276 (47): 43860-70.   
https://doi.org/10.1074/jbc.M103404200. 
Nishiuchi, Ryoko, Junichi Takagi, Maria Hayashi, Hiroyuki Ido, Yoshiko Yagi, 
Noriko Sanzen, Tsutomu Tsuji, Masashi Yamada, and Kiyotoshi Sekiguchi. 
2006. “Ligand-Binding Specificities of Laminin-Binding Integrins: A 
Comprehensive Survey of Laminin–Integrin Interactions Using 
Recombinant Α3β1, Α6β1, Α7β1 and Α6β4 Integrins.” Matrix Biology 25 (3):
  189–97. https://doi.org/10.1016/j.matbio.2005.12.001. 
Nusrat, A R, and H A Chapman. 1991. “An Autocrine Role for Urokinase in Phorbol 
Ester-Mediated Differentiation of Myeloid Cell Lines.” Journal of Clinical 
Investigation 87 (3): 1091–97. https://doi.org/10.1172/JCI115070. 
Owens, David M., and Fiona M. Watt. 2001. “Influence of Β1 Integrins on 
Epidermal Squamous Cell Carcinoma Formation in a Transgenic Mouse 
Model.” Cancer Research 61 (13): 5248. 
Parsons, J. Thomas, Alan Rick Horwitz, and Martin A. Schwartz. 2010. “Cell 
Adhesion: Integrating Cytoskeletal Dynamics and Cellular Tension.” Nature 
Reviews Molecular Cell Biology 11 (9): 633-43.   
https://doi.org/10.1038/nrm2957. 
Pawar, Sangita C., Manolis C. Demetriou, Raymond B. Nagle, G. Tim Bowden, 
and Anne E. Cress. 2007. “Integrin Α6 Cleavage: A Novel Modification to 
Modulate Cell Migration.” Experimental Cell Research 313 (6): 1080-89.   
https://doi.org/10.1016/j.yexcr.2007.01.006. 
Pećina-Šlaus, Nives. 2003. “Tumor Suppressor Gene E-Cadherin and Its Role in 
Normal and Malignant Cells.” Cancer Cell International 3 (1): 17.  
https://doi.org/10.1186/1475-2867-3-17. 
Petrovics, Gyorgy, Aijun Liu, Syed Shaheduzzaman, Bungo Furasato, Chen Sun, 
Yongmei Chen, Martin Nau, et al. 2005. “Frequent Overexpression of ETS-
Related Gene-1 (ERG1) in Prostate Cancer Transcriptome.” Oncogene 24 
(23): 3847–52. https://doi.org/10.1038/sj.onc.1208518. 
Piccolo, Stefano, Sirio Dupont, and Michelangelo Cordenonsi. 2014. “The Biology 
of YAP/TAZ: Hippo Signaling and Beyond.” Physiological Reviews 94 (4): 
1287–1312. https://doi.org/10.1152/physrev.00005.2014. 
Ports, M. O., R. B. Nagle, G. D. Pond, and A. E. Cress. 2009. “Extracellular 
Engagement of 6 Integrin Inhibited Urokinase-Type Plasminogen Activator-
Mediated Cleavage and Delayed Human Prostate Bone Metastasis.” 
Cancer Research 69 (12): 5007–14. https://doi.org/10.1158/0008-
5472.CAN-09-0354. 
Rabinovitz, Isaac, and Arthur M. Mercurio. 1996. “The Integrin Α6β4 and the 
Biology of Carcinoma.” Biochemistry and Cell Biology 74 (6): 811-21.  
https://doi.org/10.1139/o96-087. 
184 
 
Ramel, Damien, Xiaobo Wang, Carl Laflamme, Denise J. Montell, and Gregory 
Emery. 2013. “Rab11 Regulates Cell–Cell Communication during Collective 
Cell Movements.” Nature Cell Biology 15 (3): 317-24.   
https://doi.org/10.1038/ncb2681. 
Ramovs, Veronika, Pablo Secades, Ji-Ying Song, Bram Thijssen, Maaike Kreft, 
and Arnoud Sonnenberg. 2019. “Absence of Integrin Α3β1 Promotes the 
Progression of HER2-Driven Breast Cancer in Vivo.” Breast Cancer 
Research 21 (1): 63. https://doi.org/10.1186/s13058-019-1146-8. 
Raymond, K. 2005. “Keratinocytes Display Normal Proliferation, Survival and 
Differentiation in Conditional 4-Integrin Knockout Mice.” Journal of Cell 
Science 118 (5): 1045–60. https://doi.org/10.1242/jcs.01689. 
Ridley, A. J. 2003. “Cell Migration: Integrating Signals from Front to Back.” Science 
302 (5651): 1704–9. https://doi.org/10.1126/science.1092053. 
Rooij, Johan de, Andre Kerstens, Gaudenz Danuser, Martin A. Schwartz, and 
Clare M. Waterman-Storer. 2005. “Integrin-Dependent Actomyosin 
Contraction Regulates Epithelial Cell Scattering.” The Journal of Cell 
Biology 171 (1): 153–64. https://doi.org/10.1083/jcb.200506152. 
Rozario, Tania, and Douglas W. DeSimone. 2010. “The Extracellular Matrix in 
Development and Morphogenesis: A Dynamic View.” Developmental 
Biology 341 (1): 126–40. https://doi.org/10.1016/j.ydbio.2009.10.026. 
Rubenstein, Cynthia S., Jaime M.C. Gard, Mengdie Wang, Julie E. McGrath, Nadia 
Ingabire, James P. Hinton, Kendra D. Marr, et al. 2019. “Gene Editing of Α6 
Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell 
Biophysical Properties in Prostate Cancer.” Cancer Research 79 (18):  
4703–14. https://doi.org/10.1158/0008-5472.CAN-19-0868. 
Rusthoven, Chad G., Bernard L. Jones, Thomas W. Flaig, E. David Crawford, 
Matthew Koshy, David J. Sher, Usama Mahmood, et al. 2016. “Improved 
Survival With Prostate Radiation in Addition to Androgen Deprivation 
Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.” 
Journal of Clinical Oncology 34 (24): 2835-42.   
https://doi.org/10.1200/JCO.2016.67.4788. 
Saramaki, O. R., A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L.J. Tammela, 
and T. Visakorpi. 2008. “TMPRSS2:ERG Fusion Identifies a Subgroup of 
Prostate Cancers with a Favorable Prognosis.” Clinical Cancer Research 
14 (11): 3395–3400. https://doi.org/10.1158/1078-0432.CCR-07-2051. 
Schafer, G., M. Narasimha, E. Vogelsang, and M. Leptin. 2014. “Cadherin 
Switching during the Formation and Differentiation of the Drosophila 
Mesoderm - Implications for Epithelial-to-Mesenchymal Transitions.” 
Journal of Cell Science 127 (7): 1511-22.  
https://doi.org/10.1242/jcs.139485. 
Schmelz, Monika, Anne E. Cress, Katherine M. Scott, Friederike Burger, Haiyan 
Cui, Karim Sallam, Kathy M. McDaniel, Bruce L. Dalkin, and Raymond B. 
Nagle. 2002. “Different Phenotypes in Human Prostate Cancer: Α6 or Α3 
Integrin in Cell-Extracellular Adhesion Sites.” Neoplasia 4 (3): 243-54.   
https://doi.org/10.1038/sj.neo.7900223. 
185 
 
Schreider, Cyrille, Peignon, Gregory, Tenet, Sophie, and Chamaz, Jean. 2002. 
“Integrin-Induced E-Cadherin–Actin Complexes.” Journal of Cell Science 
115 (3): 543–52. 
Selvaraj, Nagarathinam, Vivekananda Kedage, and Peter C Hollenhorst. 2015. 
“Comparison of MAPK Specificity across the ETS Transcription Factor 
Family Identifies a High-Affinity ERK Interaction Required for ERG Function 
in Prostate Cells.” Cell Communication and Signaling 13 (1): 12.  
https://doi.org/10.1186/s12964-015-0089-7. 
Shariat, Shahrokh F., Claus G. Roehrborn, John D. McConnell, Sangtae Park, Nina 
Alam, Thomas M. Wheeler, and Kevin M. Slawin. 2007. “Association of the 
Circulating Levels of the Urokinase System of Plasminogen Activation With 
the Presence of Prostate Cancer and Invasion, Progression, and 
Metastasis.” Journal of Clinical Oncology 25 (4): 349-55.   
https://doi.org/10.1200/JCO.2006.05.6853. 
Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. 2019. “Cancer 
Statistics, 2019.” CA: A Cancer Journal for Clinicians 69 (1): 7-34   
https://doi.org/10.3322/caac.21551. 
Smith, Harvey W., and Chris J. Marshall. 2010. “Regulation of Cell Signalling by 
UPAR.” Nature Reviews Molecular Cell Biology 11 (1): 23-36.  
https://doi.org/10.1038/nrm2821. 
Song, Min Sup, Leonardo Salmena, and Pier Paolo Pandolfi. 2012. “The Functions 
and Regulation of the PTEN Tumour Suppressor.” Nature Reviews 
Molecular Cell Biology 13 (5): 283–96. https://doi.org/10.1038/nrm3330. 
Spadafora, C. 2008. “Sperm-Mediated ‘reverse’ Gene Transfer: A Role of Reverse 
Transcriptase in the Generation of New Genetic Information.” Human 
Reproduction 23 (4): 735–40. https://doi.org/10.1093/humrep/dem425. 
Sroka, I. C., C. P. Sandoval, H. Chopra, J. M. C. Gard, S. C. Pawar, and A. E. 
Cress. 2011. “Macrophage-Dependent Cleavage of the Laminin Receptor 6 
1 in Prostate Cancer.” Molecular Cancer Research 9 (10): 1319-28.   
https://doi.org/10.1158/1541-7786.MCR-11-0080. 
Sroka, Isis C., Todd A. Anderson, Kathy M. McDaniel, Raymond B. Nagle, Matthew 
B. Gretzer, and Anne E. Cress. 2010. “The Laminin Binding Integrin Α6β1 
in Prostate Cancer Perineural Invasion.” Journal of Cellular Physiology 224 
(2): 283–88. https://doi.org/10.1002/jcp.22149. 
Sroka, Isis C, Harsharon Chopra, Lipsa Das, Jaime M C Gard, Raymond B Nagle, 
and Anne E Cress. 2016. “Schwann Cells Increase Prostate and Pancreatic 
Tumor Cell Invasion Using Laminin Binding A6 Integrin.” Journal of Cellular 
Biochemistry 117 (2): 491–99. https://doi.org/10.1002/jcb.25300. 
Stewart, Rachel L., Dava West, Chi Wang, Heidi L. Weiss, Tamas Gal, Eric B. 
Durbin, William O’Connor, Min Chen, and Kathleen L. O’Connor. 2016. 
“Elevated Integrin Α6β4 Expression Is Associated with Venous Invasion and 
Decreased Overall Survival in Non–Small Cell Lung Cancer.” Human 
Pathology 54 (August): 174-83.   
https://doi.org/10.1016/j.humpath.2016.04.003. 
186 
 
Stipp, Christopher S. 2010. “Laminin-Binding Integrins and Their Tetraspanin 
Partners as Potential Antimetastatic Targets.” Expert Reviews in Molecular 
Medicine 12 (January). https://doi.org/10.1017/S1462399409001355. 
Sun, H., R. Lesche, D.-M. Li, J. Liliental, H. Zhang, J. Gao, N. Gavrilova, B. Mueller, 
X. Liu, and H. Wu. 1999. “PTEN Modulates Cell Cycle Progression and Cell 
Survival by Regulating Phosphatidylinositol 3,4,5,-Trisphosphate and 
Akt/Protein Kinase B Signaling Pathway.” Proceedings of the National 
Academy of Sciences 96 (11):  6199–6204. 
https://doi.org/10.1073/pnas.96.11.6199. 
Suvarna, Kim S., Christopher Layton, and John D. Bancroft, eds. 2013. Theory 
and Practice of Histological Techniques. 7. ed. Edinburgh: Elsevier Churchill 
Livingston. 
Suzuki, Hiroyoshi, Diha Freije, Deborah R. Nusskern, Kenji Okami, Paul Cairns, 
David Sidransky, William B. Isaacs, and G. Steven Bova. 1998. “Interfocal 
Heterogeneity of <em>PTEN/MMAC1</Em> Gene Alterations in Multiple 
Metastatic Prostate Cancer Tissues.” Cancer Research 58 (2): 204. 
Talmadge, J. E., and I. J. Fidler. 2010. “AACR Centennial Series: The Biology of 
Cancer Metastasis: Historical Perspective.” Cancer Research 70 (14): 
5649–69. https://doi.org/10.1158/0008-5472.CAN-10-1040. 
Tamura, M., J. Gu, H. Tran, and K. M. Yamada. 1999. “PTEN Gene and Integrin 
Signaling in Cancer.” JNCI Journal of the National Cancer Institute 91 (21): 
1820–28. https://doi.org/10.1093/jnci/91.21.1820. 
Tamura, Masahito, Jianguo Gu, Takahisa Takino, and Kenneth M. Yamada. 1999. 
“Tumor Suppressor PTEN Inhibition of Cell Invasion, Migration, and Growth: 
Differential Involvement of Focal Adhesion Kinase and P130Cas.” Cancer 
Research 59 (2): 442. 
Tamura, R. N. 1990. “Epithelial Integrin Alpha 6 Beta 4: Complete Primary 
Structure of Alpha 6 and Variant Forms of Beta 4.” The Journal of Cell 
Biology 111 (4): 1593–1604. https://doi.org/10.1083/jcb.111.4.1593. 
Taylor, Barry S., Nikolaus Schultz, Haley Hieronymus, Anuradha Gopalan, 
Yonghong Xiao, Brett S. Carver, Vivek K. Arora, et al. 2010. “Integrative 
Genomic Profiling of Human Prostate Cancer.” Cancer Cell 18 (1):   
11–22. https://doi.org/10.1016/j.ccr.2010.05.026. 
Titford, M. 2005. “The Long History of Hematoxylin.” Biotechnic & Histochemistry 
80 (2): 73–78. https://doi.org/10.1080/10520290500138372. 
Tomlins, Scott A., Rohit Mehra, Daniel R. Rhodes, Lisa R. Smith, Diane Roulston, 
Beth E. Helgeson, Xuhong Cao, et al. 2006. “TMPRSS2:ETV4 Gene 
Fusions Define a Third Molecular Subtype of Prostate Cancer.” Cancer 
Research 66 (7): 3396–3400. https://doi.org/10.1158/0008-5472.CAN-06-
0168. 
Tomlins, Scott A., Bharathi Laxman, Sooryanarayana Varambally, Xuhong Cao, 
Jindan Yu, Beth E. Helgeson, Qi Cao, et al. 2008. “Role of the TMPRSS2-
ERG Gene Fusion in Prostate Cancer.” Neoplasia 10 (2): 177-188.  
https://doi.org/10.1593/neo.07822. 
187 
 
Usher, Pernille Autzen, Ole Frøkjaer Thomsen, Peter Iversen, Morten Johnsen, 
Nils Brünner, Gunilla Høyer-Hansen, Peter Andreasen, Keld Danø, and 
Boye Schnack Nielsen. 2005. “Expression of Urokinase Plasminogen 
Activator, Its Receptor and Type-1 Inhibitor in Malignant and Benign 
Prostate Tissue: Proteolysis in Prostate Cancer.” International Journal of 
Cancer 113 (6): 870-80.  https://doi.org/10.1002/ijc.20665. 
VanderVorst, Kacey, Courtney A. Dreyer, Sara E. Konopelski, Hyun Lee, Hsin-Yi 
Henry Ho, and Kermit L. Carraway. 2019. “Wnt/PCP Signaling Contribution 
to Carcinoma Collective Cell Migration and Metastasis.” Cancer Research 
79 (8): 1719–29. https://doi.org/10.1158/0008-5472.CAN-18-2757. 
Varzavand, Afshin, Justin M. Drake, Robert U. Svensson, Mary E. Herndon, Bo 
Zhou, Michael D. Henry, and Christopher S. Stipp. 2013. “Integrin Α3β1 
Regulates Tumor Cell Responses to Stromal Cells and Can Function to 
Suppress Prostate Cancer Metastatic Colonization.” Clinical & 
Experimental Metastasis 30 (4): 541–52. https://doi.org/10.1007/s10585-
012-9558-1. 
Varzavand, Afshin, Will Hacker, Deqin Ma, Katherine Gibson-Corley, Maria 
Hawayek, Omar J. Tayh, James A. Brown, Michael D. Henry, and 
Christopher S. Stipp. 2016. “Α3β1 Integrin Suppresses Prostate Cancer 
Metastasis via Regulation of the Hippo Pathway.” Cancer Research 76 (22): 
6577–87. https://doi.org/10.1158/0008-5472.CAN-16-1483. 
Vaughan, R. B., and J. P. Trinkaus. 1966. “Movements of Epithelial Cell Sheets 
<em>In Vitro</Em>.” Journal of Cell Science 1 (4): 407. 
Wang, J., Y. Cai, W. Yu, C. Ren, D. M. Spencer, and M. Ittmann. 2008. “Pleiotropic 
Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene 
Transcripts.” Cancer Research 68 (20):  8516–24. 
https://doi.org/10.1158/0008-5472.CAN-08-1147. 
Wang, Mengdie, Raymond B. Nagle, Beatrice S. Knudsen, Gregory C. Rogers, 
and Anne E. Cress. 2017. “A Basal Cell Defect Promotes Budding of 
Prostatic Intraepithelial Neoplasia.” Journal of Cell Science 130 (1): 104-10.
  https://doi.org/10.1242/jcs.188177. 
Watanabe, T., K. Sato, and K. Kaibuchi. 2009. “Cadherin-Mediated Intercellular 
Adhesion and Signaling Cascades Involving Small GTPases.” Cold Spring 
Harbor Perspectives in Biology 1 (3):  a003020–a003020. 
https://doi.org/10.1101/cshperspect.a003020. 
Weber, G. F., M. A. Bjerke, and D. W. DeSimone. 2011. “Integrins and Cadherins 
Join Forces to Form Adhesive Networks.” Journal of Cell Science 124 (8): 
1183–93. https://doi.org/10.1242/jcs.064618. 
Wei, Jueyang, Leslie Shaw, and Arthur Mercurio. 1997. “Integrin Signaling in 
Leukocytes: Lessons from the Α6β1 Integrin.” Journal of Leukocyte Biology 
61 (May): 397–407. https://doi.org/10.1002/jlb.61.4.397. 
Weinel, Rolf J, Annette Rosendahl, Elisabeth Pinschmidt, Oliver Kisker, Babette 
Simon, and Sentot Santoso. 1995. “The (X6-1ntegrin Receptor in 
Pancreatic Carcinoma” 108 (2): 10. 
188 
 
Weiner, A B, R S Matulewicz, S E Eggener, and E M Schaeffer. 2016. “Increasing 
Incidence of Metastatic Prostate Cancer in the United States (2004–2013).” 
Prostate Cancer and Prostatic Diseases 19 (4):  395–97. 
https://doi.org/10.1038/pcan.2016.30. 
Wu, L., J. C. Zhao, J. Kim, H.-J. Jin, C.-Y. Wang, and J. Yu. 2013. “ERG Is a Critical 
Regulator of Wnt/LEF1 Signaling in Prostate Cancer.” Cancer Research 73 
(19): 6068–79. https://doi.org/10.1158/0008-5472.CAN-13-0882. 
Yamada, Kenneth M., and Masaru Araki. 2001. “Tumor Suppressor PTEN: 
Modulator of Cell Signaling, Growth, Migration and Apoptosis.” Journal of 
Cell Science 114 (13): 2375. 
Yanez-Mo, M., R. Tejedor, P. Rousselle, and F. Sanchez-Madrid. 2001. 
“Tetraspanins in Intercellular Adhesion of Polarized Epithelial Cells: Spatial 
and Functional Relationship to Integrins and Cadherins.” Journal of Cell 
Science 114 (3): 577. 
Yang, Jing, Sendurai A Mani, Joana Liu Donaher, Sridhar Ramaswamy, Raphael 
A Itzykson, Christophe Come, Pierre Savagner, Inna Gitelman, Andrea 
Richardson, and Robert A Weinberg. 2004. “Twist, a Master Regulator of 
Morphogenesis, Plays an Essential Role in Tumor Metastasis.” Cell 117 (7): 
927-39.  https://doi.org/10.1016/j.cell.2004.06.006. 
Yano, Hajime, Yuichi Mazaki, Kazuo Kurokawa, Steven K. Hanks, Michiyuki 
Matsuda, and Hisataka Sabe. 2004. “Roles Played by a Subset of Integrin 
Signaling Molecules in Cadherin-Based Cell–Cell Adhesion.” The Journal 
of Cell Biology 166 (2): 283–95. https://doi.org/10.1083/jcb.200312013. 
Yoshimoto, Maisa, Anthony M Joshua, Isabela W Cunha, Renata A Coudry, 
Francisco P Fonseca, Olga Ludkovski, Maria Zielenska, Fernando A 
Soares, and Jeremy A Squire. 2008. “Absence of TMPRSS2:ERG Fusions 
and PTEN Losses in Prostate Cancer Is Associated with a Favorable 
Outcome.” Modern Pathology 21 (12): 1451-60.   
https://doi.org/10.1038/modpathol.2008.96. 
Yu, Fa-Xing, Bin Zhao, and Kun-Liang Guan. 2015. “Hippo Pathway in Organ Size 
Control, Tissue Homeostasis, and Cancer.” Cell 163 (4): 811-28.  
https://doi.org/10.1016/j.cell.2015.10.044. 
Zhong, Cuiling, Michael S. Kinch, and Keith Burridge. 1997. “Rho-Stimulated 
Contractility Contributes to the Fibroblastic Phenotype of Ras-Transformed 
Epithelial Cells.” Molecular Biology of the Cell 8 (11): 2329-44.   
https://doi.org/10.1091/mbc.8.11.2329.     
189 
 
Zhou, Bo, Katherine N. Gibson-Corley, Mary E. Herndon, Yihan Sun, Elisabeth 
Gustafson-Wagner, Melissa Teoh-Fitzgerald, Frederick E. Domann, Michael 
D. Henry, and Christopher S. Stipp. 2014. “Integrin Α3β1 Can Function to 
Promote Spontaneous Metastasis and Lung Colonization of Invasive Breast 
Carcinoma.” Molecular Cancer Research 12 (1): 143-54.  
https://doi.org/10.1158/1541-7786.MCR-13-0184. 
Zhou, Hua, and Randall H. Kramer. 2005. “Integrin Engagement Differentially 
Modulates Epithelial Cell Motility by RhoA/ROCK and PAK1.” Journal of 
Biological Chemistry 280 (11): 10624-35.  
https://doi.org/10.1074/jbc.M411900200. 
Zhou, Ming. 2018. “High-Grade Prostatic Intraepithelial Neoplasia, PIN-like 
Carcinoma, Ductal Carcinoma, and Intraductal Carcinoma of the Prostate.” 
Modern Pathology 31 (S1): 71–79. 
https://doi.org/10.1038/modpathol.2017.138. 
 
